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ABSTRACT 
Tissue engineering demands a highly porous scaffold that can replace mechanical 
function temporarily and degrade at rates appropriate to tissue regeneration, in addition 
to biocompatibility and cell delivering ability. Unfortunately this is not the way that the 
existing biocompatible materials usually behave in a biological environment. 
Mechanically stable materials tend to be bioinert, while degradable materials are 
generally fragile. Therefore, a novel materials science strategy is required to address the 
issue. In this study, 3D highly porous, mechanically competent scaffolds have been 
fabricated for the first time from 45S5 Bioglass® by a replication technique. Their 
mechanical strength is conferred by extensive densification of the foam struts and 
formation of fine crystalline particles during the sintering stage. Poly(D,L-lactic acid) 
(PDLLA) was incorporated as a coating onto the Bioglass®-based glass-ceramic foams 
by dipping them in PDLLA-dimethyl carbonate (DMC) solution. The work of fracture 
of the Bioglass®-based foams was significantly improved by the PDLLA coating. 
Surface silanization was applied to the scaffolds to improve cell attachment. A 
significant discovery is that the mechanically strong crystalline phase can transform into 
a degradable amorphous phase in a highly porous scaffold under biological conditions 
(tested in contact with simulated body fluid), which does not usually occur in dense 
materials at the body temperature. Moreover, it was found that the kinetics of the phase 
transformation, which was influenced by the sintering conditions and surface 
functionalisation conditions, was tailorable. This phase transformation effectively 
combines mechanical strength (associated with the crystalline phase) with tailorable 
biodegradability (associated with the amorphous phase) in one scaffold. In vitro cell 
culture demonstrated that cell proliferation was not hampered by crystallisation. The 
present work shows that the goal of an optimised scaffold for bone tissue engineering 
that provides mechanical support temporarily and biodegrades in a controlled manner 
upon implantation is achievable with the developed Bioglass®-based glass-ceramic 
scaffolds. 
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glass-ceramic, hydroxyapatite-like spheres being marked by arrows, and (c) 
sintered and surface-functionalised 45S5 Bioglass®-derived glass-ceramic.. 159 
Fig. 7.3 Cell proliferation data up to 6 days on the different materials investigated.... 160 
Fig. 7.4 Scaiming electron micrographs of cultured MG 63 osteoblast-like cells on 
unsintered 45S5 Bioglass® pellets cultured for 1 or 6 days, (a) Residual islets 
(some marked by arrows) as a result of the peeling surface layer of a pellet, and 
(b) cells on a residual islet, after culture for 1 day. (c) Residual islets as a result 
of the peeling surface layer of a pellet, as marked by arrows, and (d) cells on a 
residual islet, after culture for 6 days 162 
Fig. 7.5 Scanning electron micrographs of cultured MG 63 osteoblast-like cells on as-
sintered 45S5 Bioglass®-derived glass-ceramic pellets 163 
Fig. 7.6 Scanning electron micrographs of cultured MG 63 osteoblast-like cells on 
sintered and surface-functionalised Bioglass®-derived glass-ceramic pellets. 
(a)-(b) Cultured for 1 day; and (c)-(d) cultured for 6 days 164 
Fig. 7.7 Cell proliferation data up to 6 days on the Bioglass®-derived glass-ceramic 
scaffolds investigated. Porosity is indicated by "pore per inch" (ppi) 164 
Fig. 7.8 Scanning electron micrographs of cultured MG 63 osteoblast-like cells on 
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Fig. 7.9 X-ray diffraction spectra of 45S5 Bioglass®-derived scaffolds sintered at 
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cultured medium (without cells), or soaking in simulated body fluid (SBF) for 
6 days. All spectra were obtained using 0.05g powder. The major peaks of 
NazCazSisOg phase and hydroxyapatite are marked by ( V ) and (•) , 
respectively 167 
Fig. 7.10 Compressive stress-strain curves of sintered Bioglass®-derived glass-ceramic 
scaffolds before and after cell culture for 6 days. The porosity of the foams was 
-0.94 168 
Fig. 7.11 Interdigitation of collagen fibres into the surface layer of HA particles after 
implantation into the ileum of a rabbit 171 
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CHAPTER ONE 
INTRODUCTION 
Tissue engineering uses a scaffold to induce the regeneration of host tissue. Ideally, the 
scaffold materials should be highly porous, support/foster cells, temporarily provide 
mechanical function and degrade at rates appropriate to tissue regeneration. 
Unfortunately a traditional material issue remains with all existing synthetic 
biomaterials, in particular for applications in bone tissue engineering, i.e. mechanically 
stable materials (e.g. crystalline hydroxyapatite) tend to be bioinert, while degradable 
materials (e.g. amorphous calcium phosphates) are generally very fragile. This issue is 
important for ceramics, polymers and their composites used in both hard and soft tissue 
engineering. This concept, however, has been learnt from the applications of dense 
biomaterials. Whether mechanically stable materials are bioinert in highly porous foam 
is questionable, as bioreaction kinetics of a highly porous material in contact with body 
fluid can be remarkably different from that of a dense product of the same material due 
to the high surface area associated with the high porosity. The primary objective of this 
project is, therefore, to design and fabricate highly porous scaffolds that combine good 
mechanical stability with adequate biodegradability, using 45S5 Bioglass® and poly(D,L-
lactic acid), suitable foaming techniques and newly designed sintering processes. The 
mechanical properties, bioreactivity, and cell seeding/fostering ability (in vitro) of the 
scaffolds were carefully and systematically investigated. The final goal is to achieve an 
ideal scaffold for bone tissue engineering that can provide adequate mechanical support 
temporarily and degrade subsequently at a tailorable rate matching the formation rate of 
new bone tissue. 
This thesis is organised as follows. Chapter two provides a literature survey, aiming at 
rationalising the materials, techniques and strategies adopted in this project. Following 
the description of the experimental procedures (Chapter]), Chapters 4-7 present the 
research work carried out. These chapters are focussed on the fabrication/ 
characterisation, PDLLA-coating incorporation, surface functionalisation and cell 
culture of the Bioglass®-derived glass-ceramic scaffolds, respectively. To maintain the 
relative independency of these four chapters such that they are readable without 
referring to other chapters. Chapters 4-7 begin with an introduction to the research 
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background of their specific topics, then go on to describe and discuss results in detail, 
and end with conclusions. At the end of this thesis a summary is provided, and further 
work is recommended (Chapter 8). 
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CHAPTER TWO 
LITERATURE REVIEW: 
SCAFFOLDS FOR BONE TISSUE ENGINEERING 
A literature review is presented in this chapter regarding the biomaterials and techniques 
used for production of synthetic scaffolds in bone tissue engineering, aiming at 
rationalising the choices of biomaterials and scaffold fabrication techniques of porous 
templates, relevant to the research topic of this thesis. 
1. TISSUE ENGINEERING DEFINITION AND PRINCIPLES 
Tissue engineering, a term formally coined in 1987 has emerged as a distinct scientific 
field from the historical evolution of medicine. In this revolutionary development, the 
fundamental of health care in the conventional practice of medicine remains with us in 
tissue engineering, i.e., the body heals itself \ This principle is rooted in the truth that 
the organs of the body have an ability to regenerate and recover when they are diseased 
or injured. The regeneration, however, can only occur within limits such that recovery is 
almost impossible in many cases without medical manipulation. 
In conventional medical treatment, practitioners support a patient's vital functions by 
optimizing the environment most conductive to healing. Basically, physicians attempt 
to neutralise hostile factors and at the same time enhance the supply of oxygen and 
nutrients that the body needs for the healing process. Surgeons eliminate hostile factors 
through excising the necrotic or malign tissue that is the source of unfavourable 
chemical agents, reconstruct tissue through the suture of the remaining tissue, auto-
/allo-/xeno- transplantation, or implantation of prosthesis, and manipulate the local 
environment to help the body heal itself by, for example, medication and blood supply 
In tissue engineering, we strive to achieve exactly the same goal. Surgeons remove the 
dead or malign tissue. Rather than the remaining tissues being sutured, organs being 
transplanted or prosthesis being implanted; living cells are harvested and expanded in 
vitro, and a designed scaffold is used to dictate the regeneration of the shape and 
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function of the desired tissue by providing structural cues. Then the scaffold which is 
cultured with sufficient cells is implanted, and the tissue engineers and surgeons 
manipulate the local environment in precisely the same manner as the physician. Under 
ideal conditions, this will then enable the body to heal itself It is when the attention of 
medical treatment focused on the regeneration of living tissues for the body in the 
laboratory (i.e., ex vivo) that the reconstructive surgery came to be called tissue 
engineering In summary, tissue engineering induces the regeneration ability of the 
host body through a designed scaffold that is populated with cells and signalling 
molecules, aiming at regenerating functional tissue as an alternative to conventional 
organ transplantation and tissue reconstruction. 
The above definition of tissue engineering is a specific concept. Tissue engineering has 
been generally defined as the application of principles and methods of engineering and 
life sciences to obtain a fundamental understanding of structure-function relationships in 
normal and pathological mammalian tissue and the development of biological 
substitutes to restore, maintain, or improve tissue function Other similar definitions 
exist. In 1993 Langer and Vacanti defined tissue engineering as an interdisciplinary 
field that applies the principles of engineering and life sciences toward the development 
of biological substitutes that restore, maintain or improve tissue function. In 1995, 
Galletti, Hellman and Nerem ' defined tissue engineering as the basic science and 
development of biological substitutes for implantation into the body or the fostering of 
tissue remodelling for the purpose of replacing, repeating, regenerating, reconstructing, 
or enhancing biological function. 
2. RATIONALE FOR BONE TISSUE ENGINEERING 
There are several clinical reasons to develop bone tissue engineering. Although 
transplantation and implantation are standard methods in the conventional clinical 
treatment, shortcomings are encountered with their usage Firstly, the application of 
bone grafts is limited by the size of the defect and the viability of the host body. There 
can be significant donor site morbidity in autografting and donor tissue scarcity for 
allografting. Allografting also introduces the risk of disease and infection. Secondly, the 
revolution of implantation, which has led to a remarkable increase in the quality of life 
for millions of patients in the last 30 years, has run the course. The orthopaedic 
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prostheses have an excellent 15 years survivability of 75-85%. However, there is a 
requirement of longer than 30 years survivability by the aging population 
Tissue engineering will ultimately have a more profound impact on our life than we can 
now appreciate. Its technical significance lies in that this treatment will address the 
transplantation crisis caused by donor scarcity, immune rejection, and pathogen transfer 
This revolution will also reach a goal of more than 30 years implant survivability. 
3. TISSUE ENGINEERING APPROACHES 
The approaches of tissue engineering are established on the fact that living bodies have 
the potential of regeneration, and on the supposition that the employment of natural 
biology (e.g., cells and biomolecules) of the living body will maximise the capacity for 
regeneration and allow for greater success in developing therapeutic strategies aimed at 
the replacement, repair, maintenance, and enhancement of tissue function 
TISSUE ENGINEERING 
___ CONSTRUCT _ 
SIGNALS CELLS 
SCAFFOLDS 
Fig. 2.1 The tissue engineering triad' 
In essence, tissue engineering is a technique of imitating nature. Natural tissues consist 
of three components: cells, extracellular matrix (ECM), and signalling systems. The 
ECM is made up of a complex of cell secretions immobilised in spaces and thus 
forming a scaffold for its cells. Hence, it is natural that the engineered tissue construct is 
a triad the three constitutes of which correspond to the above mentioned three basic 
components of natural tissues. Fig.2.1 illustrates the triad, i.e., living cells, scaffolds, 
and signal molecules. 
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New functional living tissue is generated by living cells in the triad system, like in a 
natural biological system. But the regeneration in the engineered system is achieved 
with the guide of a scaffold. Such scaffolds can be natural, man-made, or a composite of 
both. The use of signalling molecules has a potential to markedly increase scaffold 
effectiveness. Living cells can migrate into the implant after implantation (acellular 
approach) or can be associated with the matrix in cell culture before implantation 
(cellular approach). Such cells can be isolated as fully differentiated cells of the tissue 
they are hoped to recreate, or they can be manipulated to produce the desired function 
when isolated from other tissues or stem cell sources. These two types of approaches in 
tissue engineering are summarised in Table 2.1 In both approaches, the tissue-like 
matrix (also called scaffolds or templates) to which specific cell types are attached 
either in vivo or in vitro is one of the most important components in the engineering of 
new functional tissues. 
Table 2.1 Two approaches of tissue engineering 6,12 
1. Acellular Approach 
This approach relies on guided regeneration of tissue materials that serve as 
templates for ingrowth of host cells and tissue in vivo. 
2. Cellular Approach 
This approach relies on cells that have been cultured with scaffold in vitro and 
then implanted as part of an engineered device. The success of such a cell-
based approach for tissue engineering of bone repair is critically dependent on 
the developments of an ECM-like scaffold for cell delivery 
4. CHALLENGES IN TISSUE ENGINEERING AND IDEAL SCAFFOLDS 
Tissue engineering involves many disciplines, including microanatomy; cell, molecular 
and developmental biology; immunology; materials science; and branches of 
engineering. Hence, the advancement of tissue engineering depends on the progresses of 
science and technology gained in these fields. Being a very much fledgling discipline, 
tissue engineering encounters a variety of challenges, which can be grouped into three 
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categories associated with the science and technology of cells, materials, and interaction 
between them, as summarised in Table 2.2 The challenges that the material scientists 
encounter are linked with the required properties of ideal scaffolds. An ideal scaffold 
should be a mimic ECM of the tissue that is to be engineered. For bone regeneration, the 
biggest challenge is a scaffold suitable to replace large cortical bone defects and capable 
of load transmission. The specific criteria for an ideal scaffold for bone regeneration are 
listed in Table 2.3. 
Table 2.2 Three categories of challenges in tissue engineering n 
1. Challenges associated with cells 
The understanding of cells and cell technology, including cell sourcing, the 
manipulation of cell function, and the future use of stem cell technology. The 
discovery that embryonic stem cells can be recovered from human foetal 
tissue and propagated for long period without losing their toti- or pluripotency 
has a huge impact on tissue engineering. Stem cells, together with signalling 
molecules, play an important role in tissue and organ development. How to 
direct their differentiation is a subject of high current interest. 
2. Challenges associated with biomaterials and scaffolds 
The design and fabrication of tissue-like materials to provide a scaffold or 
template. It has been documented that there are certain biocompatible 
materials that enable cells to be seeded onto a synthetic scaffold, and that 
some types of cells are capable of undergoing subsequent differentiation to 
generate new functional tissue after being cultivated in vitro and implanted 
with scaffold into living bodies. Bone cells are in this category. One of the 
challenges in bone tissue engineering is to develop ECM-like scaffolds that 
can deliver cells, provide proper mechanical stability, and be degradable at the 
desired rate until replaced by newly formed bone. 
3. Challenges associated with interaction between cells and scaffolds 
Integration into living systems. The interface between the cells and the 
scaffold must be clearly understood so (hat the interface can be optimized. 
Their design characteristics are major challenges for the field of bone tissue 
engineering, and should be considered at a molecular chemical level. 
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Table 2.3 Criteria of an ideal scaffold for bone engineering 13-15 
1. Ability to deliver cells 
The material should not only be biocompatible (i.e. harmless), but also 
foster cell attachment, differentiation, and proliferation. 
2. Osteoconductivity 
It would be best if the material encourages osteoconduction with host bone. 
Osteoconductivity not only eliminates the formation of encapsulating tissue 
but also brings about a strong bond between the scaffold and host bone. 
3. Biodegradability 
The composition of the material, combined with the porous structure of the 
scaffold, should lead to biodegradation in vivo at rates appropriate to tissue 
regeneration. 
4. Mechanical properties 
The mechanical strength of the scaffold, which is determined by both the 
properties of the biomaterial and the porous structure, should be sufficient to 
provide mechanical stability to constructs in load bearing sites prior to 
synthesis of new extracellular matrix by cells. 
5. Porous structure 
The scaffold should have an interconnected porous structure with porosity > 
90% and diameters between 300-500 |im for cell penetration, tissue 
ingrowth and vascularisation, and nutrient delivery. 
6. Fabrication 
The material should possess desired fabrication capability, e.g., being 
readily produced into irregular shapes of scaffolds that match the defects in 
bone of individual patients. 
7. Commercialisation 
The synthesis of the material and fabrication of the scaffold should be 
suitable for commercialisation. 
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5. SCAFFOLD MATERIALS FOR BONE TISSUE ENGINEERING 
The first step in achieving a successful scaffold is to design and produce a bone-matrix-
like biomaterial. Natural bone matrix is a composite composed of biological ceramic (a 
natural apatite) and biological polymer [See Appendix A for a description of bone 
tissue]. Table 2.4 gives a brief description of bone matrix composition. It is not 
surprising that polymers, ceramics, or their composites have been chosen for bone repair 
They can be either synthetic or naturally occurring. Table 2.5 lists synthetic and 
natural scaffold biomaterials that have been most widely investigated for bone 
regeneration, some of which are well-established and clinically applicable. In Table 2.5, 
the natural occurring polymers are grouped into (1) carbohydrates (polysaccharides) and 
(2) proteins, which are two of four types of biological molecules [the other two types 
are (3) nucleic acids and (4) lipids] In the following sections, the biocompatibility, 
biodegradability, and mechanical properties of these scaffold materials are reviewed. 
They are the most important factors to be considered in a design of a bone regeneration 
scaffold. 
Table 2.4 Composition of natural bone matrix 
1. Biological ceramic 
Carbonated hydroxyapatite Caio(P04)6(OH)2 accounts for nearly 2/3 of the 
weight of bone. The inorganic component provides compressive strength to 
bone. 
2. Biological Polymer 
Roughly 1/3 of the weight of bone is from collagen fibres. Collagen fibres 
are tough and flexible, and thus tolerate stretching, twisting, and bending. 
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Table 2.5 List of promising scaffold biomaterials for bone regeneration 
Biomaterial 
T W 
Abbreviation Application 
1. Ceramic 
Calcium phosphate 
Hydroxyapatite 
Tricalcium phosphate 
Biphasic calcium phosphate: HA and TCP 
Bio active glasses 
Bioglass® 
Phosphate glass 
Bioactive Glass-Ceramic 
Apatite-Wollastonite 
Ceravital® 
2. Polymer 
Synthetic degradable polymer 
Bulk biodegradable polymer 
Aliphatic polyester 
Poly(lactic acid) 
Poly(D-lactic acid) 
Poly(L-lactic acid) 
Poly(D,L-lactic acid) 
Poly(glycolic acid) 
Poly(lactic-co-glycolic acid) 
Poly(s-caprolactone) 
Poly(hydroxyalkanoate) 
Poly(3 or 4-hydroxybutyrate) 
Poly(3-hydroxyoctanoate) 
Poly(3 -hydroxyvalerate) 
Poly (p-dioxanone) 
Poly(propylene fumarate) 
Poly(l,3-trimethylene carbonate) 
Surface bioerodible polymer 
Poly(ortho ester) 
Poly (anhydride) 
Poly(phosphazene) 
Natural degradable polymer 
Polysaccharide 
Hyaluronan 
Alginate 
Gelatine 
Chitosan 
Protein 
Collagen 
Fibrin 
3. Composite ^ 
Selected combinations of above ceramics and 
polymers, as discussed in the relevant context 
CaP 
HA 
TCP 
BCP 
A/W 
PLA 
PDLA 
PLLA 
PDLLA 
PGA 
PLGA 
PCL 
PHA 
PHB 
PHO 
PHV 
PPD or PDS 
PPF 
PTMC 
POE 
PA 
PPHOS 
HyA 
Dental 
Drug delivery 
Scaffolds 
Dental 
Drug delivery 
Scaffolds 
Dental 
Drug delivery 
Scaffolds 
Sutures 
Dental 
Orthopaedic 
Drug delivery 
Scaffolds 
Drug delivery 
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5.1. BIOCERAMICS; CALCIUM PHOSPHATES 
5.1.1. Biocompatibility 
Since almost 2/3 of the weight of bone is hydroxyapatite Caio(P04)6(OH)2, it seems 
logical to use this ceramic as the major component of scaffold materials for bone tissue 
engineering. Actually, hydroxyapatite and related calcium phosphates (CaP) (e.g., (3-
tricalcium phosphate) have been intensively investigated As expected, calcium 
phosphates have an excellent biocompatibility due to their close chemical and crystal 
resemblance to bone mineral Although they have not shown osteoinductive ability, 
they certainly possess osteoconductive properties as well as a remarkable ability to bind 
directly to bone Huge amounts of in vivo and in vitro assessments have reported 
that calcium phosphates, no mater which forms (bulk, coating, powder, or porous) and 
which phases (crystalline or amorphous) they are in, always support the attachment, 
differentiation, and proliferation of cells (such as osteoblasts and mesenchymal cells), 
with hydroxyapatite being the best one among them . While the excellent biological 
performance of hydroxyapatite and related calcium phosphates has been well 
documented, the slow biodegradation of their crystalline phases and the weak 
mechanical strength of their amorphous states limit their application in engineering of 
new bone tissue, especially at load-bearing sites. 
5.1.2. Degradability 
Typically, crystalline calcium phosphates have long degradation time in vivo, often on 
the order of months, even years The dissolution rates of synthetic hydroxyapatite 
depends on the type and concentration of the buffered or unbuffered solutions; pH of the 
solution; degree of the saturation of the solution; solid/solution ratio; the length of 
suspension in the solution; and the composition and crystallinity of the hydroxyapatite. 
In the case of crystalline hydroxyapatite, the degree of micro- and macro-porosities, 
defect structure and amount and type of other phases present also have significant 
influence Crystalline hydroxyapatite exhibits the slowest degradation rate, compared 
with other calcium phosphates. The dissolution rate decreases in the following order 
Other amorphous CaP > Amorphous HA > other crystalline CaP > crystalline HA. 
5.1.3. Mechanical Properties 
In the body, the mechanical properties of natural bone change with their biological 
location because the crystallinity, porosity, and composition of bone adjust according to 
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their biological environment. The properties of synthetic calcium phosphates vary 
significantly with their crystallinity, grain size, porosity, and composition (e.g., calcium 
deficiency) as well. In general, the mechanical properties of synthetic calcium 
phosphates decrease significantly with increasing content of amorphous phase, 
microporosity, and grain size. High crystallinity, low porosity, and small grain size tend 
to give higher stiffness, higher compressive and tensile strength, and greater fracture 
toughness \ It has been reported that the flexural strength and fracture toughness of 
dense hydroxyapatite are much lower in a dry condition than in a wet condition 
If we compare the properties of hydroxyapatite and related calcium phosphates with 
those of bone (Table 2.6), we find that bone has a reasonably good compressive strength 
though it is lower than that of hydroxyapatite, and better tensile strength and 
significantly better fracture toughness than hydroxyapatite. The apatite crystals in bone 
tissue make it strong enough to tolerate compressive loading. The high tensile strength 
and fracture toughness of bone are attributed to the tough and flexible collagen fibres. 
Hence, calcium phosphates alone cannot be used for load-bearing scaffolds in spite of 
its good biocompatibility and osteoconductivity. 
Table 2.6 Comparison of mechanical properties of calcium phosphates and human bone 
Ceramics Compressive Tensile Elastic Fracture Reference 
Strength Strength Modulus Toughness 
/MPa /MPa / GPa /MPaVm 
C ^ c i i ^ 20-900 30-200 30-103 <1.0 
Phosphates 
Hydroxyapatite >400 ~40 -100 ~ 1.0 
Cortical Bone 130-180 50-151 12-18 6-8 
44-47 
5.2. BIOCERAMICS: BIOACTIVE SILICATE GLASSES 
5.2.1. Biocompatibility 
As early as in 1969, Hench and colleagues discovered that certain silicate glass 
compositions had excellent biocompatibility as well as the ability of bone bonding 
Through interfacial and cell-mediated reactions, bioactive glass develops a calcium-
deficient, carbonated calcium phosphate surface layer that allows it to chemically bond 
to host bone. This bone-bonding behaviour is referred to as bioactivity and has been 
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associated with the formation of a carbonated hydroxyapatite layer on the glass surface 
when implanted or in contact with biological fluids The stages that are involved in 
forming the bone bond of bioactive glasses and bioactive glass-ceramics were 
summarised by Hench as shown in Fig. 2.2. Although many details remain unknown at 
present, it is clearly recognized that for a bond with bone tissue to occur a layer of 
biologically active carbonated hydroxyapatite (CHA) must form (stages 4 and 5). This 
conclusion is based on the finding that CHA is the only common characteristic of all the 
known bioactive implant materials Bioactivity is not an exclusive property of 
bioactive silicate glasses. Hydroxyapatite and related calcium phosphates also show an 
excellent ability to bond to bone, as discussed above. The capability of an implant to 
form a biological interface with surrounding tissue is critical in elimination of scaffold 
loosening. 
Bioactive glasses have also been found to support enzyme activity vascularization 
foster osteoblast adhesion, growth, and differentiation; induce the differentiation of 
mesenchymal cells into osteoblasts and osteoconductivity 
A significant finding for the development of bone engineering is that the dissolution 
products from bioactive glasses exert a genetic control over osteoblast cycle and rapid 
expression of genes that regulate osteogenesis and the production of growth factors 
Silicon has been found to play a key role in the bone mineralization and gene activation, 
which has led to the substitution of silicon for calcium into synthetic hydroxyapatite. 
Investigations in vivo have shown that bone ingrowth into silicon-substituted HA 
granules was remarkably greater than that into pure HA 
The above-mentioned advantages make the well-known 45S5 Bioglass® successfully 
applied in clinic as treatment of periodontal disease (PerioGlas®) and as a bone filler 
material (NovaBone®) Bioglass® implants have also been used to replace damaged 
middle ear bones, restoring hearing to patients Recently bioactive glasses have 
gained attention as promising scaffold materials But this application has 
encountered a hurdle caused by an apparent conflict between the properties of 
biodegradability and mechanical reliability, which will be discussed in the next two 
sections 5.2.2 and 5.2.3, respectively. 
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Bioactive glass 
Fig. 2.2 Sequence of interfacial reactions involved in forming a bond between bone and 
bioactive ceramics and glasses 52 ,70 
5.2.2. Composition and Biodegradability 
The basic constituents of the most bioactive glasses are SiOz, NaiO, CaO, and P 2 O 5 . 
The well-known 45S5 Bioglass® (first bioactive composition) contains 45% SiOz, 
24.5% NaaO, 24.4% CaO and 6 % P 2 O 5 , in weight percent. The bioreactivity of the 
material is composition-dependent. Hench and co-workers have systematically 
studied a series of glasses in the four-component systems with a constant 6 wt. % P2O5 
content. This work is summarised in the ternary SiOi-NazO-CaO diagram shown in Fig. 
2.3. In region A the glasses are bioactive and bond to bone. In region B, glasses are 
nearly-inert when implanted. Compositions in region C are resorbed within 10-30 days 
in tissue. In region D the compositions are not technically practical. 
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Sip2 
A-WGC 
(high PiOs) 
CaO NaiO 
Fig. 2.3 Compositional dependence (in weight %) of bone bonding and soft tissue 
bonding of bioactive glasses and glass-ceramics. Bioactivity index Is is defined 
as /g = 1 0 0 / ^ 5 , where 5 is the time taken for 50% of the interface to bond to bone. All 
compositions have a constant 6 wt % of P 2 O 5 . In region A the glasses are bioactive and 
bond to bone. In region B, glasses are nearly-inert when implanted. Compositions in 
region C are resorbed within 10-30 days in tissue. In region D the compositions are not 
teclinically practical. In the region where /b > 8 (called region E), soft tissue bonding 
occurs. Apatite-wollastonite glass ceramic (A-WGC) has higher P 2 O 5 content, 52 
The key advantage that makes bioactive glasses promising scaffold materials is the 
possibility of controlling a range of chemical properties and thus the rate of 
bioresorption. The structure and chemistry of glasses, in particular sol-gel derived 
glasses can be tailored at a molecular level by varying either composition, or 
thermal or environmental processing history. It is possible to design glasses with 
degradation properties specific to a particular application of bone tissue engineering. 
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However, it was reported that crystaUisation of bioactive glasses decreased the level of 
bioactivity and even turned a bioactive glass into an inert material This is one of 
disadvantages that limit the application of bioactive glasses as scaffold materials, as full 
crystallisation happens prior to significant densification upon heat-treatment (i.e. 
sintering) Extensive sintering is necessary to densify the struts of a scaffold, which 
would otherwise be made up of loosely packed particles and thus too fragile to handle. 
5.2.3. Mechanical Properties 
The primary disadvantage of bioactive glasses is their mechanical weakness and low 
fracture toughness (Table 2.7) due to their amorphous structure. Hence, bioactive 
glasses alone have limited application in load-bearing situations owing to poor 
mechanical strength that mismatch with surrounding bone. However, these materials 
can be used in combination with polymers to form composite materials having bone 
repair potential 
Table 2.7 Mechanical properties of hydroxyapatite, 45S5 Bioglass®, glass-ceramics, and 
human cortical bone 
Ceramics 
Compression 
Strength 
/ M P a 
Tensile Elastic Fracture 
Strength Modulus Toughness Reference 
/ M P a / G P a / M P a V m 
Hydroxyapatite 
45S5 Bioglass® 
A-W 
Parent Glass of 
A-W 
Bioverit®! 
Cortical Bone 
- 6 0 0 
1080 
NA 
500 
130-180 
- 4 0 
42 
215(bend) 
72 (bend) 
140-180 
(bend) 
50-151 
-100 ~ 1.0 40,43 
35 0.5-1 43,74 
118 2.0 27 
NA 0.8 27 
70-90 1.2-2.1 75 
12-18 6-8 44-47 
5.3. BIOCERAMICS: GLASS-CERAMICS 
Glass-ceramics are fine-grained polycrystalline materials formed when glasses of 
suitable compositions are heat treated and thus undergo controlled crystallisation to the 
lower energy, crystalline state. Only specific glass compositions are suitable precursors 
for glass-ceramics, such as some bioactive glasses. Some glasses are too stable and 
difficult to crystallise (e.g. window glass), whereas other crystallise too readily in an 
uncontrollable manner resulting in undesirable microstructures 
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Usually a glass-ceramic is not fully crystalline; typically the microstructure is 50-95 vol. 
% crystalline with the reminder being residual glass. The mechanical properties of 
glass-ceramics are superior to those of the parent glass Almost all bioactive glasses 
can be strengthened by the formation of crystalline particles upon heat-treatment into a 
glass-crystal region of its phase diagram The resultant glass-ceramics can exhibit 
better mechanical properties than both the parent glass and sintered crystalline ceramics 
(Table 2.7). There are many biomedical glass-ceramics available for the repair of 
damaged bone. Among them, apatite-wollastonite (A-W), Ceravital®, and Bioverity® 
glass-ceramics have been intensively investigated 8^,19,27-29,75-8] 
5.3.1. A-W Glass-Ceramic 
In A-W glass-ceramic, the glass matrix is reinforced by P-wollastonite (CaSiO]) and a 
small amount of apatite phase, which precipitate successively at 870°C and 900°C, 
respectively Some mechanical properties of this glass-ceramic have been listed in 
Table 2.7. The high bending strength (215 MP a) of A-W glass-ceramic is due to the 
precipitation of the wollastonite as well as apatite. These two precipitates also give the 
glass-ceramic a higher fracture toughness than both the glass and ceramic phases. It is 
believed that the wollastonite effectively prevents straight propagation of cracks, 
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causing them to turn or branch out ' ' . 
A-W glass-ceramic is capable of binding tightly to living bone in a few weeks after 
implantation, and the implants do not deteriorate in vivo The excellent bone-bonding 
ability of A-W glass-ceramic is attributed to the glass matrix and apatite precipitates, 
whereas the in vivo stability as a whole plant is due to the inertness of P wollastonite. 
Although the long-term integrity in vivo is desirable in the application of non-resorbable 
prosthesis, it does not match the goal of tissue engineering which demands 
biodegradable scaffolds. 
5.3.2. Ceravitaf' Glass-Ceramics^^ 
"Ceravital" was coined to mean a number of different compositions of glasses and 
glass-ceramics and not only one product. Their basic network components include SiOa, 
Ca(P02)2, CaO, Na^O, MgO and K2O, with ceramic additions being A I 2 O 3 , Ta205, 
TiOi, B 2 O 3 , A1(P03)3, SrO, La203, or GdiO]. This material system was developed as 
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solid fillers in the load bearing conditions for the replacement of bone and teeth. It 
turned out, however, that their mechanical properties do not serve the purpose. 
The surface bioreactivity of Ceravital® products is such that the long -term stability of 
the materials is eventually endangered by the process. However, this degradability is a 
favourite property in tissue engineering application. 
5.3.3. Bioverit® Glass-Ceramics 
Bioverit® products are mica-apatite glass-ceramics. Mica crystals (aluminium silicate 
minerals) give the materials good machinability, and apatite crystals ensure the 
bioactivity of the implants. The mechanical properties of Bioverit® materials (Table 2.7) 
allow them to be used as fillers in dental application. As regards bioreactivity, Bioverit® 
implants show a hydrolytic stability in vivo. 
5.4. NATURALLY OCCURRING BIOPOLYMERS 
Much research effect has been focused on naturally occurring polymers such as 
demineralised bone extracellular matrix (ECM) purified collagen and chitosan 
for tissue engineering applications. Theoretically, naturally occumng polymers 
should not cause foreign materials response when implanted in humans. They provide a 
natural substrate for cellular attachment, proliferation, and differentiation in its native 
state. For the above-mentioned reasons, natural occurring polymers could be a favourite 
substrate for tissue engineering Table 2.8 presents some of the naturally occurring 
polymers, their sources and applications. Among them, collagen and chitosan are most 
widely investigated for bone engineering and are briefly introduced here. 
5.4.1. Collagen and ECM-Based Materials 
The most commonly used naturally occurring polymers have been the structural protein 
collagen. Biomaterials derived from ECM include collagen and other naturally 
occurring structural and functional proteins. Natural polymers must be modified and 
sterilised before clinic use. All methods of stabilisation and sterilisation can moderately 
or severely alter the rate of in vivo degradation and change the mechanical and physical 
properties of the native polymers. Each method has certain advantages and 
disadvantages, and thus should be selectively utilised for scaffolds of specifically sited 
bone tissue engineering 
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Table 2.8 List of naturally occurring polymers and their main application fields 87 
Polymer Source Main Application Fields 
Collagen Tendons and 
ligament 
Multi-applications, including bone 
tissue engineering 
Collagen-GAG 
(Alginate) Copolymers 
Artificial skin grafts for skin 
replacement 
Albumin In blood Transporting protein, used as coating 
to form a thromboresistant surface 
Hyaluronic Acid In the ECM of 
all higher 
animals 
An important starting material for 
preparation of new biocompatible and 
biodegradable polymers that have 
applications in drug delivery, tissue 
engineering, and 
viscosupplementation 
Fibrinogen-Fibrin Purified from 
plasma in blood 
Multi-applications, including bone 
tissue engineering 
Chitosan Shells of shrimp 
and crabs 
Multi-applications, including bone 
tissue engineering 
Polyhydroxyalkanoates By fermentation Cardiovascular and bone tissue 
engineering 
5.4.2. Chitosan 
The use of chitosan for bone tissue engineering has been widely investigated This 
is in part due to the apparent osteoconductive properties of chitosan. Mesenchymal stem 
cells cultured in the presence of chitosan have demonstrated an increased differentiation 
to osteoblasts compared to cell cultured in the absence of chitosan It is also 
speculated that chitosan may enhance osteoconduction in vivo by entrapping growth 
factors at the wound site 
5.5. SYNTHETIC POLYMERS 
Although naturally occurring polymers possess the above mentioned advantages, their 
poor mechanical properties and variable physical properties with different sources of the 
protein matrices have hampered progress with these approaches. Concerns have also 
arisen regarding immunogenic problems associated with the introduction of foreign 
collagen 
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Following the developmental efforts using naturally occurring polymers as scaffolds, 
much attention has been paid to synthetic polymers. Synthetic polymers are thought to 
have a future in tissue engineering due to not only their excellent processing 
characteristics, which can ensure the off-the-shelf availability; but also their advantage 
of being biocompatible and biodegradable Synthetic polymers have predictable and 
reproducible mechanical and physical properties (e.g., tensile strength, elastic modulus, 
and degradation rate), and can be manufactured with great precision. Although they are 
unfamiliar to cells and many suffer some shortcomings, such as eliciting persistent 
inflammatory reactions, being eroded, incompliant or unable to integrate with host 
tissues, they may be replaced in vivo in a timely fashion by native tissue. It has become 
widely realised that an ideal tissue engineered bone substitute should be a synthetic 
scaffold, which is biocompatible and provides for cell attachment, proliferation and 
maturation, has mechanical properties to match those of the tissues at the site of 
implantation, and degrades at rates to match tissue replacement. Table 2.9 lists selected 
properties of synthetic, biocompatible polymers that have been intensively investigated 
as scaffold materials for tissue engineering, type I collagen fibres being included for 
comparison. 
5.5.1. Bulk Degradable Polymers 
5.5.1.1. Saturated poly-a-hydroxy esters (PLA, PGA and PCL) 
The biodegradable synthetic polymers most often utilised for three-dimensional scaffold 
in tissue engineering are the poly(a-hydroxy acids), including poly(lactic acid) (PLA) 
and poly(glycolic acid) ( P G A ) , as well as poly(lactic-co-glycolide) ( P L G A ) copolymers 
P L A exists in three forms: L - P L A ( P L L A ) , D - P L A ( P D L A ) , and racemic mixture of 
D . L - P L A ( P D L L A ) . 
These polymers remain popular for a variety of reasons, among which biocompatibility 
and biodegradability are the first. These materials have chemical properties that allow 
hydrolytic degradation through de-esterification. Once degraded, the monomeric 
components of each polymer are removed by natural pathways: PGA can be converted 
to other metabolites or eliminated by other mechanisms, and PLA can be cleared 
through tricarboxylic acid cycle. The body already contains highly regulated 
mechanisms for completely removing monomeric components of lactic and glycolic 
acids. Due to these properties, PLA and PGA have been used in products such as 
degradable sutures and have been proved by US food and drug administration (FDA) 
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Other properties of special interest are that they have very good processability, and that 
a wide range of degradation rates, physical, mechanical and other properties can be 
achieved by PLA and PGA of various molecular weights and its copolymers. However, 
these polymers undergo a bulk erosion process in contact with body fluids such that 
they can cause scaffolds to fail prematurely. In addition, abrupt release of these acidic 
degradation products can cause a strong inflammatory response 
In general, PGA degrades faster than PLA, as listed in Table 2.9. Their degradation 
rates decrease in the following order. 
PGA > PDLLA > PLLA 
Degradation rates decrease 
Table 2.9 also lists the mechanical properties of type I collagen, which is the major 
organic component of extracellular matrix in bone. The strength and ductility (e.g. 
ultimate elongation) of PLA and PGA are comparable to those of type I collagen 
fibbers. 
PDLLA has been extensively investigated as a biomedical coating material because of 
its excellent features with respect to implant coating In addition to its high 
mechanical stability PDLLA also shows excellent biocompatibility in vivo and good 
osteoinductive potential PDLLA of low molecular weight can be combined with 
drugs like growth factors antibiotics or thrombin inhibitor to establish a 
locally acting drug-delivery system. It is because of these desirable features that much 
more attention has recently been paid to PDLLA for applying it as a scaffold material 
for tissue engineering. 
Highly porous 3D scaffolds made of Bioglass®-filled PDLLA and PLGA were first 
fabricated by Boccaccini et al Since then an increasing number of publications have 
emerged on this subject. Porous PDLLA foams and Bioglass®-filled PDLLA composite 
foams have both been fabricated, using thermally-induced-phase-separation (TIPS) 
technique Bioglass®-filled PDLLA composite foams exhibit high bioactivity, 
assessed by the formation of HA on the strut surfaces upon immersion in SBF It has 
also been shown that the foams support the migration, adhesion, spreading and viability 
of MG-63 cells (osteosarcoma cell line) 
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Table 2.9 Physical properties of synthetic, biocompatible, and biodegradable polymers investigated as scaffold materials 
Polymers Melting 
Point Jm / 
°C 
Glass 
Transition 
Point Tg / °C 
Degradation 
Time / 
months 
Tensile or 
Compressive 
Strength / MPa 
Modulus / GPa Ultimate 
Elongation (%) 
Ref 
1. Bulk degradable polymers 
PDLLA Amorphous 
PLLA 
PGA 
PLGA 
PPF 
PCL 
PHB 
173-178 
225-230 
Amorphous 
55-60 
60-65 
35-40 
45-55 
58 
177 
2. Surface erodative polymers 
Poly(anhydrides) 150-200 
Poly(ortho-esters) 30-100 
Polyphosphazene -66-50 
3. Type I collagen 
-72 
242 
12-16 
>24 
6-12 
Adjustable 
Bulk 
Bulk 
Surface 
Surface 
Surface 
Bulk 
Pellet: 35-150 
Film or disk: 29-35 
Pellet: 40-120 
Film or disk: 28-50 
Fibre: 870- 2300 
Fibre: 340-920 
41.4-55.2 
2 - ^ * _ 
To-15 
Very slow 25-45_ 
Film or disk: 1.9-2.4 
Film or disk: 1.2-3.0 
Fibre: 10-16 
Fibre: 7-14 
1.4-2.8 
25-27 
30-40* 
4-16* 
NA 
Uncross-linked fibre: 
0.91-7.2 
Cross-linked fibre: 
46.8-68.8 
Pellet: 0.5-8.0 
Film or disk: 5.0-6.0 
Pellet: 2.0-10.0 
Film or disk: 2.0-6.0 
Fibre: 12-26 
Fibre: 15-25 
3-10 
0.15-^33 
1 3 - T . ^ " 
0,14-1.4 
2.5-4.4 
Uncross-linked fibre: 
1X^46x10^ 
Cross-linked fibre: 
0.383-0.766 
400-1200 
25 
NA 
NA 
NA 
Uncross-linked fibre: 
24.1-68.0 
Cross-linked fibre: 
11.6-15.6 
92,108,109 
92,108 
92,110,111 
29 
29,31 
n2-TT4 " 
iisrng 
29,31,117 
29,118 
119,120 
121 
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Poly(8-caprolactone) (PCL) is also an important member of the aliphatic polyester 
family. It has been used to effectively entrap antibiotic drugs and thus a construct made 
with PCL can be considered as a drug delivery system, being used to enhance bone 
ingrowth and regeneration in the treatment of bone defects The degradation of 
PCL and its copolymers involves similar mechanisms to PLA, proceeding in two stages: 
random hydrolytic ester cleavage and weight loss through the diffusion of oligometric 
species from the bulk. It has been found that the degradation of PCL system with a high 
molecular weight ( M „ o f 50,000) is remarkably slow, requiring 3 years for complete 
removal from the host body 
5.5.1.2. Polyhydroxyalkanoates (PHB, PHBV, P4HB, PHBHHx, PHO) 
Recently, another type of polyesters: polyhydroxyalkanoates (PHAs) have been 
suggested for tissue engineering due to their controllable biodegradation and high 
biocompatibility They are aliphatic polyesters as well, but produced by 
microorganisms under unbalanced growth conditions They are generally 
biodegradable (via hydrolysis) and thermo-processable, making them attractive as 
biomaterials for applications in medical devices and tissue engineering. Over the past 
years, PHA, particularly poly 3-hydroxybutyrate (PHB), copolymers of 3-
hydroxybutyrate and 3-hydroxyvalerate (PHBV), poly 4-hydroxybutyrate (P4HB), 
copolymers of 3-hydroxybutyrate and 3-hydroxyhexanoate (PHBHHx) and poly 3-
hydroxyoctanoate (PHO) were demonstrated to be suitable for tissue engineering and 
are reviewed in detail in ref 
Dependent on the property requirement by different applications, PHA polymers can be 
either blended, surface modified or composed with other polymers; enzymes or 
inorganic materials to further adjust their mechanical properties or biocompatibility. 
The blending among the several PHA themselves can change dramatically the material 
properties and biocompatibility 
PHB is of particular interest for bone tissue application as it was demonstrated to 
produce a consistent favourable bone tissue adaptation response with no evidence of an 
undesirable chronic inflammatory response after implantation periods up to 12 months. 
Bone is formed close to the material and subsequently becomes highly organized, with 
up to 80% of the implant surface lying in direct apposition to new bone. The materials 
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showed no evidence of extensive structural breakdown in vivo during the implantation 
period of the study 
However, a drawback of some PHA polymers is their limited availability and the time 
consuming extraction procedure from bacteria cultures that is required for obtaining 
sufficient processing amounts as described in the literature Therefore, the 
extraction process might be a challenge to a cost effective industrial upscale production 
for large amounts of some PHA polymers. 
5.5.1.3. Polypropylene fumarate (PPF) 
Poly(propylene fumarate) (PPF) is an unsaturated linear polyester. Similarly to PLA and 
PGA, the degradation products of PPF via hydrolysis (i.e., propylene glycol and fumaric 
acid) are biocompatible and readily removed from the body. The double bond along the 
backbone of the polymer permits cross-linking in situ, which causes a mouldable 
composite to harden within 10-15 minutes. Mechanical properties and degradation time 
of the composite may be controlled by varying the PPF molecular weight. Therefore, 
preservation of the double bonds and control of molecular weight during PPF synthesis 
are critical issues PPF has been suggested for use as scaffold for guided tissue 
regeneration, often as part of an injectable bone replacement composite and has 
been used as a substrate for osteoblast culture 
5.5.2. Surface Bioeroding Polymers 
There is a family of hydrophobic polymers that undergo a heterogeneous hydrolysis 
process that is predominantly confined to the polymer-water interface. This property is 
referred to as surface eroding as opposed to bulk degrading behaviour. These surface 
bioeroding polymers have been intensively investigated as drug delivery vehicles. The 
surface-eroding characteristics offers three key advantages over bulk degradation when 
used as scaffold materials; (1) retention of mechanical integrity over the degradative 
lifetime of the device, owing to the maintenance of mass to volume ratio, (2) minimal 
toxic effects (i.e., local acidity), owing to lower solubility and concentration of 
degradation products, and (3) significantly enhanced bone ingrowth into the porous 
scaffolds, owing to the increment in pore size as the erosion proceeds 
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Poly(anhydrides) 
Poly(l,3-bis-p-carboxyphenoxypropane anhydride) and poly (erucic acid dimer 
anhydride) are biodegradable polymers for controlled drug delivery in a form of 
implant or injectable microspheres. Studies in rabbits have shown that the 
osteocompatibility of poly(anhydrides) that undergo photocuring are comparable to 
PLA and that the implants of poly(anhydrides) show enhanced integration with 
surrounding bone in comparison to PLA controls 
Poly(ortho-esters) (POE) 
POE scaffolds were coated with cross-linked acidic gelatine to improve surface 
properties for cell attachment. Preliminary in vitro and in vivo results revealed that POE 
showed no inflammation and had little or no effect on bone formation while PLA 
provoked a chronic inflammatory response and inhibited bone formation 
Polyphosphazenes 
These polymers have shown promise as bioerodible materials capable of controlled 
degradation and sustained drug delivery for therapeutic and bone regeneration 
140,141 tailored side groups enable a wide variety of hydro lytic properties to be 
designed into selected polymers for applications in biological environments without the 
release of harmful degradation products at physiological concentration. 
5.6. BIOCOMPOSITES 
From a biological perspective, it is a natural strategy to combine polymers and ceramics 
to fabricate scaffolds for bone tissue engineering because native bone is the combination 
of a naturally occurring polymer and biological apatite. From the materials science point 
of view, a single material type does not always provide the necessary mechanical and/or 
chemical properties desired for a particular application. In these instances, composite 
materials designed to combine the advantages of both materials may be most 
appropriate. Polymers and ceramics that degrade in vivo should be chosen for designing 
biocomposites for tissue engineering scaffolds. While massive release of acidic 
degradation from polymers causes inflammatory reactions the basic 
degradation of calcium phosphate or bioactive glasses would buffer the acidic by-
products of polymers and may thereby help to avoid the formation of an unfavourable 
environment for cells due to a decreased pH. Mechanically, bioceramics are much 
stronger than polymers and play a critical role in providing mechanical stability to 
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constructs prior to synthesis of new bone matrix by cells. However, as mentioned above, 
ceramics and glasses are very fragile due to their intrinsic brittleness and flaw 
sensitivity. To capitalise on their advantages and minimise their shortcomings, ceramic 
and glass materials can be combined with various polymers to form composite 
biomaterials for osseous regeneration. Table 2.10 lists selected ceramic/glass-polymer 
composites, which were designed as biomedical devices or scaffold materials for bone 
tissue engineering, and their mechanical properties. 
In general, all these synthetic composites have good biocompatibility. Kikuchi et al, for 
instance, combined TCP with FLA to form a polymer-ceramic composite, which was 
found to possess the osteoconductivity of P-TCP and the degradability of PLA 
The research team led by Laurencin synthesized porous scaffolds containing PLGA and 
HA, which was reported to combine the degradability of PLGA with the bioactivity of 
HA, fostering cell proliferation and differentiation as well as mineral formation 
The composites of bioactive glass-PLA were observed to form calcium phosphate layers 
on their surfaces and support rapid and abundant growth of human osteoblasts and 
osteoblast-like cells when culture in vitro 6 '^i04-io7,i48-is4 
A comparison between the dense composites and cortical bone indicates that the most 
promising synthetic composite seems to be HA fibre-reinforced PLA composites 
which however exhibit mechanical property values close to the lower values of the 
cortical bone. Up to now, the best composite scaffolds reported in literature seem to be 
those from Bioglass® and PLLA or PDLLA They have a well-defined 
porous structure, at the same time their mechanical properties are close to (but lower 
than) those of cancellous bone. 
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Table 2.10 Biocomposites designed for bone tissue engineering 
Biocomposite Percentage Porosity Pore Compressive (C), Modulus Ultimate Toughness Ref. 
Ceramic Polymer of ceramic (%) (%) size / nm 
Tensile(T), 
Flexural (F), 
Bending (B) 
Strength / MPa 
/ MPa strain (%) / kJ/m^ 
1. Dense Composites 
HA fibre PDLLA 2-10.5 (vol.) 45(F) 1.75-2.47x103 156 
PLLA 10-70 (wt.) 50-60 (F) 6.4-12.8x103 0.7-2.3 155 
HA PLGA 40-85 (vol.) 22(F) l.lxlO^ 5 2 9 157-159 
Chitosan 40-85 (vol.) 12(F) 2.15x10^ 0.092 158 
Chitosan+PLGA 
PPhos 
40-85 (vol.) 
85-95 (wt.) 
Not Applicable 43(F) 2.6x10^ 9 J 7 
158 
160 
Collagen 50-72 (wt.) 161 
p-TCP PLLA-co-PEH 75 (wt.) 5 1 0 0 5.18x10^ 144 
PPF 25 (wt.) 7.5-7.7 (C) 191-134 162 
A/W PE 10-50 (vol.) 18-28 (B) 0.9-5.7x10^ 163-165 
Ca3(C03)2 PLLA 
Human Cortical Bone 
30 (wt.) 
70(wt.) 
50 
50-150(T) 
3.5^6x103 
12-18x103 
166 
44-47 
130-180 (C) 
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Table 2.10 Continued 
2. Porous composites 
Amorphous CaP PLGA 28-75 75 > 1 0 0 65 167,168 
(wt.) 
P-TCP Chitosan- 10-70 322-355 0.32-0.88 (C) 3.94-10.88 169 
Gelatin (wt.) 
170 HA PLLA 50 (wt.) 85-96 100x300 0 3 9 ( C ) 10-14 
PLGA 60-75 81-91 800-1800 0.07-0.22 (C) 2/A5 171 
(wt.) 
147 PLGA 30-40 110-150 337-1459 
Bioglass® PLGA 75 (wt.) 43 89 0.42 (C) 51 65,148,149 
PLLA 20-50 77-80 ~ lOO(macro) 1.5-3.9 (T) 137-260 1.1-13.7 150 
(wt.) ~ lO(micro) 
PLGA 0.1-1 (wt.) 50-300 151 
PDLLA 5-29 (wt.) 94 ~ lOO(macro) 0.07-0.08 0.65-1.2 7.21-13.3 106,107,152 
10-50(micro) 
153 Phosphate Glass PLA-PDLLA 40 (wt.) 93-97 
A/W PDLLA 20-40 85.5-95.2 98-154 0.017-0.020 (C) 0.075-0.12 
(va) 
172-174 Human Cancellous Bone 4-12 (C) 100-500 1.65-2.11 
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5.7. SUMMARY 
While the ideal tissue engineered bone substitute should be a material, which is 
bioresorbable, biocompatible and supports cell attachment, proliferation and maturation, 
and which is ultimately resorbed once new bone has formed allowing this bone to 
undergo remodelling, this goal has not been achieved so far. Material scientists must 
continue to strive to design and fabricate a synthetic material so as to make the dream of 
a "tissue engineered bone substitute" a reality. To design a composite scaffold, it is 
necessary to weight up the "pros and cons" of the potential precursor materials, which 
are summarised in Table 2.11. Among the bioactive ceramics and glasses listed in Table 
2.11, bioactive (silicate) glasses offer remarkable advantages. The ability to enhance 
vascularization, the role of silicon in rapid gene expression that regulate osteogenesis, 
and the tailorable degradation rate make bioactive glasses promising scaffold materials 
over others, and thus they are the material of choice as the inorganic component of 
composite scaffolds in this study. Although bioactive glasses are brittle with low 
fracture toughness (Table 2.7), these materials can be used in combination with 
polymers to form composite materials. 
It can be argued that the controllable biodegradability of bioactive glasses makes them 
advantageous over HA and related crystalline calcium phosphates. Nano-sized 
carbonated HA is a stable component of natural bone, though it metabolises like all 
tissues. Hence, it would be fundamentally wrong if one expected HA to degrade fast in 
a physiological environment. In fact, it has been well-documented in the literature that 
HA degrades very slowly, nearly inert This should make HA less favoured as a 
scaffold material for use in tissue engineering. The degradation rates of amorphous HA 
and TCP are high, but they are too fragile to build a 3D porous network. 
Between the two types of polymers: the bulk degradable type is more promising than 
the surface-erosive group, considering that being replaced by new bone tissue is one of 
the important criteria of an ideal scaffold material (Table 2.3). Among these bulk-
degradable polymers, amorphous PDLLA is one of the most interesting materials as a 
polymer component of scaffolds because it can be combined with biomolecules, such as 
growth factors and antibiotics to establish a locally acting drug-delivery system. 
It is expected that the local drug-delivery system will promote bone regeneration and 
eliminate inflammatory responses upon scaffold degradation. 
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Table 2.11 Advantages and disadvantages of synthetic scaffold biomaterials in bone tissue engineering 
Biomaterial Positive Negative 
Calcium phosphates 
(e.g. HA, TCP, and biphase CaP) 
Bioactive silicate glasses 
Bioactive glass-ceramics 
(e.g. A-W) 
Bulk biodegradable polymers 
Poly(lactic acid) 
Poly(glycolic acid) 
Poly(lactic-co-glycolic acid) 
Poly(propylene fumarate) 
Surface bioerodible polymers 
Poly(ortho esters) 
Poly(anhydrides) 
Poly(phosphazene) 
Composites 
(containing bioactive phases) 
(1) Excellent biocompatibility. 
(2) Supporting cell activity. 
(3) Good osteoconductivity. 
(1) Excellent biocompatibility. 
(2) Supporting cell activity. 
(3) Good osteoconductivity. 
(4) Vascularization. 
(5) Rapid gene expression. 
(6) Tailorable degradation rate. 
(1) Brittle. 
(2) They biodegrade too slowly in the 
crystalline state and are mechanically 
too weak in the amorphous state. 
(1) Mechanically brittle and weak 
(1) Excellent biocompatibility. 
(2) Supporting cell activity. 
(3) Good osteoconductivity. 
(1) Brittle. 
(2) Too slow degradation rate. 
(1) Good biocompatibility. 
(2) Biodegradable (with a wide range of degradation rates). 
(3) Bioresorbable. 
(4) Good processability. 
(5) Good ductility. 
(1) Inflammatory caused by acid 
degradation products. 
(2) Accelerated degradation rates cause 
collapse of scaffolds 
(1) Good biocompatibility. 
(2) Retention of mechanical integrity over the degradative 
lifetime of the device. 
(3) Significantly enhanced bone ingrowth into the porous 
scaffolds, owing to the increment in pore size. 
(1) Excellent biocompatibility. 
(2) Supporting cell activity. 
(3) Good osteoconductivity. 
(4) Tailorable degradation rate. 
(5) improved mechanical properties 
(1) They cannot be completely replaced by 
new bone tissue. 
(1) Still not as good as natural bone matrix. 
(2) Fabrication techniques can be complex. 
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6. TECHNOLOGY OF SCAFFOLD FABRICATION 
6.1. DESIGN PARAMETERS OF THREE-DIMENSIONAL SCAFFOLDS 
In an organ, cells and their extracellular matrices (ECM) are usually organised into 
three-dimensional tissues. Therefore, in tissue engineering a highly porous 3-
dimensional matrix (scaffold) is often necessary to accommodate cells and to guide their 
growth and tissue regeneration in three dimensions. The structure of bone tissue varies 
with its location in the body. Hence, the selection of configurations, as well as 
appropriate biomaterials, will depend on the anatomic site for regeneration, the 
mechanical loads present at the site, and the desired rate of incorporation. Ideally, the 
scaffold should be porous to support cell penetration, tissue ingrowth and rapid vascular 
invasion, and nutrient delivery; the matrix should be designed to guide the formation of 
new bone in anatomically relevant shapes; and its degradation kinetics should be such 
that the biodegradable scaffold retains its physical (or mechanical) properties for at least 
6 months (i.e. 4 months for cell culturing and 2 months in vivo) Important design 
parameters are listed in Table 2.12. 
Table 2.12 Scaffold design parameters for bone engineering 143 
Parameters Requirement 
Porosity 
Pore size 
Pore structure 
Mechanical properties: 
Cancellous bone 
Maximum with compromising mechanical properties 
300-500 |Lim 
Interconnected 
Tension and compression 
Strength: 5-10 MPa 
Modulus: 50-100 MPa 
Cortical bone Tension 
Strength: 80-150 MPa 
Modulus: 17-20 GPa 
Compression 
Strength: 130-220 Mpa 
Modulus: 17-20 GPa 
Fracture Toughness; 6-8 MPaVw 
Degradative properties 
Degradation time 
Degradation mechanism 
Must be tailored to match the application in patients 
Bulk or surface erosion 
Biocqmpatibility 
Sterilizabihty 
No chronic inflammation 
Sterilizable without altering material properties. 
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It has been reported that the compressive strength of a hydroxyapatite scaffold increases 
from - 1 0 MP a to - 3 0 MPa due to tissue ingrowth in vivo ' ' ' . This finding led to a 
perception that it is not necessary to have a starting scaffold with a mechanical strength 
equal to bone because cultured cells on the scaffold in vitro will create a biocomposite 
and increase the strength of the scaffold significantly. There has not been any 
quantitative study, however, to determine the exact contribution of new bone tissue to 
the mechanical strength of composite constructs. Nonetheless, a scaffold should have an 
adequate initial strength and toughness for handling. 
6.2. FABRICATION OF POLYMER SCAFFOLDS 
Numerous techniques have been developed to process porous polymer scaffolds for use 
in tissue engineering. Excellent reviews can be found in the literature -pable 
2.13 lists currently applied 3D polymer scaffold fabrication technologies, based on Ref 
1 7 5 
6.3. FABRICATION OF COMPOSITE SCAFFOLDS 
While intensive efforts were made to develop the processing technologies of polymer 
scaffolds, relatively less attention was paid to the fabrication of porous composite 
scaffolds. Among the technologies in Table 2.13, solvent casting with/without particle 
leaching iso,133,154,171 thermally induced phase separation (TIPS) combined with 
freeze-drying 104-107,169,no been applied to the fabrication of polymer-ceramic 
composite scaffolds. In addition there are other two methods: microsphere sintering and 
foam coating, which are developed for the combination of ceramic and polymeric 
materials, as listed in Table 2.14 and shown in Figure 2.4. This section will briefly 
introduce the processing techniques of polymer-ceramic composite scaffolds. 
6.3.1. Solvent Casting 
Solvent casting of the biocomposite scaffolds involves the dissolution of the polymer in 
an organic solvent, mixing with ceramic granules, and casting the solution into a 
predefined three-dimensional mould. The solvent is subsequently allowed to evaporate. 
The main advantage of this processing technique is the ease of fabrication without the 
need of specialised equipment. The primary disadvantages of solvent casting are (1) the 
limitation in the shapes (typically flat sheets and tubes are the only shapes that can 
formed); (2) the possible retention of toxic solvent within the polymer; and (3) the 
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denaturation of the proteins and other molecules incorporated into the polymer by the 
use of solvents. The use of organic solvents to cast the polymer may decrease the 
activity of bioinductive molecules (e.g., protein). The detailed processing steps can be 
found in protocol A of Ref 
6.3.2. Solvent Casting / Particle Leaching and Microsphere Packing 
Polymer-ceramic constructs can be fabricated by the solvent casting method. The 
polymer microspheres are at first formed from traditional water oil/water emulsions. 
Polymer-ceramic scaffolds can then be constructed by mixing solvent, salt or sugar 
particles, ceramic granules, and pre-hardened microspheres A three-dimensional 
structure of controlled porosity is formed based on this method combined with particle 
leaching and microsphere packing. This method shares similar advantages and 
disadvantages with the solvent casting technique. For the details of the method, readers 
may refer to protocol B in Ref 
6.3.3. Thermally Induced Phase Separation / Freeze-Drying 
Porous structure can also be achieved through phase-separation and evaporation. One 
approach to induce phase separation is to lower the temperature of the suspension of 
polymer and ceramic materials. The solvent is solidified first, forcing the polymer and 
ceramic mixture into the interstitial spaces. The frozen mixture is then lyophilised using 
a freeze-dryer, in which the ice solvent evaporates <''''i07,i69,i70 
6.3.4. Microsphere-Sintering 
In this process, microspheres of a ceramic and polymer composite are synthesized first, 
using emulsion/solvent evaporation technique. Sintering the composite microspheres 
together yields a 3-dimensional, porous scaffold 
6.3.5. Foam-Coating 
An alternative approach to address the combination of polymeric and ceramic materials 
is to coat bioactive ceramics onto polymeric foams The inverse method, namely 
polymer-coated ceramic scaffolds, has also been investigated but to a much less 
extent. 
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Table 2.13 3D fabrication technologies of polymer scaffolds 175 
Fabrication Required properties Reproducibility Available pore Porosity (%) Architecture 
Technology of materials size (|uim) 
Solvent casting / particle Soluble User, material and 30-300 20-50 Spherical pores 
leaching technique sensitive 
Membrane lamination Soluble User, material and 30-300 < 8 5 Irregular pores 
technique sensitive 
Textile technology Fibres Machine controlled 20-100 <95 
Melt moulding Thermoplastic Machine controlled 50-500 < 8 0 
Extrusion / particle Thermoplastic Machine controlled < 100 < 8 4 Spherical pores 
leaching 
Emulsion freeze drying Soluble User, material and <200 < 9 7 High volume of 
technique sensitive interconnected micropores 
Thermally induced phase Soluble User, material and <2#0 < 9 7 High volume of 
separation technique sensitive interconnected micropores 
Gas foaming Amorphous Material and technique <100 10-30 High volume of non-
sensitive interconnected micropores 
Gas foaming / particle Amorphous Material and technique Micropores <50 < 9 7 Low volume of non-
leaching sensitive Macropores < interconnected micropores 
400 combined with high volume 
of interconnected 
macropores 
3D Printing Soluble Machine and computer 45-150 < 6 0 100% interconnected 
controlled macrospores 
Fused deposition Thermoplastic Machine and computer > 150 < 8 0 100% interconnected 
modelling controlled macrospores 
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Table 2.14 Fabrication methods of 3-dimensonal porous composite scaffolds 
Fabrication Technique Biocomposite Percentage of Porosity Pore size Ref 
ceramic (%) (%) (fim) 
Ceramic Polymer 
Solvent casting/particle HA PLGA 60-75 (wt.) 81-91 800-1800 171 
leaching Bioglass® PLLA 20-50 (wt.) 77-80 ~ lOO(macro) 150 
~ lO(micro) 
153 Phosphate glass PLA-PDLLA 40 (wt.) 93-97 
A/W PDLLA 20-40 (wt.) 85.5-95.2 98-154 154 
Thermally induce phase p-TCP Chitosan-Gelatin 10-70 (wt.) 322-355 169 
separation /freeze-drying HA PLLA 50 (wt.) 85-95 100x300 170 
Bioglass® PDLLA 5-29 (wt.) 94 ~ lOO(macro) 104-107,152,187 
10-50(micro) 
Microsphere/sintering Amorphous CaP PLGA 28-75 (wt.) 75 > 100 167,168 
Bioglass® PLGA 75 (wt.) 43 89 149 
Polymer foam/ceramic HA PLGA 40-85 (vol.) 158,159 
coating Bioglass® PDLLA 177,183,184 
Ceramic foam/ HA foam PDLLA 185,186 
polymer coating 
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Fig. 2.4 Typical structures of porous biocomposites by various teclmiques 
(a) Solvent casting / particle leaching 
168 
(b) Phase separation / freeze drying 
(c) Microsphere /sintering 
(d) Foam /coating 
170 
6.4. FABRICATION OF CERAMIC SCAFFOLDS: POWDER-FORMING 
Porous ceramics can be divided in two general groups. If the substance of which the 
porous ceramic is made is contained only in cell edges, the ceramic is termed open-cell, 
or reticulate ceramics. If the substance also exists in the form of cell faces, the porous 
ceramic is termed closed-cell product and the individual cells are isolated from one 
another. There is clearly the possibility that porous ceramics can be partly open and 
partly closed Porous materials with very high porosities (above -70%) are 
usually called foams or cellular solids. Below -70%, there is a transition from a cellular 
structure to one which is better thought of as a solid that contains isolated pores 
Porous ceramics can be produced by a variety of different processes which may be 
classified into two categories: (1) manual-based processing techniques and (2) 
computer-controlled fabrication processes: such as solid free-form (SFF) technology, 
which is also commonly known as rapid prototyping (RP) Manual-based processing 
techniques can further be divided into: conventional powder-forming processes and sol-
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gel techniques ***. A flowchart which is common to all powder forming processes is 
shown in Fig. 2.5. 
Start with a ceramic powder 
r 
Prepare slurry from the powder 
r 
Form a green body from the slurry 
1 r 
Heat treatment of the green body to 
burn out the organic additives and 
sinter the ceramic structure 
r 
End with a porous ceramic 
Add Additives 
e.g. porogen, binder). 
Fig. 2.5 Flowchart of the powder-sintering method to produce a porous ceramic scaffold 
6.4.1. Preparation of Slurries 
A slurry is a suspension of ceramic particles in a suitable liquid (e.g. water or ethanol) 
that will be used to prepare green bodies. The inherent mechanism of pore formation in 
a green-body is illustrated in Fig. 2.6. Agglomeration of particles is caused by attractive 
forces which consist of hydrogen bonds, van de Waals forces, Coulomb's forces, and 
physical friction between particles. Porosity can be increased by adding fillers to the 
slurry, such as sucrose, gelatine, and PMMA micro beads and a wetting agent (i.e. a 
surfactant). These chemicals, which are called porogens, are evaporated or burned out 
during sintering, and as a result pores are formed One successful formulation has 
been the use of hydroxyapatite powder slurries (dispersed with vegetable oil) added 
with gelatine solution Porous scaffolds were formed with interconnected 
interparticle pore diameters of -100 i-im. A similar process has been used to prepare 
melt-derived Bioglass® scaffolds using camphor (CioHieO) as the porogen 67 
Binders are also added to slurries. The most important function of the binder is to 
improve the strength of the green body in order to provide structural integrity for 
handling (green strength) before the product is sintered Frequently added binders in 
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bioceramic slurries are polysaccharides polyvinyl alcohol (PVA) and polyvinyl 
butyl (PVB) 199 
primary particle 
pore Eimong 
agglomerates 
pore among 
primary parlicles 
agglomerate 
(agglomeration of 
primary particles) 
Fig. 2.6 Schematic illustration of pores among agglomerates and particles 192 
Table 2,15 List of methods of obtaining green bodies for 3D porous ceramics 192 
Dry Process 
1. Loose-packing 
2. Compaction 
Uniaxial-pressing 
Cold-isostatic-pressing (CIPing) 
Wet Process 
3. Slip-casting 
4. Injection-moulding 
5. Phase separation / Freeze-drying 
6. Polymer-replication 
7. Gel-casting 
6.^.2. Formation of Green Bodies 
In porous ceramic production, a green body is porous, and its structure largely 
determines that of the sintered product. Table 2.15 lists different methods of obtaining 
green bodies for 3 dimensional porous ceramics. These methods can be classified into 
two categories: dry and wet processes They lead to different porous structures 
within green bodies. Some techniques, such as tape-casting, extrusion, slurry-dipping 
and spraying are not included here; because they aim at, instead of achieving porous 
structure in ceramics, a geometric shape (such as rods, tubes, sheets, and coating films) 
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of ceramic products. Except for injection-moulding, all these conventional processes 
have been applied to synthesize ceramic scaffolds for tissue engineering. 
6.4.2.1. Compaction 
The simplest way to prepare green bodies is the dry process, in which the powder is 
directly compressed by pressing into moulds or dies, thereby forming green bodies. Pore 
diameters decrease and mechanical properties increase as the packing density of the 
spheres in the green bodies increases. Mechanical properties can be increased further by 
hot-isostatic-pressing (HIPing), which decreases the pore diameter as well. The addition 
of porogens, such as sucrose and camphor, can enhance the formation of pores 
6.4.2.2. Slip-Casting 
A slip is a creamy (relative thick) slurry that contains solid particles. In this method, the 
slurry is cast into a porous mould. The liquid of the slurry is absorbed into the porous 
mould and as a result, the particles in the slurry are filtered and adhered on the mould 
surface. After this process, a porous green body is obtained through drying 
6.4.2.3. Phase Separation / Freeze-Drying 
This process will be introduced in section 6.4.3 as a synthetic technique for production 
of composite scaffolds. The ceramic slurry is poured into a container which is immersed 
in a freezing bath. Thus, ice is stimulated to grow and ceramic particles piled up 
between the columns of the growing ice. After the slurry is completely frozen, the 
container is dried in a drying vessel 
6.4.2.4. Replication Technique 
This method, which is also called the 'polymer-sponge' method, was patented for the 
manufacture of ceramic foams in 1963 It is similar to the slip-casting technique in 
which ceramic particles are adhered on the mould surface. In the polymer-replication 
process, the green bodies of ceramic foams are prepared by coating a polymer (e.g., 
polyurethane) foam with a ceramic slurry. The polymer foam, having already the 
desired macrostructure, simply serves as a sacrificial template for the ceramic coating. 
The polymer template is immersed in the slurry, which subsequently infiltrates the 
structure and coats the ceramic particles to the surface of the polymer substrate. Excess 
slurry is squeezed out leaving a ceramic coating on the foam struts. After drying, the 
polymer is slowly burned out in order to minimise damage to the porous coating. Once 
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the polymer has been removed, the ceramic is sintered to the desired density. The 
process replicates the macroporous structure of the polymer foam, and results in a rather 
distinctive microstructure within the struts. A flowchart of the process is given in Fig. 
2.7 This method has been applied for the preparation of porous calcium phosphates 
and other inert bioceramics 
Apart from the slurry-immersion coating, electrospray coating techniques have also 
been applied together with the polymer-sponge process to produce A I 2 O 3 foams. Unlike 
the foams produced by the slurry-immersion method, the struts of the ceramic foams 
produced by electrospraying did not contain numerous holes and large cracks. This 
microstructure led to improved mechanical properties of the foams 203 
Ceramic powder 
1 r 
Prepare slurry from the powder 
r 
Coat a polymer foam with the slurry 
r 
Dry, burn out the polymer substrate 
and sinter the green body 
r 
Ceramic foam 
Add Binder 
Fig. 2.7 Flowchart of the replication process to produce a ceramic foam 
6.4.2.5. Gel-Casting 
A full term for this method should be direct-forming/gel-casting. This method adopts 
mechanical stirring (one of direct-foaming techniques listed in Table 2.16) to achieve 
highly porous green bodies. The foamed suspension is set through a direct-consolidation 
technique (Table 2.16); i.e. polymerisation of organic monomers (i.e., gelation) in 
which the particles of the slurry are consolidated through polymerisation reaction. A 
green body is formed after the gel is cast in a mould Fig. 2.8 illustrates the 
flowchart of the gel-casting process. 
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Two factors are critical in the gel-casting process: (1) the gelation speed must be fast 
enough to prevent foam collapse; and (2) the gel rheology is important because the 
process involves casting. Systems of high fluidity are required in order to enable easy 
filling of small details in moulds to allow production of high complexity shapes. Direct-
forming/ gel-casting techniques have been applied to produce hydroxyapatite foams 
177,208,209 Qg^.^asting has also been combined with the replication process to produce 
hydroxyapatite scaffolds with interconnected pores 
Table 2.16 Techniques of direct-foaming and direct-consolidation 
Technique Reference 
Direct-Foaming 
1. Injection of gasses tlirough the fluid medium 
2. Mechanically agitating particulate suspension 
3. Blowing agents 
4. Evaporation of compounds 
5. Evaporation of gas by in-situ chemical reaction. 
Direct-Consolidation 
1. Gel casting 
2. Direct coagulation consolidation (DCC) 
3. Hydrolysis assisted solidification (HAS) 
4. Freezing (Quick Set®) 
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6.4.3. Sintering 
The final step in the production of a ceramic foam is the densification of the green 
bodies, which are normally dried at room temperature for at least 24 hours prior to 
sintering. In this step, controlled heating is important to prevent collapse of the ceramic 
network. The heating rate is 0.5-2°C/min for hydroxyapatite foams The 
sintering temperatures and holding time, which depend on the ceramic starting 
materials, are in the range of 1200-1350°C for 2-5 hours in the case of porous 
hydroxyapatite >''''^ '185,208,211 
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Ceramic powder 
1 r 
Prepare suspension from the powder 
1 f 
Foam the suspension using one of 
foaming techniques in table 2.16 
1 f 
While the foamed suspension is poly-
merised to form a gel, cast the gel 
1 
Dry and sinter the green body 
^ Add ^Dispersant , surfactant, 
monomer, cross linkei^ 
Add 
Initiator, catalyst 
Ceramic foam 
Fig. 2.8 Flowchart of the gel-casting method to produce a ceramic foam 
6.5. FABRICATION OF CERAMIC SCAFFOLDS; SOL-GEL 
6.5.1. Basic Concepts 
i) Sol-gel 
The sol-gel process is defined as the chemical synthesis of ceramic materials by 
preparation of a sol, gelation of the sol (gel), and the removal of the solvent. That is, the 
sol-gel process involves the transition of a system from a liquid "sol" into a solid "gel" 
phase. The chemical involved in the process is based on inorganic polymerisation 
reactions of metal alkoxide 
ii) Colloid, sol and gel 
A colloid is a suspension in which the dispersed phase is so small that it exhibits 
Brownian motion, which is a random walk driven by the momentum imparted by 
collision with molecules of the suspending medium. Types of colloids (also called 
colloidal suspensions) are listed in Table 2.17. A sol is a dispersion of solid particles (~ 
0.1-1 |a.m) in a liquid where only the Brownian motions suspend the particles. A gel is a 
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state where both liquid and solid are dispersed in each other, which presents a solid 
network containing liquid components. 
Table 2.17 Types of colloids (also called colloidal suspensions) 
Dispersed Phase Suspending Medium Colloid 
Solid Liquid Sol 
Solid Gas Aerosol (smoke) 
Liquid Gas Aerosol (fog) 
Liquid Liquid Emulsion 
6.5.2. Sol-Gel Process and Synthesis of Aerogel Ceramics 
The sol-gel technique is a versatile solution process for making ceramic and glass 
materials. Applying the sol-gel process, it is possible to fabricate ceramic or glass 
materials in a wide variety of forms: ultra-fine or spherical shaped powders, thin film 
coatings, ceramic fibres, microporous inorganic membranes, monolithic ceramics and 
glasses, or extremely porous aerogel materials. An overview of the sol-gel process is 
presented in Fig.2.9 
The processing path of aerogel ceramics is indicated by the heavy arrows in Fig.2.9. 
Alkoxide precursors, such as tetraethyl orthosilicate (TEOS) and triethoxyl 
orthophosphate (TEP), undergo hydrolysis and condensation reactions to form a sol. 
Polymerisation o f -S i -OH groups continued after hydrolysis is complete, beginning the 
formation of the silicate (-Si-O-Si-) network. The network comiectivity increases until it 
spans tliroughout the solvent medium. Eventually a wet gel forms. The wet gel is then 
subjected to controlled thermal processes of aging to strengthen the gel, drying to 
remove the liquid by-product of the polycondensation reaction, and thermal stabilisation 
(or sintering) to remove organic species from the surface of the material; and as a result, 
a porous aerogel forms 
6.5.3. Production of Highly Porous Aerogel Glasses 
Highly porous glasses (or glass foams) have been developed by directly foaming the sol 
with the use of a surfactant and catalysts The precursors of the glass foams are 
Ca(N03)2 and two alkoxides: TEOS and TEP. A flowchart of the process is given in 
Fig. 2.10. Sol-gel derived bioactive glass foams and gel-cast HA scaffolds 
showed favourable results in both in vitro and in vivo tests for bone regeneration. 
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Fig. 2.9 Graph of sol-gel process 213 
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Add ^Ca ta lys i s ( H N O 3 ) to 
\ s p e e d up hydrolysis 
Add Surfactant for foaming, 
Catalyst (HF) for gelation 
Alkoxides: TEOS and TEP 
Glass foam 
Foam the sol by vigorous agitation 
Age, dry and sinter the gel 
When the gelation of the foamed sol is 
nearly completed, cast the gel in moulds 
Prepare a sol from the alkoxides and 
Ca(N03)2 in deionised water solvent 
Fig. 2.10 Flowchart of the production of bioactive glass foams using sol-gel technology 
6.6. FABRICATION OF CERAMIC SCAFFOLDS: SOLID-FREE-FORM 
Solid free-form (SFF) techniques, also known as rapid prototyping (RP), are computer-
controlled fabrication processes. They can rapidly produce highly complex 3D objects 
using date generated by computer aided design (CAD) systems. An image of a defect in 
a patient can be taken, which is used to develop a 3D CAD computer model. The 
computer can then reduce the model to slices or layers. The 3D objects are constructed 
layer-by-layer using rapid prototyping techniques of fused deposition modelling (FDM), 
selective laser sintering (SLS), 3D printing (3D-P), stereo lithography, or extrusion free-
forming Calcium phosphate scaffolds have been produced using the fused 
deposition modelling process selective laser sintering, 3D printing processes 
extrusion free-forming and stereo lithography as well as RP combined with 
replication technique The typical process chain for all SFF techniques is 
presented in Fig. 2.11. 
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SFF Fabrication 
Post Processing 
Finishing and cleaning 
SFF System Computer 
(Generation of slice data, etc) 
Medical Imaging 
• CT, MRI, etc 
3D Solid Model Creation in CAD 
• Pro/Engineer (PTC) 
Fig. 2.11 Flowchart of typical rapid prototyping (RP) process 193 
Up to now, only a small number of SFF techniques, such as 3D-P, FDM and SLS, have 
been adapted for tissue engineering scaffolds. The following paragraphs give brief 
introductions to the principles of these three techniques. Their technical details can be 
found in previous reviews available 
6.6.1. Three-Dimensional Printing (3D-P) 
3D-printing employs ink jet printing technology for processing powder materials. 
Therefore, this technique is a combination of solid free-form (SFF) and power-sintering. 
During fabrication, a printer head is used to print a liquid binder onto thin layers of 
powder following the object's profile being generated by the system computer. The 
subsequent stacking and printing layer recreates the full structure of the desired object. 
6.6.2. Fused Deposition Modelling (FDM) 
FDM employs the concept of melt extrusion to deposit a parallel series of material roads 
that forms a material layer. In FDM, filament material stock (generally thermoplastic) is 
fed and melted inside a heated liquefier head before being extruded through a nozzle 
with a small orifice. 
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An indirect fabrication method involving FDM has been applied to produce porous 
bioceramic implants. FDM was employed to fabricate wax moulds containing the 
negative profiles of the desired scaffold microstructure. Ceramic scaffolds were then 
cast from the mould via a lost mould technique 
6.6.3. Selective Laser Sintering (SLS) 
This technique employs a CO2 laser beam to selectively sinter polymer or polymer-
ceramic composite powders to form material layers. The laser beam is directed onto the 
powder bed by a high precision laser scanning system. The fusion of material layers that 
are stacked on top of one another replicates the objects height 
Table 2.18 collects the porosity, pore size, and mechanical properties of porous 
ceramics produced by different techniques. Generally, they are very brittle. Eventually 
they become too fragile to handle with when the porosity increases up to 90% An 
approach to improve the mechanical properties of ceramic scaffolds is to coat the 
scaffold network with polymeric materials However, few works have been reported 
with respect to this approach. 
6.7. COMPARISON OF FABRICATION TECHNIQUES FOR CERAMIC FOAMS 
Fig. 2.12 shows typical structures of porous ceramics produced by different techniques. 
A comparison of the porous structures of ceramic scaffolds (Shown in Fig. 2.12) with 
that of trabecular bone reveals that the porous structure produced by the replication 
technique is the most similar one to that of cancellous bone, containing completely 
interconnective pores and solid materials forming only the struts. The ceramic foams 
synthesised by gel-casting and sol-gel techniques come next in terms of structural 
similarity to cancellous bone, but sol-gel derived foams exhibit only limited pore 
connectivity. The advantages of the replication method over other techniques are 
summarised in Table 2.19. In brief, the replication technique meets the criteria (5)-(7) 
listed in Table 2.3. Therefore, the replication technique has been chosen as a suitable 
technique for production of bioactive glass scaffolds in this research. 
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Table 2.18 Porous structures and mechanical properties of porous ceramics produced by different techniques 
Technique Material Porosity (%) Pore Size / iu,m Closed (C) or Open (O) 
Compressive or 
Flexural* 
Strength / MPa 
Ref 
1. Powder-Forming-Sintering 
(1) Dry process with porogens Hydroxyapatite 
Hydroxyapatite 
45S5 Bioglass® 
NA 
67 
21 
42 
Predominately 0.4, but C 
varying between 0.4-100 
250-400 O 
200-300 C 
80 C 
NA 198 
234 
67 
68 
69 
(2) Slip-casting with porogens PZT 60-90 100-1000 C NA 190 
(3) Phase separation/ freeze-drying AI2O3 -50 in width, 0 NA 2D"0 
300-500 in length 
(4) Replication technique /coated by 
Slurry-immersion AI2O3 87 Up to 800 0 NA 190 
TiO? 74 38^^00 0 197 
Glass-reinforced HA 85-97.5 Ave; 420-560 0 0.01-0.175 211 
Hydroxyapatite 69-86 490-1130 0 0.03-0.29 185 
HA coated by PLGA 69-86 490-1130 0 0.31-4.03 185 
Electrospray AI2O3 96 -800 0 203 
(5) Gel-casting / foamed by 
Starch AI2O3 23-70 10-80 c NA 205 
Vigorous stirring AI2O3 70-92 Ave size:260-700 Partly 0/C 206 
Range in 50-2000 
AI2O3 NA NA NA 3-20 207 
Hydroxyapatite 76.7-80.2 20-1000 Partly 0/C 4.4-7.4 208 
Hydroxyapatite 48 50-300 Partly 0/C 8* 177 
Hydroxyapatite NA Cell: 100-500 Partly 0/C 1.6-5.8 209 
Window: 30-120 
Replication technique Hydroxyapatite 70-77 200-400 0 0.55-5 210 
P-TCP + HA 73 NA 0 9.8 235 
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Table 1.28 Continued 
2, Sol-Gel/Foamed by 
(1) Burning PMMA beads 
(2) Decomposition of H2O2 
(3) Burning EO-PO-EO blocks 
(4) Vigorous stirring 
Ca0-Si02 glass 
(CH30)4Si 
SiOz glass 
Bioactive glasses 
3. Solid-Free-Form (SFF) 
( l ) F D M 
(2) SLS 
70-95 
~0.5 
<(X7 
1-10 
up to 600, size of cell 
windows mostly in 80-
120 
Partially 0 / C 
Partially 0 / C 
Partially 0 / C 
Partially 0 / C 
236 
237 
238 
217 
/UjCt; 29-44 305-480 
p-TCP 29-44 305-480 
(:aO-Al2(D3 29-44 300 
PP-TCP composite 36-52 160 
Calcium phosphates 30 200 
O 
O 
o 
o 
o 
62-128 
0.25-1.45 
2-24 
12.7-10 
13.8 
239 
239 
240 
222 
241 
67 
% 
500|.im 
m 
i j 100 um 
;@d* 
m 
200 
Fig. 2.12 Typical structures of porous ceramics produced by different techniques 
(a) Porous HA produced by the powder method combined with PVA as a 
porogen additive 
(b) Porous alumina by freeze-drying method 
(c) Porous HA by gel-casting method 
(d) 70S30C bioactive glass foams by sol-gel technique 
(e) Porous glass-HA by the replication technique 
(f) P-TCP + HA foam produced by gel-casting method combined with the 
216 
replication technique 235 
(g) Porous P-TCP by solid free-form technique 
(h) Porous structure of cancellous bone 
239 
68 
Table 2.19 Advantages of the replication technique to produce highly porous ceramic 
scaffolds over other methods 
1. Cancellous bone-like macroporous structure 
The porous structure produced by the replication technique is the most similar 
to sponge bone: highly porous and with open pores, compared with the rest of 
the techniques. 
2. High commercialisation potential 
This technique is the simplest method, and thus most suitable for 
commercialisation, compared with SFF. SFF Rapid-prototyping is an expensive 
process, which may be a method for producing specific and complex scaffold 
architectures. 
3. Safety 
It does not involve any toxic chemicals, compared with sol-gel and gel-casting 
techniques which use HF to accelerate polymerisation. 
4. Irregular or complex shape production ability 
It can produce a scaffold in irregular or complex shapes, compared with 
standard dry powder processing. 
6.8. SUMMARY 
The structural pre-requisites listed in Table 2.12 indicate that the major goal in scaffold 
production for bone tissue engineering is to achieve a microstructure (pore size about 
400|j,m, and porosity above 90%) that can provide proper mechanical function 
temporarily and degrade later at a rate matching the growth rate of new bone tissue. 
It has been recognised that biocomposites made from bioactive glasses and polylactides 
are the promising scaffold materials, at the same time the synthesis of biocomposite 
scaffolds is at its very fledging stage, as shown in Fig. 2.4. Among the approaches that 
have been investigated to a very limited extent, the strategy that a ceramic (or glass) 
foam is produced first and then coated with a biodegradable polymer (such as PLLA 
and PDLLA) shows promise to develop optimal scaffolds. This led us to focus the 
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present research project in this particular technology. The reason is based on our 
extensive literature review above and in a comparison of various scaffold synthesis 
techniques and scaffold properties achieved, as discussed in section 6.7. 
7. OBJECTIVES AND AIMS OF THIS PROJECT 
The objectives of this PhD research project are: 
(1) To design and fabricate highly porous scaffolds from melt-derived 45S5 
Bioglass® powder using replication technique, aiming at achieving mechanically 
strong (relative to cancellous bone) foam-like structure. 
(2) To coat the above 45S5 Bioglass®-based glass-ceramic foams with PDLLA, in 
order to improve the mechanical reliability (i.e. work of fracture) of the scaffolds. 
(3) To functionalise the strut surfaces of the foams, in order to improve the ability of 
the glass-ceramic scaffolds to bind proteins and thus to serve as optimal support 
for cells. 
(4) To carry out in vitro cell culture investigations on the glass-ceramic foams in 
order to assess the ability of the scaffolds to support and foster cells, and to 
investigate the possible improvement of the mechanical reliability of the foams in 
the cell-culturing environment. 
The final goal is to achieve an ideal scaffold for bone tissue engineering that can 
provide adequate mechanical support temporarily and degrade subsequently at a 
tailorable rate matching the formation rate of new bone tissue. 
70 
APPENDIX A 
ANATOMY AND HISTOLOGY OF BONE 
To fabricate a tissue-like scaffold that can meet the task of reconstituting tissues, one 
needs to learn the characteristics of the relevant biological tissue at a micro level. This 
section will give a concise introduction on the anatomy and histology of bone. 
A.l . ANATOMY OF BONE 
A typical long bone (Fig. Ala) has a diaphysis (or shaft) with walls of compact bone 
and two epiphyses (or heads) filled with spongy bone A metaphysis separates the 
diaphysis and epiphysis at each end of the shaft. A thin layer of hyaline cartilage called 
articular cartilage (in blue color) covers the epiphysis where the bone forms a joint with 
another bone. In the diaphysis zone (Fig. Alb), the compact bone is the main constitute 
and there is a thin layer of spongy bone. At centre is the marrow cavity. 
Spongy 
bone 
Blood vessels 
Epiphysis 
Metaphysis 
Compact bone 
Marrow cavity 
Endosteum 
Spongy 
bone Diaphysis 
Penosteum 
Marrow 
cavity 
See Fig. A2 
Metaphysis 
Epiphysis 
Compact bone 
Articular cartilage 
(b) 
Fig. A1 Gross anatomy of a representative bone, the humerus 243 
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A.2. HISTOLOGY OF BONE 
There are two types of bone, or osseous tissue: compact bone and sponge bone. They 
have the same matrix composition, but differ in the three-dimensional arrangement of 
bone cells, extracellular matrix (ECM), and canaliculi (Fig. A2) 2 4 3 
Interstitial lamellae 
Small vein 
Capillary 
Circumferential lamellae 
Osteons 
/ Periosteum 
See Fig. 1.5 
- r i l i n g ; 
Central 
canal 
Perfora t ing 
cana l 
Spongy bone 
Fig. A2 Compact and spongy bone 2 4 3 
COMPACT BONE The basic unit of compact bone is the cylindrical osteons (Figs. A2 
and A3), among which filled with interstitial lamellae (Fig. A2). There are also outer 
circumferential lamellae, called periosteum (Fig. A2). Within an osteon, bone cells 
(called osteocytes) and the ECM (or bone matrix) are arranged in concentric layers 
around a central canal (Fig. A3). The layers of the bone matrix are called lamellae. 
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Fig. A3 Osteon and osteocyte 2 4 3 
SPONGY BONE is also called cancellous bone. The primary differences between 
spongy bone and compact bone are: (1) in spongy bone, osteocytes and lamellae form 
little beams called trabeculae, the arrangement of which is an open framework (Fig. 
A4a); and (2) on the surfaces of the trabeculae lines a cellular endosteum (Fig. A4a), 
which is made up of osteoblasts and osteoclasts (Fig. A4b). In terms of the osteocytes 
and the structure and composition of the bone matrix, spongy bone is no different from 
compact bone. 
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Fig. A4 Spongy bone 243 
COMPOSITION OF BONE MATRIX Carbonated hydroxyapatite Caio(P04)6(OH)2 
accounts for nearly 2/3 of the weight of bone. These inorganic components provide 
compression strength to bone. Roughly 1/3 of the weight of bone is from collagen 
fibres. Collagen fibres are tough and flexible, and thus tolerate stretching, twisting, and 
bending. 
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CHAPTER THREE 
MATERIALS AND EXPERIMENTS 
1. MATERIALS 
The bioactive glass used in this study was melt-derived 45S5 Bioglass® provided by Dr. 
ID Thompson (King's College, London, UK). 45S5 Bioglass® is the original bioactive 
glass composition developed by Prof. LL Hench in 1971 The actual composition of 
the present 45S5 Bioglass®, which was analysed by EDX, is given in Table 3.1. The 
mean particle size of the glass powder was in the range 5-10|im and 10-20 |im for the 
work reported in Chapters 4-5 and Chapters 6-7, respectively. The distributions of 
particle size of the powders are shown in Fig. 3.1. Poly (O.L-lactic acid) (PDLLA) 
(Purasorb®) was purchased from Purac Biochem, Gorinchem, the Netherlands. 
Purasorb® PDLLA (with a density of 1.26 g/cm^ and an inherent viscosity of 1.58 dl/g) 
was completely amorphous and was used without further purification. Dimethyl 
carbonate (DMC) of >99% purity was used as solvent. 
A fully reticulated polyester-based polyurethane foam with 60ppi (pores per inch) from 
Recticel UK (Corby) was used as sacrificial template for the replication method. The 
foam was supplied in large samples of 20mm in thickness, and it was cut to prismatic 
bodies of dimensions 10mmxl0mmx20mm for compression strength tests and to 
1 Ommxl 0mmX60mm for bending strength tests. The macroporous structure of the 
polyurethane foam used is shown in Fig. 3.2. 
Table 3.1 Composition of the present 45S5 Bioglass® and nominal 45S5 composition 
Present Bioglass® 
mol % 
Nominal Bioglass® 
mol% 
SiOz 45.89 46.14 
NazO 23.13 24.35 
CaO 28.06 26.91 
P2O5 2.92 2.60 
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Fig. 3.1 Particle size distribution of the Bioglass powder used in the work reported in 
(a) Chapters four and five, (b) Chapters six and seven. 
, .... f 
Fig. 3.2 Macroporous structure of 60ppi polyurethane sponge (Recticel UK, Corby) 
3-aminopropyl-triethoxysilane (APTS, 99%, 440140) and glutaraldehyde (GA, 2.6 M in 
water, 49630) were purchased from Sigma Aldrich and Fluka. Rat-tail type I collagen 
(2.10 mg/mL protein in 0.6% acetic acid, Batch # RTC3824) was obtained from First 
Link Ltd. West Midlands, UK. 10 mM phosphate buffer solutions (PBS) with pH 7.4 
were prepared from tablets (Sigma Aldrich P4417). The Bradford reagent was 
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purchased from Sigma Aldrich as well (B6916). Double deionised water with an 
electrical resistance of >18 Mflcm was used for all experimental work. 
2. FABRICATION OF BIOGLASS® FOAMS 
The replication method involves preparation of green bodies of ceramic (or glass) foams 
by coating a polymer (e.g. polyurethane) foam with a ceramic (or glass) slurry (Fig. 3.3, 
see also Fig. 2.7). The polymer, having the desired pore structure, simply serves as a 
sacrificial template for the ceramic coating. The polymer template is immersed in the 
slurry, which subsequently infiltrates the structure and ceramic (glass) particles adhere 
to the surfaces of the polymer. Excess slurry is squeezed out leaving a more or less 
homogeneous coating on the foam struts. After drying, the polymer is slowly burned out 
at temperatures between 300-500°C in order to minimise damage to the ceramic (glass) 
coating. Once the polymer has been removed, the ceramic (or glass) network is sintered 
to a desired density. The process replicates the macrostructure of the starting sacrificial 
polymer foam, and results in a rather distinctive and well-defined microstructure within 
the struts. 
After 
coating 
After 
sintering 
SDonae'^ Slurry -Dipping Ceramic-Coated 
^ Sponge 
Ceramic foam 
Fig. 3.3 Replication technique for fabrication of glass or ceramic foams 
The technique, to the author's knowledge, had never been used before for production of 
45S5 Bioglass® scaffolds. Hence, the optimisation of the processing steps was an 
innovative aspect of the experimental programme in this research project, as discussed 
in the following paragraphs. 
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2.1. PREPARATION OF 45S5 BIOGLASS® POWDER SLURRY 
In our experiments, the slurry for the impregnation of the polyurethane foam was 
prepared using the following recipe. 3g PDLLA (used as a binder) was dissolved in 100 
ml DMC. Then 45S5 Bioglass® powder was added to the PDLLA-DMC solution up to a 
concentration of 40 wt.%. Each procedure was carried out under vigorous stirring using 
a magnetic stirrer for one hour. 
2.2. PREPARATION OF GREEN BODIES 
The polyurethane foams cut to shape were immersed in the above prepared slurry and 
remained in it for 15min. The foams were manually retrieved from the suspension as 
quickly as possible, and the extra slurry was completely squeezed out. The samples 
(green bodies) were then placed on a smooth surface and dried at ambient temperature 
for at least 12 hours. The coating thickness of a green body could be increased by 
repeating the above coating procedure. Unless otherwise indicated, all green bodies 
were prepared by single-coating the polyurethane foams in this study. 
2.3. HEAT TREATMENT OF THE GREEN BODIES 
2.3.1. Heat Treatment Program 
Fig. 3.4 demonstrates the heat treatment program of green bodies. The burning 
condition of the polyurethane foam was set at 400°C for 1 hr. The heating and cooling 
rates were determined to be 2°C/min and 5°C/min, respectively, which were based on 
the results of other ceramic (e.g. TiOi) foams produced by replication technique 189 
R.T. 
Sintering conditions 
2°C/min 
400°C/1 
5°C/miri 
2°C/min 
Time 
Fig. 3.4 Heat treatment program designed for burning-out polyurethane templates and 
sintering of 45S5 Bioglass® green bodies. The optimal sintering conditions were 
determined to be 900-1000°C/0-2hrs in this work. 
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2.3.2. Design of Sintering Conditions 
2.3.2.1. Theoretical Consideration 
In general, for satisfactory sintering the amount and viscosity of the liquid phase must 
be such that densification occurs in a reasonable time without the sample slumping 
under the force of gravity. The rates of these two processes (shrinkage and deformation) 
determine to large extent the temperature suitable for satisfactory firing Similarly, in 
the present case an optimal sintering condition should achieve a maximum density in 
foam struts while the macroporous structure of the foam and the foam shape are 
maintained. 
To design such sintering condition, one needs to understand the mechanisms of 
sintering. The changes taking place during the transformation of an originally porous 
compact to a strong, dense ceramic body are illustrated in Fig. 3.5. This process is the 
"welding" together of separate powder particles into a single solid material, which takes 
place below the melting point of the material, but at a temperature sufficiently high to 
allow an acceptable rate of diffusion or viscous flow (in the case of glasses) to occur. 
Sintering kinetics can be quantitatively described by the ratio of neck radius x and 
particle radius ro, i.e. —. 
Representation of the initially 
msiTitered. powder particles. 
Represention of Sintered 
Powder Particles 
Fig. 3.5 Schematic graph to show changes in pore shape and shrinkage, during sintering 
of a powder compact 
In silicate systems, in which viscous flow is the major densification mechanism, the 
vitrification kinetics can be expressed as 77 
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^ Syr ^2 (3.1) 
where y is the particle surface tension (or surface energy), t is sintering time, r[ is glass 
viscosity that is a function of sintering temperature T, and p is the density of the silicate 
glass. The sintering kinetics can also be quantitatively expressed by the change of 
relatively density with sintering time, i.e. 
dp' 3y 
or 
( 1 - p ' ) , (32) 
p' = l - ( l - P o ) e , (3.3) 
where the relative density p' is defined as the bulk density divided by the true density 
of the material, and p^ is the initial relative density. For complete densification, 
(3.4) 
T 
The surface energy y of a NazO-SiOi-CaO system is about 3*10^ Joule/cm^, and the 
viscosity ^ of a typical soda silicate system is 10-10^ Pascal second at the temperature 
range of 1100-800°C 245 
The good agreement of this theoretical calculation with experimental results has led to 
the application of this theory to vitrification processes in general In the present 
study, the initial particle mean size is 5-10|im, and the initial relative density Pg is 
0.68+0.03. Fig. 3.6 illustrates the theoretical densification kinetics of viscous bodies 
under isothermal conditions, calculated from Eq. 3.3 and the data in Ref 
Fig. 3.6 shows that after isothermal sintering for 2 hrs the relatively density of a typical 
NaaO-SiOa-CaO- system (with a mean particle size being between 5 to 10|im) reaches 
97-98%. Therefore sintering conditions could be designed to be around 1000°C/2hrs. 
However, considering the slow heating rate and cooling rate used in the heating 
program (Fig. 3.4), the real dwelling time around the sintering temperature will be 
longer than a pre-set isothermal sintering duration. Hence, 1000°C/lhrs was adopted as 
a provisional sintering condition for a sintering shrinkage test, which serves as an 
experimental basis for the sintering condition of the Bioglass® foams. 
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Fig. 3.6 Isothermal densification of typical NaaO-SiOi-CaO- systems for two different 
particle sizes and sintering temperatures 
2.3.2.2. Shrinkage Measurement 
A curve of relative density (i.e. — w h e r e p and Pgg are the densities of a sintered 
'BG 
pellet and of a fully densified Bioglass material) against sintering temperature (from 
600 to 1100°C, holding time being 1 hr at each temperature) was determined, as shown 
in Fig. 3.7. The pellets, which were prepared from 0.5g 45S5 Bioglass® powder under 
uniaxial pressure of 40 kPa, were sintered following the program of Fig. 3.4. It can be 
seen that the maximum density (0.96) was achieved at around 1000°C, and that further 
raising the sintering temperature did not increase the density further. 
It should be noted that glass particles are packed much more loosely in green bodies 
made from slurries than in pellets made from dried powders, and thus the sintering 
kinetics of pellets is expected to be different to some extent from that of green bodies 
made by slurry-dipping, mainly because of the differences in the extent of interparticle 
contacts and green density. Nonetheless, the primary factor in controlling sintering 
kinetics of glasses is the viscosity of the material at the sintering temperature, and thus 
the effect of particle packing is a secondary aspect Hence, Figs. 3.6 and 3.7 still 
provide a useful guideline in designing the sintering conditions of the foams prepared 
by slurry-dipping, which had been determined to be temperature: 900-1100°C and 
holding time: 0-5hrs. 
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Fig. 3.7 Change of density of 45S5 Bioglass® pellet with sintering temperature (holding 
time at each temperature is 1 hr) 
3. COATING PDLLA ONTO BIOGLASS® FOAMS 
The PDLLA coating solution was prepared as follows: PDLLA was dissolved in 
dimethyl carbonate (DMC) at the ratio of 5g PDLLA per 100 ml DMC, by magnetically 
stirring for two hours. A dip coating process was used for applying the PDLLA coating, 
as described below. Bioglass®-based foams were completely soaked in the PDLLA-
DMC solution for 30 min (the ratio between foam and coating solution volumes being 
about 1:50), during which the container was manually shaken so that the foams were 
coated homogeneously. After the coating procedure, the foams were taken out as 
quickly as possible, dried in air at room temperature for at least 12 hours. 
4. SURFACE FUNCTIONALISATION 
4.1. SILANIZATION 
The scaffold and pellet samples were surface functionalized by adapting the protocols 
from previous studies The working mechanism of silanization is shown in Fig. 
3.8. An aqueous APTS solution of 0.45 mol / L was prepared and the pH value adjusted 
to 8 by addition of 1 N HCl, resulting in a total volume of 70 ml. The samples to be 
82 
functionalized were immersed into the obtained aqueous solution, contained in a glass 
bottle with the lid fastened. The solution was heated up to 80 °C in an oil bath under 
stirring conditions. After 4 hrs the samples were taken out and cleaned for 5 min in 300 
ml of deionised water. The samples were subsequently dried and immersed for 1 h in a 
50 ml GA solution (1 mol / L) at ambient conditions. Finally, the surface functionalized 
samples were cleaned again in deionised water and dried at ambient conditions. Control 
samples were prepared exactly in the same way but without using APTS and GA. They 
were only water-treated at 80 °C for 4 hrs at pH 8. These control samples are referred to 
as "water-treated" samples throughout the text. The three groups of foams investigated 
in this work are listed in Table 3.2. 
- O H + E t - 0 - S i 
80°C 
O - Si 
- O H 
-NhL 
+ 3 CjHjOH 
A P T S 
Substrate (3-Aminopropyl-triethoxysilane) 
Fig. 3.8 Silanization of glass surface by the sol - gel precursor APTS 
Table 3.2 Three treatment processes on the Bioglass -derived foams 
Foams Trea tment 
As-sintered Sintered at 1000°C for 1 hr 
Surface-modified Sintered at 1000°C for 1 lu, followed by surface 
(or Surface- modification in buffered (pH=8) water with APTS at 80°C 
functionalised) for 4hrs and in GA solution at room temperature for 1 hr 
Water-treated Sintered at 1000°C for 1 hr, followed by treatment in 
buffered (pH=8) water at 80°C for 4hrs 
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4.2. PROTEIN GRAFTING 
After scaffold fabrication and surface modification, cubic samples of 0.20 g were cut 
with a razor blade for all protein loading steps and protein / ion release measurements. 
The specific surface area was 0.80 m^/g measured by BET (Quantachrome Nova Series 
1000). Protein loading of as-fabricated, water-treated and surface-functionalized 
scaffolds was carried out in closable containers. The scaffolds were immersed in 5 ml 
collagen solutions at pH 3 with a concentration of 0.336 mg/ml. The containers were 
stored at 25 °C for 24 hrs with fastened lids. Hereafter, the samples were rinsed with 
deionised water and dried for one day at ambient conditions. 
4.3. PROTEIN RELEASE MEASUREMENT 
Previously dried samples were immersed in closable containers filled with 5 ml of 10 
mM phosphate buffered saline (PBS) and shaken for 5 min. The buffer was completely 
removed and replaced by a fresh PBS buffer at several time points ranging from 3 to 
168 hrs. The protein concentration of each replaced buffer was analyzed by UV / VIS 
spectroscopy using the Bradford reagent The same procedures were also applied 
in the investigation of collage release in SBF. 
5. CHARACTERISATION 
The density of the scaffolds was determined from the mass and volumes of the 
foams before and after coating with PDLLA. The porosities before (/?,) and after (p^) 
coating were detemiined as follows. Let and Wj stand for the weight of a foam 
before and after coating with PDLLA, respectively; and Vj for the volume of the 
foam before and after coating with PDLLA, respectively; then p, and P j were 
calculated by: 
w, 
r/ 
Pi =1-
(3 5) 
VPBG PPDLLA J! 
18 
where Pgg (= 2.7g/cm ) is the theoretical density of Bioglass , and P p d l l a ( ~ 1 - 2 6 
g/cm^) is the density of solid PDLLA (provided by the supplier). 
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The microstructure of the foams was characterised in a JEOL 5610LV scanning electron 
microscope (SEM), before and after immersion in simulated body fluid (SBF). Samples 
were gold-coated and observed at an accelerating voltage of 15-20 kV. Energy 
dispersive X-ray (EDX) spectra (Ka line) were collected at 20 kV in a field emission 
gun (PEG) SEM (Leo 15). They were processed using an INC A (Oxford instruments) 
program, using standard reference spectra. At least 5 measurements were taken from 
each condition investigated. 
Selected foams were also characterised using X-ray diffraction (XRD) analysis with the 
aim to assess the crystallinity after sintering and formation of HA crystals on strut 
surfaces after different times of immersion in SBF. The foams were first ground into a 
powder. Then O.lg of the powder was collected for XRD analysis. A Philips PW 1700 
Series automated powder diffractometer was used, employing Cu ka radiation (at 40kV 
and 40mA) with a secondary crystal monochromator. Data were collected over the 
range of 29 = 5-100° using a step size of 0.04° and a counting time of 25s per step. 
The surface roughness of the sintered pellets before and after cell culture was 
characterised by surface topography measurements using a Zygo® light interferometer 
instrument. 
6. MECHANICAL TESTING 
The compression strength of foams was measured using a Zwick/Roell ZOIO. The 
samples were rectangular in shape, with dimensions; 10mm in height and 5mmx5mm in 
cross-section. During compression testing, the load was applied until densification of 
the porous samples started to occur. 
Three-point bending strength tests were carried out using a Hounsfield testing machine. 
The size of the specimens was ~3mmx4mmx40mm. The load was applied over a 30mm 
span and at the mid-point of the 4mmx40mm surface. All tests were performed with a 
plastic tape placed between a sample and the cross-head, using a cross-head speed of 
0.5mm/min and a loading cell of IkN. The bending strength was calculated according to 
the equation 
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CTf -
3P,L 
26A2 
(3 6) 
where Pf is the load at fracture, L = 30mm is the sample length over which the load is 
applied, 6 % 4mm is the sample width, and /zw 3mm is the sample height. 
7. ASSESSMENT OF BIO ACTIVITY IN SIMULATED BODY FLUID 
The bonding capability of a biomaterial to living tissues is referred to as bioactivity and 
has been associated with the formation of a carbonated hydroxyapatite (HA) layer on 
the surface of the material when implanted or in contact with biological fluids Hence, 
the bioactivity of a potential biomedical device can be assessed in vitro in simulated 
body fluid via monitoring the formation of HA on its surface. The composition of 
simulated body fluid (SBF) is given in Table 3,3. 
Table 3.3 Reagents for preparing SBF and comparison of the ionic concentrations of 
SBF to human blood plasma 
Reagent 
Amount 
/g/1 
Concentration / mM 
Simulated 
Ion 
body fluid 
Human blood 
plasma 
NaCl 7.996 Na+ 142X) 142.0 
NaHCO] &350 HCO^' 4.2 27\0 
KCl 0.224 K+ 5.0 5.0 
K2HPO4.3H2O 0.228 HPO/- 1.0 1.0 
MgCli. 6H2O 0305 1.5 1.5 
IN HCl 40 ml c r 147.8 103.0 
CaCl2.2H20 0.278 Ca:+ 2.5 2.5 
NazSO^ 0.071 8042- 0.5 0.5 
((:H2()H)3Cr4H2 6.057 
In this work, we used the standard in vitro procedure described by Kokubo et al . The 
foams were immersed in 75 ml of acellular SBF in clean conical flasks, which had 
previously been washed using HCl and deionised water. The conical flasks were placed 
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inside an incubator at controlled temperature of 37 °C. The pH of the solution was 
maintained constant at 7.25. The size of all samples for these tests was 
lOmmxlOmmxlOmm. Two samples were extracted from the SBF solution after given 
times of 0.5, 1 , 2 , 4 and 8 weeks. The SBF was replaced twice a week because the 
cation concentration decreased during the course of the experiments, as a result of the 
changes in the chemistry of the samples. Once removed from the incubation, the 
samples were rinsed gently, firstly in pure ethanol and then using deionised water, and 
left to dry at ambient temperature in a desiccator. 
8. IN VITRO ASSESSMENT -CELL CULTURE 
8.1. PREPARATION OF OSTEOBLAST-LIKE CELLS 
MG63 osteoblast-like cells were in-house stocks in Eastman Dental Institute at 
University of College London. They were grown in a 75cm^ flask in Dulbecco Modified 
Eagles's Medium (DMEM) supplemented with 10% foetal calf serum (PCS), lOOU of 
penicillin / ml and 10 |a.g streptomycin/ml, and kept at 37°C in an atmosphere of 5% 
CO2. Then the MG63 cells were washed with phosphate buffered saline (PBS) and 
detached from the 75 cm^ flask by trypsinisation using 3 ml trypsin-EDTA. The cells 
were incubated for 5 min to allow detachment. Observation using phase microscopy 
was carried out to make sure the cells were detached and floating. Then 7 ml fresh 
media was added into the trypsinized live cells to inhibit the trypsinization, followed by 
centrifuging at 200g for 5 min. The supernatant was decanted without disturbing the cell 
pellet. A fiirther 8 ml media was supplemented before cell counting using Trypan blue 
dye protocol. The cell proliferation was investigated by using AlamarBlue™ assay (see 
next section). 
8.2. CELL PROLIFERATION 
The three groups of pellets used to assess cell proliferation are listed in Table 3.4. The 
amiealed glass pellets were cut to the same size of sintered pellets, i.e. 14.5 mm in 
diameter. All pellets were sterilised in dry heat at 180°C for 2h prior to cell culture. 
MG63 cells were seeded on the sterilized pellets at a concentration of 2000 cells per 
pellet. The samples were kept at 37°C in atmosphere of 5% CO2 for incubation periods 
of 1 and 6 days. Samples were removed from their respective wells and placed in new 
wells after each time point in order to ensure that only cells attached to the test samples 
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were considered for analysis. Control cultures were grown on tissue culture treated 
plastic coverslips (Thermanox). 
Table 3.4 Three groups of pellets made from Bioglass® 
Pellet Treatment 
Bioglass powder compact Annealed at 500°C for 24 hrs, used as control 
As-sintered Bioglass Sintered at 11000 °C for 1 hr 
Sintered and surface- Sintered at 1100 °C for 1 hr, followed by surface 
modified Bioglass® modification in buffered (pH = 8) water with APTS at 
80 °C for 4 hrs 
Proliferation was determined using the AlamarBlue™ assay (Life Technologies), which 
is a redox indicator used to quantitatively measure proliferation of cells As the cells 
grow in culture, their metabolic activity maintains a reducing environment in the 
surrounding culture medium, whilst growth inhibition produces an oxidised 
environment. Reduction causes colour change of the AlamarBlue™ indicator from non-
fluorescent (blue) to fluorescent (red). At the selected time points, 10% v/v medium 
from all the wells under test was removed and replaced with lOOfxl of AlamarBlue™, 
and incubated at 37°C in a humidified atmosphere at 5% CO2 for 4 h. The fluorescence 
was detected with a Fluoroskan fluorimeter (Ascent, Life Science International) using 
absorption at 560 nm and emission at 590 m%. 
8.3. ASSAY OF CELL-SEEDING ABILITY OF THE SCAFFOLDS 
The sintered scaffolds were sterilised in dry heat at 180°C for 2h before cell culture. 
The procedures of cell seeding and culture onto the scaffolds were the same as on the 
pellets. The samples were kept at 37°C under normal culture conditions for 6 days. 
Scaffolds were taken out and washed with PBS. Three samples were cut into two halves 
to examine the infiltration and viability of cells in the centre region of the scaffolds. The 
other three scaffolds were crushed to measure their compression strength, and then the 
powders were used for XRD analysis. 
8.4. PREPARATION OF SEM SAMPLES 
Specimens were fixed in 2.5% glutaraldehyde in 0.14 M sodium cacodylate buffer (pH 
7.3) (both Sigma-Aldrich) at 4°C overnight then dehydrated in a graded series of 
alcohols (50%, 70%, 90%, and two changes of 100% ethanol), washed with 
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hexamethyldisilazane (TAAB Laboratories, Aldermaston, UK) for 1-2 min and placed 
in a desiccator overnight. After 24 h, the samples containing fixed cells were mounted 
onto stubs using Araldite (Devcon, Wellingborough, UK) and Liquid Dag (Neubauer 
Chemikalen, Munster, Germany) and left to air-dry overnight. Specimens were then 
sputter-coated with gold/palladium using a Polaron ESI00 coating device (Polaron 
CVT, Milton Keynes, UK) and observed using a Cambridge Stereoscan S90B 
(Cambridge Instruments, Crawley, UK) and a Leo Gemini field emission gun (PEG) 
SEM. 
8.5. STATISTICS 
The in vitro cellular proliferation tests were performed on triplicate samples for each 
material, and the data represented as mean ± SD. Statistical difference was analysed 
using one-way analysis of variance (ANOVA), and a p value of <0.05 was considered 
significant. 
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CHAPTER FOUR 
SYNTHESIS AND CHARACTERISATION OF 45S5 
BIOGLASS®-BASED SCAFFOLDS 
1. i n t r o d u c t i o n 
As mentioned in Chapter 2, the specific criteria for ideal scaffolds used in bone tissue 
engineering are 
(1) Ability to deliver/support cells in addition to excellent biocompatibility, 
(2) Osteoconductivity and bioactivity (for bone engineering), 
(3) Controllable biodegradability, 
(4) Appropriate mechanical properties, 
(5) Porous structure with a porosity -90% and pore diameters >400-500|j.m, 
(6) Irregular shape fabrication ability, and 
(7) Potential for commercialisation. 
Bio active glasses meet the first three criteria: excellent osteoconductivity and 
bioactivity •^^ -26,51,62^  ability to deliver cells and controllable biodegradability 
The most popular bioactive glass composition 45S5 Bioglass®, which contains 45% 
SiOi, 24.5% NaiO, 24.4% CaO and 6% P2O5 by weight percent, has been approved by 
the US Food and the Drug Administration and has been applied clinically as a filling 
material for bone repair and dental implants during the last 20 years Bioglass® can 
also meet criteria (5) to (7) when combined with the replication technique to produce 
highly porous structures (see also Section 6.7, Chap. 2). In brief, all criteria for an ideal 
tissue engineering scaffold, except that related to mechanical competence, could be 
satisfied by 45S5 Bioglass® foams fabricated by the replication process. 
The replication method has been applied to produce scaffolds of hydroxyapatite (HA) 
185,186,211 Surprisingly, this technique, however, has never been considered before to 
produce scaffolds from bioactive glasses. Bioactive glass scaffolds have only been 
fabricated by dry-powder processing with porogen additions and by sol-gel and gel-
casting techniques 
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The major hurdle in the production of highly porous Bioglass -based foam-like 
scaffolds has been caused by the following apparently irreconcilable issues of this glass; 
(a) It has been reported that crystallisation of 45S5 Bioglass® turns a bioactive glass 
into an inert material 
(b) Full crystallisation of the glass occurs prior to significant densification and 
(c) Extensive densification is required to strengthen the struts of a foam, which would 
otherwise be made of loosely bonded particles and thus be too fragile to handle. 
According to these three factors, to obtain a mechanically competent 45S5 Bioglass®-
based scaffold, one must sinter it at a high temperature where extensive densification of 
struts occurs. But the bioactivity of the 45S5 Bioglass®-based foam is expected to be 
severely retarded or even suppressed by crystallisation occurring before densification. 
Consequently, to maintain the bioactivity of 45S5 Bioglass®, one should sinter the foam 
at a relatively low temperature at which crystallisation does not take place or does not 
occur to a great extent. However, sufficient densification by sintering will not happen 
under this condition, and a very fragile scaffold made of loosely packed 45S5 Bioglass® 
particles would be produced. A new approach is, therefore, required to address the 
hurdle encountered in the synthesis of highly porous, mechanically competent and 
bioactive Bioglass®-based scaffolds from melt-derived Bioglass® powder. 
The above dilemma might be solved in the light of the recent work of Clupper and 
Hench who carried out quantitative investigations on the effect of crystallinity 
on the apatite formation on Bioglass® surface in vitro. Their convincing findings 
revealed that the crystal phase NaaCaaSisOp slightly decreased the kinetics but it did not 
suppress the formation of an apatite layer Moreover it is recognised that the 
bioreaction kinetics of a highly porous network can be very different from that of a 
dense product of the same chemical composition due to a high surface area associated 
with high porosity (e.g. in foams). Hence it might be possible to find a new sintering 
protocol leading to mechanically competent foams through extensive densification of 
the struts, while inducing the formation of a bioactive and biodegradable crystalline 
phase. The objectives of this part of the research project, therefore, were to synthesize 
45S5 Bioglass® scaffolds using the replication technique, to achieve mechanically stable 
3D scaffolds through a tailored sintering schedule, and to assess the bioactivity and 
biodegradability of the scaffolds using simulated body fluid (SBF). The replication 
technique was introduced and discussed in detail in Chapter two. 
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2. RESULTS 
2.1. POROUS STRUCTURE OF FOAMS 
The porosities of 45S5 Bioglass®-based foams prepared by the rephcation method and 
sintered under different conditions are given in Fig. 4.1. Except for three of the foams 
having porosity in the range of 89-90%, all other foams had a porosity higher than 90%. 
There is a scatter of results at each sintering condition, which indicates that the porosity 
of a sintered foam is very sensitive to the fabrication procedure. Nonetheless, the 
obvious trend that porosity decreases with increasing sintering temperature and time can 
be confirmed. The scatter might be caused by (1) the initial irregular thickness of the 
glass coating on the polymer foams, and (2) the inhomogeneous temperature field inside 
the furnace. 
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Fig. 4.1 Porosities of 45S5 Bioglass®-based foams sintered at different conditions. The 
green bodies were prepared by single-coating, following the scheme of Figs.2.7 and 3.4. 
The cell size of sintered scaffolds was estimated as follows. The cell size of the as-
received polymer foam was in the range 740-1040|im. The volume ratio between a 
Vn 
polymer template to its sintered 45S5 Bioglass®-based scaffold was defined as BG-fbam 
F, PU-fbam 
and it was determined, tlirough measuring the volumes of the starting polymer and 
sintered 45S5 Bioglass®-based foams, to be 33% on average for the sintering condition 
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of 1000°C/llir. Therefore, the hnear ratio L BG-fbam 
L. 
K 
x l /3 
BG-fbam 
V ^ PU"foam y 
would be -70%. 
-'PU-fbam 
Finally, the range of cell sizes of the foams sintered at 1000°C for Ihr was calculated to 
be 0.70x(740-1040)|im = 510-720|im. 
'•^"1 msm 
400 jim 
Fig. 4.2 Pore structures of 45S5 Bioglass -based foams sintered at (a) 900°C for 5hrs; 
950°C for (b) 0, (c) 2 and (d) 5hrs; 1000°C for (e) 0.5 and (f) Ihr. All images were 
taken at the same magnification. 
Typical pore structures of the foams are illustrated in Fig. 4.2. Highly porous scaffolds 
were produced at all sintering conditions. A comparison of Figs. 4.2a-d with Figs. 4.2e-f 
shows that the cell struts are considerably denser when sintered at 1000°C for 0.5-lhrs 
than at 900-950°C for 2-5hrs. Therefore, it can be envisaged that the scaffolds produced 
at 1000°C for 0.5-lhrs will be stronger than those sintered at 950°C for 2-5hrs and 
900°C for 5hrs. In fact, the foam synthesized at 900°C for 5hrs was very fragile such 
that its struts were severely broken by hand manipulation during SEM examination, as 
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seen in Fig. 4.2a. The above observations indicate that 1000°C/lhr is an optimal 
sintering condition (see also Figs. 4.3f and 4.4 and the analysis on mechanical strength 
in Section 3.3), at which the struts of foams were fully densified while their 
macroporous structure was maintained. 
Fig. 4.3 Microstructures of struts in the 45S5 Bioglass -based foams that were sintered 
at (a) 900°C for 5hrs; 950°C for (b) 0, (c) 2, and (d) 5hrs; and 1000°C for (e) 0.5 and (f) 
Ihr. 
It was observed at high magnification that extensive sintering of 45S5 Bioglass® 
particles did not occur at 900°C even after 5hr sintering (Fig. 4.3a), but densification, 
which occurs by a viscous flow sintering mechanism in glass, increased significantly 
when the foams were heated up to 950°C and above (see Fig. 3.4 in Chapter 3). At 
950°C and 1000°C, the struts became dense with increasing sintering time, as shown in 
Figs. 4.3b-f. A significant reduction in microporosity was observed after sintering at 
1000°Cfor Ihr. 
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Fine crystalline grains of ~0.5|am in diameter could be detected by SEM observation in 
foams sintered at this condition (Fig. 4.3f). The combination of low porosity and the 
presence of a crystalline phase in the struts of scaffolds sintered at 1000°C for Ihr are 
expected to lead to improved mechanical properties of these foams, as anticipated in the 
Introduction. Hence, mechanical tests and experiments to assess the bioactivity in SBF 
were carried out on foams sintered at this optimum condition, as described in sections 
2.3 and 2.4. 
The hollow nature of a strut and its wall microstructure are shown in Fig. 4.4. Similar 
morphologies have been reported for a variety of sintered ceramic foams synthesised by 
the polymer-sponge method It can be seen that the wall of the strut has been nearly 
fully densified after sintering at 1000°C for Ihr. 
Fig. 4.4 The hollow centre of a well-densified strut in a foam sintered at 1000°C for Ihr. 
2.2. CRYSTALLISATION 
Fine crystalline grains in the strut microstructure were observed by SEM on all samples 
sintered at 950°C and 1000°C (Fig. 4.5), but not at 900°C. The XRD investigation, 
however, revealed that crystallisation had already occurred extensively in samples 
sintered at 900°C for 5hrs (Fig. 4.6), though bonding of particles was not obvious at this 
sintering condition (Fig. 4.3a). This observation confirmed the result of Clupper and 
Flench that extensive crystallisation happens prior to significant viscous f l o w sintering 
in 45S5 Bioglass® and related bioactive glasses This phenomenon is common to all 
glass materials and associated with their thermodynamic nature, as explained below. In 
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principle, an amorphous phase of any material is less stable than its crystalline 
counterpart in terms of Gibbs free energy. Hence, the glass phase always tends to 
crystallise when heated at elevated temperatures prior to softening Therefore, it is 
not surprising that crystallisation occurs prior to significant viscous f l o w which takes 
place when viscosity is sufficiently low. 
Fig. 4.5 Crystalline microstructures of foam struts after sintering at 950°C for (a) 0 and 
(b) 5hrs; 1000°C for (c) 0.5 and (d) Ihr. Fine crystalline grains of ~0.5|im in diameter 
were formed at these sintering conditions. 
The intensities of the XRD peaks were lower for the sample sintered at 900°C for 5hrs 
than in samples sintered at 1000°C for Ihr. This indicates that the crystallinity is lower 
in the former than in the latter foam. 
In Fig. 4.6, both angular location and intensity of the peaks match the standard PDF 
#22.1455, which indicates that the crystalline phase is NagCaiSisOg. The same 
crystalline phase has been formed and identified in previous studies on sintered 
bioactive glasses Meanwhile very weak peaks of an apatite-like phase are 
apparently present in the spectra of sintered samples both at 900°C for 5hrs and 1000°C 
for llir. This observation is in agreement with previous findings The minor 
apatite-like phase has been reported to form at temperatures in the range of 800-1000°C 
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in this silicate glass composition 
NazCazSisOg crystallisation. 
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Fig. 4.6 XRD spectra of 45S5 Bioglass® powder unsintered, sintered at 900°C for 5hrs 
and at 1000°C for Ihr. All spectra were obtained using O.lg powder. The major peaks of 
the phase NaiCaiSisOg [PDF #22.1455 are marked by (V). 
The present 45S5 Bioglass®-based foams are in fact of a glass-ceramic nature, as the 
crystallinity of the sintered 45S5 Bioglass® material cannot be 100%. From the 
components of 45S5 Bioglass® and NazCagSigOg (Table 4.1), one can find that the 
NaaCaiSisOg phase would demand too much CaO to fully crystallise from Bioglass®. 
Eventually CaO is depleted when the crystallinity reaches 80.7mol % (i.e. 77.4 wt %), 
which is thus the maximum crystallinity achievable by the 45S5 Bioglass® composition. 
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Table 4.1 Components of 45S5 Bioglass® and crystalline phase NaiCa^SisOg (mol.%) 
45S5 Bioglass® Na2Ca2Si309 
SiOz 46T34 50 
NazO 2435 16.667 
CaO 26.912 33333 
P2O5 2.6038 0 
2.3. MECHANICAL PROPERTIES 
Compressive and bending strength tests were carried out on foams prepared by single-
or double-coating and sintered at 1000°C for Ihr. A typical compressive stress-strain 
curve is shown in Fig. 4.7, which is jagged and has three distinct regimes. 
In general, the present foams exhibited progressive fracture due to their inhomogeneous 
strut thickness. They cracked first in thin struts at stress-concentrating sites, causing the 
apparent stress to drop temporarily. But the foam, as a whole, still had the ability to bear 
higher loads, causing the stress to rise again. The repetition of this procedure gave a 
jagged stress-strain curve, as shown in Fig. 4.7. 
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Fig. 4.7 
sintered 
A typical compressive stress-strain curve of the 45S5 Bioglass®-based foams 
at 1000°C for Ihr. The porosity of the foam was 91.0%. 
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In stage I (Fig. 4.7), the stress-strain curve has a positive slope until a maximum stress 
is reached. This maximum stress causes the thick struts of the foam to fracture and as a 
result the stress-strain curve has a negative slope in stage II. In Stage III, densification 
of the fractured foams occurs as stress increases, which is the typical behaviour of 
foams under compression 
The raw data of compressive strength are plotted against the foam porosities in Fig.4.8. 
The compressive tests were frequently accompanied by shearing, which was mainly 
caused by the end effects imposed on the specimen during the test. It has been reported 
that if the faces of the foam sample were slightly misaligned with the loading platen, 
large stress concentrations could occur causing local buckling, which in turn leads to 
shearing and thus results in an underestimation of both Young's modulus and strength 
In Fig. 4.8, the apparent strength values of the foams that failed by shearing 
(marked by A) were much lower than those of purely compressed samples (marked by 
solid triangles A). The more the foam was sheared, the lower its strength value was. It 
is reasonable to consider that the strength values obtained from pure compression tests 
represent the compressive strength of the foams. 
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Fig. 4.8 Experimental compressive strength values of Bioglass -based scaffolds in the 
present work, and those of hydroxyapatite-based foams reported in literature 
The foams with porosity lower than 89% were prepared by double-coating. 
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Figure 4.9 illustrates a typical force-displacement curve in a three-point bending 
strength test. Like in the compressive strength test, thin struts cracked first at stress-
concentrating sites, giving a typical jagged curve. When a maximum stress (bending 
strength) was reached, the sample fractured into two pieces, causing the stress to drop to 
zero abruptly. The raw data of three-point bending strength of as-sintered foams are 
given in Fig. 4.10. 
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Fig. 4.9 A typical force-displacement curve of 45S5 bioglass®-based foam in three-point 
bending strength test. 
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Fig. 4.10 Bending strength values of Bioglass®-based scaffolds. The foams with 
porosity lower than 89% were prepared by double-coating. 
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2.4. BIOACTIVITY ASSESSMENT IN SBF 
Assessment of bioactivity was carried out on foams sintered at 1000°C for 0.5 and Ihr. 
Figs. 4.11 and 4.12 show the XRD spectra of the 45S5 Bioglass®-based foams after 
immersion in SBF for 3-28 days, together with the XRD patterns of 45S5 Bioglass® in 
as-received and as-sintered conditions. 
A significant phenomenon, in addition to the growing peaks of HA-like phase detected 
in the spectra of soaked samples, was that the crystallinity of the sintered 45S5 
Bioglass®-based foams decreased with increasing immersion time in SBF. Eventually 
the sharp diffraction peaks of the NazCazSisOg phase disappeared from the XRD 
spectrum after soaking in SBF for 28 days, leaving a typical broad halo (produced by an 
amorphous phase) overlapped by the sharp diffraction peaks of the HA phase. This 
indicates that at least under the detection limits of XRD, the sintered 45S5 Bioglass®-
based material was mainly composed of an amorphous phase and crystalline apatite 
after soaking in SBF for 28 days. A comparison of Fig. 4.11 with Fig. 4.12 reveals that 
the kinetics of apatite formation is slightly slower in foams sintered at 1000° for Ihr 
than in those sintered at 1000° for 30min. 
Typical surfaces of different samples immersed in SBF for different time periods are 
shown in Figs. 4.13 and 4.14. The microstructural evolution in these two investigated 
foams is summarized in Table 4.2. It can be concluded that the rate of bioactive 
reactions is slower in foams sintered at 1000°C for Ihr than in foams sintered at 1000°C 
for 30min, with the time difference for the formation of a similar hydroxyapatite 
microstructure being 1 week. This is obviously linked with the lower level of 
crystallinity in the material sintered at 1000°C/30min compared to that sintered at 
1000°C for Ihr. In general, diffusion, which is a mechanism involved in the formation 
of apatite, is considerably slower in a crystalline phase than in its amorphous 
counterpart due to the difference in atomic (or ion) packing density 
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Fig. 4.11 XRD spectra of 45S5 Bioglass®-based foams sintered at 1000°C for 30min, 
and immersed in SBF for 3, 7, 14, and 28 days. All spectra were obtained using O.lg 
powder. The major peaks of NazCa^SisOg phase and hydroxyapatite are marked by ( V ) 
and (•) , respectively. The diffraction lines of crystalline hydroxyapatite are also shown 
for comparison. 
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Fig. 4.12 XRD spectra of 45S5 Bioglass®-based foams sintered at 1000°C for 1 hr, and 
immersed in SBF for 3, 7, 14, and 28 days. All spectra were obtained using O.lg 
powder. The major peaks of NagCaiSisOg phase and hydroxyapatite are marked by ( V ) 
and (•) , respectively. 
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Fig. 4.13 Hydroxyapatite formed on the surfaces of struts after immersion in simulated 
body fluid (SBF) for (a) 3 days, (b) 7 days, (c) 14 days, and (d) 28 days. The foams 
were sintered at 1000°C for 30 minutes. In all cases, two different magnifications are 
shown. 
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Fig. 4.14 Hydroxy apatite formed on the surfaces of struts after immersion in simulated 
body fluid (SBF) for (a) 3 days, (b) 7 days, (c) 14 days, and (d) 28 days. The foams 
were sintered at 1000°C for Ihr. In all cases, two different magnifications are shown. 
105 
Table 4.2 Summary of characteristics of 45S5 Bioglass 
in SBF 
-based foams after immersion 
Immersion 
time in SBF 
1000°C / 30min 1000°C / Ihr 
3 days Sparsely distributed apatite* 
precipitates 
Very few apatite* precipitates 
1 week Strut surface was unevenly covered 
by aggregated apatite spheres 
Sparsely distributed apatite* 
precipitates 
2 weeks Apatite* spheres were fused 
together. 
Strut surface was fully covered 
by a large amount of apatite 
spheres, size being -lp,m 
4 weeks The whole foam is made of the 
amorphous calcium phosphate and 
crystalline hydroxyapatite 
Apatite* spheres grew, size 
being ~2.5iJ,m. 
The term 'apatite' is used here to indicate amorphous and crystalline HA and 
tricalcium phosphates. 
3. DISCUSSION 
In this section, the results of the investigation are discussed in relation to mechanical 
properties, micro structure, and bioactivity. 
3.1. COMPARISON OF 45S5 BIOGLASS®-BASED FOAMS WITH SPONGY 
BONE 
The foams produced by using the polymer-sponge method are very similar to spongy 
bone (also called cancellous bone) in terms of their pore structure. It is thus of 
importance to find out whether or not the mechanical strength of the foams is 
comparable to that of cancellous bone. 
There have been many reports on the mechanical properties of cancellous bone, which 
have been reviewed in R e f I t is generally accepted that the mechanical properties of 
struts in cancellous bone are close to those of cortical bone. Typical values are: 12 GPa 
for Young's modulus, 136 MP a for compressive strength, and 105 MPa for tensile 
strength The compressive strength of spongy bone (not the strut) is in the range of 
0.2-4 MPa, when the relative density is -0.1 Hence, the measured compressive 
strength (0.3-0.4 MPa) of the present foams falls in this range, but lies closer to the 
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lower bound. Our experience indicates that the strength of 0.3-0.4 MP a is sufficient for 
the foam to be handled, during manipulation for SBF tests and cutting of the samples 
for mechanical tests. 
In addition, it has been reported that the compressive strength of HA scaffolds 
significantly increases [e.g. from - 1 0 to ~30 MPa ' ' ' ] due to tissue ingrowth in vivo. It 
has also been speculated that it might not be necessary to fabricate a scaffold with a 
mechanical strength equal to bone because cultured cells on the scaffold and new tissue 
formation in vitro will create a biocomposite and will increase the time-dependent 
strength of the scaffold significantly An ideal scaffold, however, should have at least 
a proper strength and fracture toughness to allow it to be manipulated adequately for 
tissue engineering applications. The present 45S5 Bioglass®-based scaffolds possess 
such a proper mechanical competence. 
There is no fracture toughness data available for cancellous bone. But it is predicted that 
the current Bioglass®-based foams will be more brittle than spongy bone due to the 
absence of a toughening component. A further study involving the incorporation of 
polyCo.L-lactic acid) as a coating layer onto the 45S5 Bioglass®-based foams is 
presented in Chapter 5, aiming at improving the fracture toughness of the scaffolds. 
3.2. COMPARISON WITH PREVIOUS INVESTIGATIONS 
There are few reports available on porous 45S5 Bioglass® and related bioactive glass-
ceramics with low porosity (21-42%) but no work has been published on highly 
porous {p > 90%) 45S5 Bioglass®-based foams, to the knowledge of the author. 
Therefore, the comparison carried out here is between the present scaffolds and highly 
porous {p > 70%) foams made from other bioactive ceramics and glasses, including HA, 
P-tricalcium phosphate (P-TCP), and 70S30C sol-gel derived glass foams. 
Table 4.3 summarises characteristics of highly porous bioactive ceramic and glass 
foams developed for bone engineering, including method of fabrication, pore structure, 
and compressive strength data. In general, the compressive strength varies significantly 
with foam porosity. For example, the compressive strength of HA foams, which were 
synthesised by the polymer-sponge method, decreased from 0.29 to 0.03MPa when the 
porosity increased from 69 to 86% Some compressive strength data of porous HA-
based foams reported in literature have been collected and are shown in Fig. 4.8 
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(marked by • ) . It is obvious that the present 45S5 Bioglass -based foams are in general 
stronger than the HA-based foams of similar porosities. 
It is unwise to directly compare foams exhibiting partially open pore structure with 
completely open pore scaffolds fabricated by the polymer-sponge method. The high 
mechanical strength of the former is obviously achieved at the cost of a less 
interconnected pore structure. The pore windows are mainly in the range of 30-120)j,m 
on the wall of these foams. 
It is apparent that gel-casting combined with the polymer-sponge technique produces 
stronger HA foams than the simple polymer-sponge method However, a 
comparison of the present 45S5 Bioglass®-based foams (with a compressive strength of 
0.42MPa at porosity 89%) with HA foams produced by Ramay and Zhang (with a 
compressive strength of 0.55MPa at porosity 77%) indicates that the polymer-sponge 
method developed here can produce foams as strong as those produced by the gel-
casting/polymer-sponge combined technique, and that the well-sintered and crystallised 
45S5 Bioglass®-based scaffolds can be as strong as HA foams. 
3.3. COMPARISON WITH THEORETICAL STRENGTH DATA 
The modelling of the mechanical behaviour of highly porous materials has been 
presented by Gibson and Ashby The theoretical compressive collapse stress ) 
can be expressed as a function of the relative density ( / P s o i i d ) o f a cellular structure 
and the size of the central hollow struts by Eq. (4.1): 
^ ^ = 0.2 
^fs 
1+ 
Pfc oarn 
Psoiid 
V O 
1-
(4.1) 
where t j t is the ratio of the void and strut sizes on a cross-section of a strut (see Fig. 
4.4) and Ofs is the modulus of rupture of the strut. Theoretical calculations show that the 
modulus of rupture of a brittle material is typically about 1.1 times larger than the 
tensile strength In our calculation, the tensile strength a,5= 42MPa of 45S5 
Bioglass® dense material (annealed) was used for the strength of the partially 
crystallised material. The ratio tJt was estimated to be 0.5 according to Fig. 4.4. 
108 
Table 4.3 Overview of structural characteristics and mechanical properties of highly porous bioactive ceramic or glass foams for bone tissue 
engineering 
Technique Material Porosity 
(%) 
Pore Size / jim Closed (C) or 
Open (O) 
Compressive 
Strength / MPa 
Ref 
Polymer-sponge 
45S5 Bioglass® 89-92 510-720 0 0.27-0.42 Present work 
Glass-reinforced HA 85-97.5 420-560 0 0.01-0.175 211 
HA 86 420-560 0 0.21 186 
69-86 490-1130 0 0.03-0.29 185 
Gel-casting / foamed by 
vigorous stirring HA 
HA 
76.7-80.2 20-1000 
Cell: 100-500 
Window: 30-120 
Partly 0 /C 
Partly 0 /C 
4.4-7.4 
1.6-5.8 
208 
209 
polymer-sponge HA 
p-TCP + HA 
70-77 
73 
200-400 
200-400 
0 
0 
0.55-5 
9.8 
210 
235 
Sol-gel / foamed by 
217 vigorous stirring Bioactive glasses 
(e.g.70S30C) 
70-95 Cell: up to 600 
Windows: 80-120 
Partly 0 /C Not Available 
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Using Eq. (4.1), the compressive strength of the present foams (with t jt=0.5) and the 
lower bound of theoretical strength (when tjt= 0) were calculated. The results are 
illustrated in Fig. 4.15. The experimental strengths determined by compressive strength 
tests are generally above the lower boundary, and most of them are in good agreement 
with the theoretical strengths when 0.5. This indicates that the cell walls have 
been sintered to be fully dense at 1000°C for 1 hr. 
Two points should be mentioned. (1) The tensile strength of sintered HA is 40MPa, 
which is very close to that of dense 45S5 Bioglass® (42MPa) Hence theoretically, the 
mechanical strength of a 45S5 Bioglass®-based scaffold should be similar to, if not 
higher than, that of a HA scaffold with a similar porous structure. (2) As t j t increases, 
the foam becomes stronger. In other words, the hollow tubular structure is beneficial to 
the mechanical performance of the foam, which is a direct result of the derivation of Eq. 
4.1 261 
A 
A 
•Theoretical s 
•Theoretical s 
Experimenta 
Experimenta 
length (ti/t=0) 
length (ti/t=0.5) 
strength with shearing involved 
strength without shearing 
Reported strength of HA-based foams in literature[31-33] 
fa 0.5 
o 0.4 
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0.84 0.86 0.88 0.9 0.92 0.94 0.96 
Porosity 
Fig. 4.15 Theoretical and experimental compressive strength values of Bioglass®-based 
scaffolds in the present work. Theoretical values were calculated from Eq. 4.1 for 
different values of ti/t. 
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3.4. POSSIBLE MECHANISMS FOR THE TRANSITION FROM NazCazSisOg TO 
AN AMORPHOUS PHASE 
Since the sintered 45S5 Bioglass® material is a glass-ceramic, one might argue that the 
bioactivity of the sintered material could be attributed to the residual glass phase. We 
suggest that the bioactivity remains also with the crystalline phase NaiCaiSisOg, based 
on two reasons: (1) the bioactivity of pure NaiCaiSisOg phase has been reported and 
(2) the transition from NazCaiSigOg to an amorphous phase provides an explanation for 
the finding that the presence of NaiCazSisOg decreased the kinetics of apatite formation 
but did not inhibit the growth of an apatite layer on the foam surfaces, which has been 
reported in the literature Actually the phase transition from Na^Ca^SisOg to an 
amorphous phase is an early step of the bioreaction of crystalline NaiCazSisOg. 
The mechanisms behind the transformation of NaiCazSigOg to an amorphous phase 
might be based in the well-known bone-bonding mechanisms of bioactive glasses, 
which were originally proposed by Hench and colleagues In the sequence of 
interfacial reactions on the surface of Bioglass® in contact with body fluids, the 
bioactive glass first dissolves to form a silica-gel layer; then an amorphous calcium 
phosphate is formed from the hydrated silica-gel; and finally apatite crystallites nucleate 
and grow from the amorphous calcium phosphate. We suggest that the general idea of 
the reaction sequence should be applicable to NaiCaiSigOg crystallites as well, which 
however dissolves at a slower rate than the glass phase. Hence, it is very likely that the 
amorphous phase detected by XRD after immersion in SBF for 28 days (Figs. 4.11 and 
4.12) is the amorphous calcium phosphate, according to Hench et a/ 's theory 
Although the kinetics of the transformation have yet to be fully understood, it is 
believed that the high surface area (including hollow centre of the struts) in the porous 
network is of relevance in maintaining bioactivity and biodegradability of the sintered 
45S5 Bioglass®-based foams. The high surface energy should assist that the 
transformation of NaiCaiSisOgto the amorphous phase of calcium phosphate occurs at a 
reasonably fast rate at the body temperature. This assumption is supported by the fact 
that the bioactive reactions only occur at the surface of a bulk solid glass. It is based on 
this fact that bioactivity is defined to be the interfacial ability to bond to bone 
I l l 
3.5. SIGNIFICANCE OF THE TRANSFORMATION OF NazCazSisOg TO THE 
AMORPHOUS PHASE 
An ideal scaffold for bone engineering serves as a temporary frame to foster new bone 
growth. It is expected to provide a temporary mechanical support and later to degrade at 
a rate matching the regeneration rate of new bone tissue. Unfortunately this is not the 
manner conventional bioceramics behave in biological conditions. Crystalline HA, for 
example, can provide reasonably strong support; but it degrades very slowly in contact 
with body fluids, the degradation time being of the order of years. Amorphous HA 
degrades much faster than crystalline HA; but it is too fragile to build highly porous 
scaffolds. Bioactive glasses encounter a similar hurdle: they have excellent bioactivity 
and tailorable biodegradability; at the same time they possess poor mechanical strength 
and low reliability. 
The above problem could be solved by designing scaffolds using the results of this 
study, which has shown that the mechanically strong crystalline phase NaiCaiSigOg 
[which is formed in 45S5 Bioglass® upon sintering at suitable temperatures (see Section 
2.2 in this chapter)] can transform into an amorphous calcium phosphate (the good 
resorbability of which has been well documented in a simulated body fluid 
enviromnent (Figs. 4.11 and 4.12). Based on this finding, it is possible to sinter 45S5 
Bioglass® green foams at optimised conditions such that both significant densification 
and controlled NaiCaiSigOg crystallisation take place. The extensive densification and 
fine crystalline nature of Na2Ca2Si309 give the scaffold a temporary good mechanical 
property. The transformation of NaiCazSisOg to the amorphous calcium phosphate, 
which is expected to occur upon exposure to a biological environment, ensures the 
bioactivity and degradability of the scaffold. 
The transformation of a crystalline phase to a degradable amorphous phase is not an 
exclusive phenomenon of 45S5 Bioglass® material. HA and related calcium phosphates 
also show a similar transition in an in vivo environment The difference compared to 
Bioglass® is that the transition in HA is too slow to match clinical expectation (it is in 
fact fundamentally wrong to expect crystalline HA to degrade fast in the body, 
considering that nano-sized HA is a stable component of natural bone). It has been 
shown that only a thin layer of amorphous phase on the surface of crystalline HA 
particles (~0.5|j.m) is formed after implantation for 3 months, and that HA particles do 
not significantly degrade even after implantation for 6 months Tissue engineering 
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applications demand that the degradation kinetics of a scaffold should match the 
regeneration kinetics of new bone in vitro and/or in vivo. In general the degradation 
time should be less than 6 months, depending on the anatomic site for regeneration, the 
mechanical loads present at the site, and the desired rate of osseointegration 
Hence, the significance of the transformation of crystalline NaiCazSigOg to an 
amorphous phase in our 45S5 Bioglass®-based foams lies in its kinetics which seems to 
be sufficiently fast for application of the material in bone regeneration. More 
importantly, the kinetics of the transformation and the scaffold degradation can be 
controlled by factors such as initial crystallinity, microporosity in struts, and grain size 
of NaiCaiSiaOg, all of which can be tailored by the sintering conditions. In general, a 
high crystallinity, a low microporosity and a large crystal size of the crystalline phase 
will lead to a slower kinetics of the transformation and thus degradation due to the 
low diffusion rate in these microstructures. Therefore, the goal of an ideal scaffold that 
provides good temporary mechanical support and biodegrades subsequently at a 
tailorable rate can be achieved with the developed 45S5 Bioglass®-based scaffolds. 
4. CONCLUSIONS 
In this part of the project, we have successfully synthesized highly porous, mechanically 
competent, bioactive and biodegradable 4585 Bioglass®-based scaffolds for bone 
engineering, using the replication technique. The main findings are: 
(1) The optimum sintering temperature is 1000°C; sintering time is Ihr; and heating 
and cooling rates are 2°C/min and 5°C/min, respectively. 
(2) The 45S5 Bioglass®-based scaffolds sintered under the optimum conditions have a 
similar macroporous structure to spongy bone: a) they are highly porous (-90%), b) 
they have completely open porosity, and c) they have appropriate pore size to 
deliver bone cells, transport nutrients, remove wastes, and to vascularize (510-
720nm) 
(3) During heat-treatment extensive densification of struts occurs, and the parent glass 
crystallises partially to NaiCaiSiaOg. The nearly full densification and the fine 
crystals of NaiCaiSisOg confer the scaffolds competent mechanical strength, which 
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is in general higher than that of equivalent HA-based foams and comparable to that 
of spongy bone. 
(4) A significant finding is that the mechanically strong crystalline phase can transform 
into a bioactive and biodegradable amorphous calcium phosphate upon immersion 
in SBF. 
(5) The goal of an ideal scaffold that provides good temporary mechanical support 
while maintaining bioactivity and that can biodegrade upon implantation at a 
tailorable rate is achievable with the present Bioglass®-based glass-ceramic 
scaffolds. 
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CHAPTER FIVE 
EFFECTS OF POLY(D,L-LACTIDE) COATING ON 
THE BIOGLASS®-BASED FOAMS 
1. INTRODUCTION 
It is essential that scaffolds mimic the extracellular matrix (ECM) of the tissue to be 
engineered From a biological perspective, it is a natural strategy to combine polymer 
and ceramic materials to fabricate composite scaffolds for bone tissue engineering 
because natural bone is a composite, the result of the combination of a naturally 
occurring polymer (type I collagen) and biological apatite. From a materials science 
point of view, a single material type does not always provide the necessary mechanical 
and/or chemical properties desired for a particular biomedical application. Polymers and 
ceramics that degrade in vivo should be chosen for designing biocomposites for tissue 
engineering scaffolds . While massive release of acidic degradation from polymers 
(e.g. polyesters) can cause inflammatory reactions the basic degradation of 
calcium phosphate or bioactive glasses would buffer the acidic degradation by-products 
of the polymers ''^ '^ 4,96,147 should thereby help to avoid the formation of an 
unfavourable environment for cells due to a decreased pH. Mechanically, bioceramics 
are much stronger than polymers and this property plays a critical role in providing 
mechanical stability to constructs prior to the in vivo formation of new bone matrix. 
However, ceramics and glasses are fragile due to their intrinsic low fracture toughness 
and high flaw sensitivity. To capitalise on their advantages and minimise their 
shortcomings, bioactive ceramics and glasses can be combined with polymers to form 
composite biomaterials for osseous regeneration 6S,66,M7,i48,i52 
The Bioglass®-based foams fabricated in this work (see Chapter 4) are brittle and 
further improvement of their mechanical properties is necessary. It is expected that the 
fracture toughness of the brittle foams can be improved by coating of the struts with a 
polymer layer. Indeed the coating of brittle glass articles by polymer layers is an 
essential procedure to increase the fracture resistance and toughness, for example in 
glass fibre production of food packaging and beverage articles However, very few 
investigations have been reported associated with coating polymers onto ceramic tissue 
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engineering scaffolds Therefore, the purpose of this investigation was to produce 
rehable, biodegradable polymer (PDLLA) coatings on the struts of Bioglass®-based 
foams, and to characterise the in vitro bioactivity and mechanical properties of the new 
composite foams that are intended for bone tissue engineering scaffolds. The 
experimental details of the materials used and coating procedure have been given in 
Chapter Two. 
2. RESULTS AND DISCUSSION 
2.1. POROUS STRUCTURE OF FOAMS 
SEM observations showed that the open pore structure of sintered foams remained after 
coating with PDLLA, with only few of the pores being blocked (clogged) by the coating 
(Fig. 5.1a). The typical strut surface morphology of a coated foam is illustrated in Fig. 
5.1b, indicating that the coating procedure developed is satisfactory in terms of 
complete coverage of the strut surfaces. 
i l 
.f p 
Fig. 5.1 (a) Macroporous structure and (b) surface morphology of struts of a foam 
sintered at 1000°C for Ihr followed by coating with poly(D,L-lactic acid). 
Fig. 5.2 gives the porosities of 4585 Bioglass®-based foams before and after coating 
with PDLLA, calculated by Eqs.(3.1). The percentage of porosity reduction Pi - Pi 
P\ 
after coating with PDLLA was only 2.2% on average. The weight percentage of 
PDLLA in coated foam was in the range 15-30%, being 22% on average. The thickness 
of the PDLLA layer applied on the foam struts was estimated as follows. 
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Fig. 5.2 Porosities of Bioglass®-based foams before and after coating with poly(D,L-
lactic acid) 
Academy Aftwofks 
Fig. 5.3 A pentagonal dodecahedron cell showing the distances D and I (adapted from 
Academic Artwork). 
Assume that the cells of the polyurethane foam used as sacrificial templates are on 
average pentagonal dodecahedra (Fig. 5.3), which is the cell shape in most commercial 
polymer foams. A pentagonal dodecahedra cell has twelve facets ( / = 12), with every 
face having five edges (i.e. Mg = 5 ) Each cell has 30 edges (i.e. M = 12x5 = 30). 
Some geometric properties of a pentagonal dodecahedra cell are given in Table 5.1, in 
which the length of an edge is assumed to be /. 
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Table 5.1 Geometric properties of a pentagonal dodecahedra polyhedron 
Number of Number of Edge Cell Surface Cell 
face ts , / edges, n length diameter, D area volume 
12 30 30Z 2.80Z 20.646/^ 7.663/^ 
The cell diameter of the present polyurethane foam is 890 p.m on average, which was 
provided by the foam supplier (Recticel UK at Corby). It has been mentioned in Chapter 
4 that the linear ratio between a Bioglass®-based foam and its polyurethane foam is 70% 
on average. Hence, in the as-sintered Bioglass®-based foam the mean diameter of cells 
is: 
D = 890x0.7 = 6 2 3 ( 5 . 1 ) 
Assume that the cells are close-packed in space, i.e. the packing network is face-centred 
cubic (FCC) or hexagonal closed-packed (HCP) structure. The FCC lattice constant a 
can be expressed as a function of the diameter D of cells as follows; 
a = (5.2) 
Therefore the cell number per volume can be given by: 
The number of edges in a unit volume is: 
A '* . = (5.4) 
3 
considering that an edge is shared by three cells on average. Then the edge length per 
volume is: 
= (5-5) 
Assuming that the cross-sections of struts are hollow with a central tubular equilateral 
triangular void, as shown in Fig. 5.4, /1 can be estimated to be 0.5 according to Fig. 
4.4. Therefore, the area of the cross-section occupied by the substrate is: 
(5.6) 
4 4 16 
and the weight of unit volume, i.e. the density of the foam, can be expressed by: 
Pfoam = e^dge-ypBG = ^3 PbG ' (5 ?) 
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t 
Fig. 5.4 A schematic cross-section of foam struts (see also Fig. 4.4) 
Finally t is given by: 
V30V6Z PsG 
where Pg^ = 2.7 g/cm^ is the density of solid Bioglass®, / = — ^ according to Table 
2.80 
5.1, D = 0.0623 cm, and can be determined by measuring the weight and size of a 
foam. Using Eq. (5.8), t was estimated to be 150p,m, which is in agreement with SEM 
observations (100-200 microns) (Fig.4.2). Therefore 
r = 150|im (5.9) 
will be used as the mean value of the dimension of struts cross section in the present 
calculation. 
Let A/? stands for the thickness of the PDLLA coating. Then the weight of PDLLA in a 
unit volume of foam can be expressed as: 
"^•^POLLA ^ 3r • A/z • I • -^ edgePPDLLA ' (5.10) 
where Pp^lla =1.26g/cm^ is the density of sohd PDLLA Finally, the coating 
thickness can be expressed as: 
AA = . (5^1) 
PDLLA 
WpPLLA can be obtained by measuring the weight and size of a foam before and after 
coating PDLLA. t is given in Eq. (5.9), / = — ^ according to Table 5.1, Z) being 0.0623 
2.80 
cm. Zedge is given by Eq.(5.5). Thus the coating thickness can be determined by Eq. 
(5.11). 
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The calculation eventually showed that the coating thickness on the present foams was 
in the range l-5)j,m, being 2.7^m on average. This coating thickness was very thin, 
compared with the mean dimension {t = 150pm) of strut cross-section in the present 
foams. Hence, the overall pore structure of the foams, discussed in detail in the previous 
chapter, did not change substantially. 
2.2. ASSESSMENT IN SIMULATED BODY FLUID 
Fig. 5.5 shows the XRD spectra of coated foams after immersion in SBF for up to 8 
weeks. The bioactivity, which was characterised by assessing the formation of HA on 
scaffold surface upon immersion in SBF, was maintained in the coated foams, as 
indicated by the increment of the HA peak height on the XRD pattern. Like as-sintered 
(uncoated) foams (Fig. 4.12), the crystalline phase NaiCaaSiaOg transformed to an 
amorphous phase when the coated foams were soaked in SBF for a certain period. Thus 
it can be assumed that the foams after coating with PDLLA will be biodegradable, as 
with the as-sintered foams. However, a comparison between Figs. 4.12 and 5.5 reveals 
that the kinetics of the transformation of NaiCaiSisOg to an amorphous phase is slower 
for coated foams than for uncoated foams, the difference being about 4 weeks. 
The formation of HA-like crystalline apatite on the surface of coated foams was clearly 
observed by SEM after immersion in SBF for 3 days and longer, as illustrated in Fig. 
5.6 (a-d). Hydroxyapatite crystals were recognised by their well-known globular, 
cauliflower shape. It was shown above that the thickness of the PDLLA films was not 
homogenous due to the roughness of the original strut surface of the as-sintered foams, 
the films being thimier at the hill positions (see Fig. 5.1b). Fig. 5.6b, for example, shows 
that the PDLLA films at these positions were perforated upon soaking in SBF. Thus the 
broken areas of the PDLLA films should provide channels for SBF to flow into and 
come in contact with the bioactive material underneath the films. With increasing 
soaking time, a large surface area of the bioactive substrate becomes exposed to SBF, 
and thus the HA-like phase formed directly on the substrate can be clearly recognised 
(Fig. 5.6c). Eventually the bioactive substrate was covered by a continuous layer of HA, 
on which agglomerates of new HA crystals were formed (Fig. 5.6d). 
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Fig. 5.5 X-ray diffraction spectra of 45S5 Bioglass® foams sintered at 1000°C for 1 hr, 
coated with poly(D L-lactic acid), and immersed in SBF for 1, 2 4, 6 and 8 weeks. All 
spectra were obtained using O.lg powder. The major peaks of NaiCaaSiaOg phase and 
hydroxyapatite are marked by ( V ) and (•) , respectively. 
At higher magnifications, the apatite formations on foams immersed in SBF for 4 weeks 
were observed to be made of very fine needle-shaped crystals, being 0.25|im in length 
and 0.05(im in diameter, as illustrated in Fig. 5.7a. The formation of the HA -like phase 
on the uncoated foams after soaking in SBF for 4 weeks is illustrated in Fig. 5.7b. A 
comparison of the morphologies of the HA-like layers formed on coated (Fig. 5.7a) and 
uncoated foams (Fig. 5.7b) reveals that HA-like crystallites are embedded in PDLLA in 
the coated foams, which means that the layer formed on the strut surfaces of coated 
foams (Fig. 5.6d) is in fact a nanocomposite of HA and PDLLA. 
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Fig. 5.6 Hydroxyapatite formed on the surfaces of Bioglass®-based foam struts after 
immersion in simulated body fluid for (a) 3 days, (b) 7 days, (c) 14 days, and (d) 28 
days. The foams were sintered at 1000°C for 1 hour and coated with poly(D,L-lactic 
acid). 
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Fig. 5.7 Morphology of hydroxyapatite formations on the surfaces of Bioglass®-based 
foam struts after immersion in simulated body fluid, (a) Foams sintered at 1000°C for 1 
hour, coated with poly(D,L-lactic acid), and immersed in SBF for 28 days, (b) Foams 
sintered at 1000°C for 1 hour (uncoated) and immersed in SBF for 28 days. 
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2.3. EDX ANALYSIS OF THE HA-LIKE PHASE 
The composition of the HA-Uke phase in uncoated and coated foams soaked in SBF for 
up to 8 weeks was analysed using the EDX technique, as shown in Figs. 5.8 and 5.9, in 
which the stoichiometric compositions of two calcium phosphates (CaP): HA and 
tricalcium phosphate (TCP) are given as well. In the HA-like layer of uncoated foams 
(Fig. 5.6), the level of sodium first decreased rapidly, while the silicon content was still 
higher at the early stage of SBF immersion (Figs. 5.8a and 5.8b). On the other hand, the 
calcium content increased fast to reach the level of CaP (Fig. 5.8b), while the level of 
phosphate was still much lower than in CaP. After soaking in SBF for 28 days, the 
composition of the surface layer of foam struts was very close to the stoichiometric 
compositions of HA and tricalcium phosphate (TCP) (EDX analysis cannot distinguish 
the compositions of HA and TCP). Although EDX analysis cannot identify whether the 
newly-formed surface layer is HA or TCP, it is highly likely that HA is the fmal product 
in an aqueous environment because the hydrolysis of TCP produces HA 
The raw spectra obtained on the coated foams are illustrated on the left column of Fig. 
5.9 (Figs. 5.9a-c). The high level of carbon was contributed by PDLLA, confirming that 
the newly formed layer was a composite of HA and PDLLA, as mentioned above. 
PDLLA also contains oxygen. To analyse the composition of the HA-like material, the 
contents of carbon and oxygen contributed by PDLLA must be removed from the EDX 
results. It is certain that the content of carbon came completely from PDLLA and thus it 
can be removed entirely. It is uncertain, however, how much oxygen should be reduced. 
An immediate thought is to subtract (if the accuracy of the carbon content is guaranteed) 
oxygen according to the ratio 0 /C in PDLLA which is 2/3, i.e. 2 at.% oxygen and 3 
at.% carbon are deducted simultaneously. Unfortunately, however, the EDX detector 
installed within the SEM used is made of a polymer, and thus the determination of 
carbon content is not reliable. 
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Fig. 5.8 Energy-dispersive x-ray results on the surfaces of as-sintered Bioglass'-based 
foam struts after immersion in simulated body fluid for (a) 3 days, (b) 2 weeks, and (c) 
4 weeks, together with the compositions of 45S5 Bioglass® and stoichiometric 
compositions of two calcium phosphates (hydroxyapatite and tricalcium phosphate). 
The foam was sintered at 1000°C for 1 hr. 
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Fig. 5.9 Energy-dispersive x-ray results on poly(D,L-lactic acid) coated Bioglass -based 
foams after immersion in simulated body fluid for (a)-(a') 3 days, (b)-(b') 4 weeks, and 
(c)-(c') 8 weeks. The foams were sintered at 1000°C for 1 lir and coated with p o l y ( D , i , -
lactic acid), (a)-(c) show the raw data, and (a')-(c') show the results after removing the 
carbon and oxygen contributed by poly(D,L-lactic acid). 
An alternative method to approach the problem is to determine an apparent 0/C ratio 
through pure PDLLA which is used as a reference material, and to deduct the oxygen 
content according to the apparent 0 /C ratio. It was found that the apparent 0/C ratio 
obtained from pure PDLLA soaked in SBF for different periods was always very close 
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to 2. Using this ratio, the level of oxygen was reduced from all EDX raw data of coated 
foams, and the data were normalised, as shown on the right column in Fig. 5.9 (Figs. 
5.9a'-c'). It can be seen that the adjusted spectra show results that are similar to those 
illustrated in Fig. 5.8, i.e. at earlier stages, the exchange between calcium and sodium 
ions was fast, as manifested by the rapid increase of calcium level and the decrease of 
sodium content (Fig. 5.9a'). At later stages, the silicon concentration reduced greatly, 
whilst the phosphate level was similar to that in CaP (Figs. 5.9b' and 9c'). 
A comparison of Figs. 5.8 with 5.9a'-c' shows that the compositions of HA-like layers 
on coated and uncoated foams both reached the standard HA composition after the 4 
weeks in SBF, indicating that the kinetics of HA formation was not considerably 
retarded by the PDLLA coating after immersion in SBF for 4 weeks. 
2.4. MECHANICAL PROPERTIES 
2.4.1. Compressive Strength of As-Coated and As-Sintered Foams 
Typical compressive stress-strain curves of uncoated and coated foams are shown in 
Fig. 5.10. The jagged curves show three regimes with increasing strain: stress increase, 
stress decrease (uncoated foam) or plateau (coated foam), and densification stage. The 
compressive stress-strain curve of the coated foam was much less jagged, compared 
with the curve of the as-sintered Bioglass®-based foams. The reduction in jagging could 
indicate that coated foams had fewer micro cracks than as-sintered samples, assuming 
that the jagged curves were caused by micro cracks on the surface of the struts. This 
improvement in mechanical stability is thought to be the result of the PDLLA coating, 
which fills micropores and microcracks on the strut surfaces. 
In addition, the incidence of shearing that is frequently a feature of compression 
deformation in uncoated foams was considerably reduced in PDLLA-coated foams. 
This could also be attributable to the low occurrence of cracking in struts when foams 
are compressed, as unbalance cracking in a foam under compression leads to shearing. 
The raw data of compressive strength are plotted against foam porosities in Fig. 5.11. In 
both Figs. 5.11a and 5.1 lb, the two lines shown are the theoretical compressive strength 
values calculated by Eq. (4.1). As t j t increases, the foam becomes stronger. Hence the 
compressive strength curve for t j t = 0 actually sets the lower bound of theoretical 
compressive strength. In Figs. 5.11a and 5.11b, the compressive strength values of a 
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coated foam are plotted against the porosity of its as-sintered counterpart and against the 
porosity of the coated material, respectively. 
Coated 
As-smtered 
N W Uil, W' O O0.1 
0 0.2 0.4 0.6 
Strain 
0.8 
Fig. 5.10 Typical compressive stress-strain curves of an as-sintered Bioglass"-based 
foam and a poly(D.L-lactic acid) coated foam. 
The compressive strength of as-sintered foams was considerably increased by coating 
with PDLLA (Fig. 5.11a). However, the overall porosity of the foam was reduced as 
well. If the compressive strength values of coated foams are plotted against the porosity 
of the final materials as shown in Fig. 5.1 lb, the values of the compressive strength are 
in the same range as those of uncoated foams. Nonetheless, the compressive strengths 
were collectively improved by coating with PDLLA because more measured strength 
values lie above the lower boundary of the theoretical compressive strength. 
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Fig. 5.11 Compressive strength of as-sintered and poly(D,L-lactic acid) coated foams. 
For poly(D,L-lactic acid) coated foams the strengths are plotted against (a) the porosities 
of the their as-sintered counterparts and (b) the porosities of the final products. The 
theoretical strength values were calculated by Eq. (4.1). 
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To summarise, the compressive strength values of coated foams remained in the same 
range as those of as-sintered foams of equivalent porosity, but the data shifted towards 
the upper boundary at this porosity range. The above phenomenon can be attributed to 
the following facts: 
(i) The PDLLA coating films were very thin (thickness: l-5|j,m), compared with the 
diameter of the struts (100-200|j,m). Hence it was not surprising that the strength of the 
coated foams was not increased considerably by such thin films. 
(ii) Such a thin coating, however, can effectively fill micropores and microcracks on the 
strut surfaces and thus improved the mechanical stability of a flaw sensitive material. 
The reduction of microcracking on the strut surfaces led to less jagging in stress-strain 
curves as seen in Fig. 5.8, and in turn decreased the incidence of shearing that resulted 
in low compressive strength values of uncoated foams. 
2.4.2. Compressive Strength after SBF Immersion 
Compressive strength tests were carried out on completely dried foams after immersion 
in SBF for given periods. The raw data are shown in Fig. 5.12. It was found that the 
mechanical strength of as-sintered foams gradually deteriorated after immersion in SBF, 
particularly when the crystalline phase transformed into the amorphous phase after 
immersion in SBF for 4 weeks (Fig. 4.12). In general, compressive strength values 
decreased to ~0.03MPa for the retrieved foams (porosity: -90%) after soaking in SBF 
for 1 month. The reduction in mechanical strength is not unexpected, considering the 
fragility of the amorphous structure in comparison with the highly crystalline structure 
of the as-sintered materials. 
However, the mechanical strength upon immersion in SBF decreased slightly in 
PDLLA-coated foams, even after immersion in SBF for 2 months, when the crystalline 
phase transformed into the amorphous phase (Fig. 5.5b). For a foam of final porosity 
89%, for example, the compressive strength was 0.23MPa, which was at the same level 
as the value measured on foams before immersion in SBF (Fig. 5.1 lb) and one order of 
magnitude higher than that of uncoated foams after immersion in SBF for 4 weeks (Fig. 
5.12). The well-maintained mechanical strength might be attributable to two opposite 
but balancing affecting factors: (a) transformation of the crystalline phase to the 
amorphous phase and (b) formation of a HA/PDLLA nanocomposite film on the strut 
surface of foams during immersion in SBF, as mention above (see Fig. 5.7a). 
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Fig. 5.12 Compressive strength values of coated and uncoated Bioglass"-based foams 
after immersion in simulated body fluid for up to 3 months, as a function of foam 
porosity. 
2.4.3. Bending Strength of As-Coated and As-Sintered Foams 
The raw data of three-point bending strength of as-sintered and coated foams are given 
in Fig. 5.13. Generally, the bending strength was higher than the compressive strength 
in foams of the same porosities (Fig. 5.13a). Like the compressive strength values 
shown in Fig. 5.11, the increment of the bending strength induced by the PDLLA 
coating was gained at the cost of a certain reduction in porosity. When the bending 
strength data were plotted against the porosity of the final material, the bending 
strengths of the coated foams were still collectively higher than those of as-sintered 
foams (Fig. 5.13b). 
Typical three-point bending force-displacement curves for as-sintered and coated foams 
are shown in Fig. 5.14. A comparison of the force-displacement curves of foams, which 
have similar porosities and the same maximum bending strengths, reveals that the 
curves of coated foams are much less jagged than those of as-sintered foams. More 
importantly, the work of fracture j f d ^ {F represents force, and .s* stands for 
displacement) was on average 3.71Nmm under the curve of coated foams, whereas it 
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was only 0.195Nmm under the curve of as-sintered foams. The former was 
approximately 20 times higher than the latter. It can thus be concluded that the work of 
fracture of the foams has been greatly enhanced by the PDLLA coating. Since the work 
of fracture of the foams has been improved without lowering their fracture strength 
values (which have even improved, see Fig. 5.11), it can also be concluded that the 
fracture toughness values of the foams have been enhanced, as high fracture toughness 
is related to high stress and strain to rupture 
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Fig. 5.13 Bending strength of as-sintered and poly(D,L-lactic acid) coated foams. For 
poly(D,L-lactic acid) coated foams the strengths are plotted against (a) the porosities of 
their as-sintered counterparts and (b) the porosities after coating. 
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Fig. 5.14 Force-displacement curves in three-point bending test for as-sintered 
(uncoated) and poly(D,L-lactic acid)-coated foams. 
3. CONCLUSIONS 
A comparative investigation has been carried out on the mechanical properties and 
bioactivity of Bioglass®-based foams before and after applying a poly(D.L-lactic acid) 
(PDLLA) coating layer (-2.7 pim thickness) on the foam struts. It was found that: 
(1) The bioactivity of Bioglass®-based foams has been maintained after application of 
PDLLA coatings. However the transformation kinetics of the crystalline phase 
NaiCajSiaOg in the as-fabricated foams to amorphous calcium phosphate phase 
upon immersion in SBF was found to be retarded in the PDLLA-coated foams, 
compared with the as-sintered foams. 
(2) The compressive and three-point bending strengths of novel Bioglass®-based foams 
have been slightly improved by coating with PDLLA. 
(3) On the other hand, their mechanical stability has been considerably enhanced by the 
coating, as demonstrated by the remarkable increase of the work of fracture in the 
coated foams. The work of fracture was on average 3.71Nmm for the PDLLA-
coated foams, whereas it was only 0.195Nmm for the uncoated foams. The former 
was approximately 20 times greater than the latter. 
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(4) The mechanical strength of as-sintered foams decreased to a large extent (from 0.3 
to 0.03 MP a) upon immersion of the foams in SBF when the crystalline phase 
Na2Ca2Si309 transformed to the amorphous calcium phosphate. However the 
mechanical performance was maintained in PDLLA coated foams even after 
immersion in SBF for 8 weeks when the crystalline phase NazCaiSigOg transformed 
to the amorphous calcium phosphate. This behaviour is thought to be the result of 
the in-situ formation of a nanocomposite film of PDLLA and hydroxyapatite 
crystals on the strut surface of the foams. 
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CHAPTER SIX 
SURFACE CHEMICAL MODIFICATION OF 
BIOGLASS®-DERIVED SCAFFOLDS 
1. INTRODUCTION 
Most cells are anchorage-dependent; i.e. they need to attach and spread out on a 
substrate before they start their proliferation. Hence, the first and foremost function of a 
scaffold in tissue engineering is its role as substratum for cell attachment. Indeed, the 
ability to support and foster cells is one of essential criteria for an ideal scaffold 
In the field of cell biology, great efforts have been invested to understand cell anchorage 
on extracellular matrix (ECM) and to utilise the knowledge to promote cell attachment 
on artificial substrates. The early empirical knowledge includes: (1) Cells adhere well to 
glass, particularly to glass with high silica content (for decades cell biologists grew cells 
almost exclusively on glass, and the term 'm vitro' usually means on/in glass) (2) 
Cells will attach to and spread on glass and plastics that have a slight net surface 
negative charge (3) A well-established piece of cell culture lore has it that used 
glassware supports cell growth better than new ones It is known that cells do not 
attach directly to any substrates (including natural ECMs and artificial substrates), 
rather they bind to intervening ECM components (i.e. proteins such as fibronectins and 
collagens) that are adsorbed (or derivatized) to the substrate and accepted by specific 
cell surface receptors (e.g. integrins) 
Based on the above facts, cell attachment and growth can be improved by pre-treating 
the substrate (a process called surface functionalisation) in two steps The first 
step is surface chemical modification, aiming at attracting specific matrix proteins. 
Three representative techniques are: i) plasma-modification of polymer surfaces 
ii) silane modification of glass and ceramic surfaces (e.g. SiOz, TiOi and AI2O3) 
219,246,247^  and iii) thiol-modification of metallic surfaces (e.g. titanium alloys) In 
fact, standard tissue culture plates are bacteriological (nonadhesive) plastic dishes that 
have been chemically treated using proprietary methods to enhance adsorption of 
serum- and cell-derived ECM proteins. The second step is surface-grafting with ECM 
proteins or artificial peptides that, in turn, attract cells to attach to the artificial substrate 
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via receptor mediated events. The aforementioned cell culture lore is the result of 
surface-grafting: the used flask can be conditioned by collagen, fibronectin or other 
matrix products released by the cells during previous cell culture. It must be noted that 
ECM components can be experimentally immobilized on the culture surface, deposited 
de novo by the adhering cells, or spontaneously adsorbed from serum. Hence, the 
second step (protein grafting) mentioned above is unnecessary for tissue engineering 
scaffolds either in vitro or in vivo, except that they incorporate a drug delivery function. 
As mentioned in Chapter 2, Bioglass® and other bioactive ceramics have an excellent 
bone-bonding ability due to their ability to deposit hydroxyapatite that has a high 
capacity to bind proteins However, the bioactive function of bioactive glasses can 
be hampered by crystallisation Therefore, surface functionalisation is necessary to 
maintain the protein-binding ability of partially crystallised silicate systems, including 
the Bioglass®-derived glass-ceramic scaffolds developed in this research project. 
Specifically, the glass-ceramic scaffolds were silanized in 3-AminoPropyl-
TriethoxySilane (APTS), followed by the attachment of a protein coupling agent: 
glutaraldehyde (GA) One of the objectives of this work was to investigate for the 
first time the efficiency and stability of the surface modification on the present 
Bioglass®-based scaffolds. 
As described in Chapter four, the transition of the mechanically competent crystalline 
phase to a biodegradable amorphous calcium phosphate at the body temperature is a 
unique feature of the Bioglass®-derived scaffolds. The kinetics of this transition, which 
controls bioreactivity and is thus a key factor to be considered in the design of scaffolds, 
is directly influenced by the surface chemistry (and surface area as well) of the porous 
network. Although there is a huge amount of literature on the bioreactivity of bioactive 
glasses and associated dissolution mechanisms, that information is hardily relevant to 
the present extensively crystallised glass-ceramic material. Therefore, the second 
objective of the work reported in this chapter was to investigate how the surface 
chemical modification carried out as mentioned above could influence the bioreactivity 
of the Bioglass®-derived glass-ceramic scaffolds. 
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2. RESULTS 
The Bioglass® powder used in the work presented in this and next chapters had a larger 
mean particle size (10-20 )am), compared to the powder used in the investigations 
presented in Chapters four and five. The large particle size considerably slowed down 
sintering kinetics, in agreement with the prediction of Eq. 3.2. As a result, the struts 
were not fully densified, exhibiting large surfaces of incompletely sintered particles 
exposed to the fluid. This eventually led to a fast degradation rate of the foams in SBF. 
The three groups of foams investigated in this part of the investigation are listed in 
Table 6.1. 
Table 6.1 Three treatment processes on the Bioglass®-derived foams 
Foams Treatment 
As-sintered Sintered at 1000 °C for 1 hr 
Surface-modified 
(or Surface-
functionalised) 
Sintered at 1000 °C for 1 hr, followed by surface 
modification in buffered (pH = 8) water with APTS at 80 
°C for 4 hrs and in GA solution at room temperature for 1 
hr 
Water-treated Sintered at 1000 °C for 1 lir, followed by treatment in 
buffered (pH = 8) water at 80 °C for 4 hrs 
2.1. XPS ANALYSIS 
XPS analysis was carried out before and after functionalisation on sintered pellets (three 
samples of each condition investigated) to determine the surface composition with a 
typical analysis depth of 5-10 nm. In addition, the surfaces were analyzed by XPS after 
immersion in SBF for 3 days. The results from sintered pellets presented in this section 
should be directly applicable to the scaffold samples, because they were fabricated 
under the same conditions and the same process parameters were used in the 
functionalisation steps. 
Due to contamination, the raw data of carbon and nitrogen concentrations did not 
represent the real carbon and nitrogen contents in the samples. On the other hand, in this 
work all samples before SBF immersion were rinsed and handled together, and were 
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examined with XPS at the same time. Hence they should have encountered a similar 
level of contamination. Similarly, the second set of the samples, which were immersed 
in SBF for 3 days, were handled together and examined with XPS at the same time to 
ensure that they had a similar level of contamination. Therefore, the non-modified 
samples (which did not contain carbon and nitrogen at all) were used as reference to 
deduct the contamination from the modified samples. However, the deduction was made 
in the two groups of samples (with or without SBF soaking) separately, because their 
XPS investigations were carried out in two different sessions. 
The processed results of XPS analysis on samples before and after immersion in SBF 
are plotted in Figs. 6.1a and 6.1b, respectively. The major results are summarised as 
follows: 
(1) Comparison of unmodified and modified samples in Figs. 6.1a and 6.1b 
The levels of Na, Ca, and P decreased after surface modification compared to those 
without modification, whereas the Si, C and N contents increased considerably. In 
the two groups (before and after SBF immersion), the level of Si was about 13 and 
15 at. % higher in the modified samples compared to that of the unmodified 
reference samples, respectively. 
(2) Comparison of samples before (Fig. 6.1a) and after (Fig. 6.1b) immersion in SBF 
There was a considerable increase (4-5 at %) in the levels of Ca and P after 
immersion in SBF for 3 days for both unmodified and modified samples (the levels 
of Na are too low to reach a conclusion, compared with the error of the 
measurement), whereas the Si level decreased by a similar level (about 15 at %) in 
both as-sintered and functionalised samples after SBF soaking. Significant 
increases in both C and N contents were detected in the samples after SBF 
incubation, compared with those in the samples before SBF immersion. This is very 
likely to be the result of residual TRIS buffer: (HOCH2)3CNH2 from SBF, which 
contains C and N. 
2.2. XRD ANALYSIS 
Fig. 6.2 shows the XRD spectra for all investigated samples. The "as-received" spectra 
represent the results for amorphous 45S5 Bioglass® powder in as-received condition. 
The diffusive peak was caused by the short range ordering of the silicate structure in the 
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glass Before immersion in SBF, all samples (with and without surface modification) 
exhibited sharp diffraction peaks, which were identified as diffractions of the 
NaiCaiSisOp phase (marked with triangles) using the standard PDF #22.1455. The same 
crystalline phase has been reported in previous studies on sintered 45S5 Bioglass® 
powders 73 
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Fig. 6.1 Surface composition measured by x-ray photoemission spectroscopy for 
sintered Bioglass®-derived glass-ceramic pellets with and without surface 
functionalisation (a) before and (b) after 3days in simulated body fluid. 
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Fig. 6.2 X-ray diffraction spectra of samples (a) sintered at 1000°C for Ihr, (b) sintered 
at 1000°C for Ihr followed by surface-modification with 3-aminopropyl-triethoxysilane 
and glutaraldehyde and (c) sintered at 1000°C for llir followed by water-treatment 
(buffered to pH = 8) at 80°C for 41ir. (V: NaiCaiSiaOg crystalline phase; • : 
hydroxyapatite) 
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After immersion in SBF for up to one week, the as-sintered sample (Fig. 6.2a), with 
neither surface modification nor water treatment, showed a reduction of crystalhnity. 
After two weeks in SBF, the sharp diffraction peaks of crystaUine phase NaiCaiSisOg 
entirely disappeared from XRD spectra, leaving HA peaks (marked with solid squares) 
overlapped on a new broad halo. This result is in agreement with previous observations 
that the crystalline phase NaiCaiSisOg in Bioglass®-based glass-ceramic scaffolds 
decomposes into an amorphous calcium phosphate upon immersion in SBF 
The same degradation process progressed remarkably faster in the surface modified 
samples (Fig. 6.2b) than in the as-sintered samples (Fig. 6.2a). It was found that the 
surface functionalised samples almost did not feature any remaining crystalline phase 
(NaiCaiSisOg) after just only 3 days in SBF, but pronounced peaks of HA were detected 
instead (Fig. 6.2b). An immediate thought about the possible cause for the accelerated 
decomposition was the treatment in the buffered (pH = 8) water at 80 °C during the 
surface modification process, rather than the use of functionalising chemicals (ARTS 
and GA). To reach a definite conclusion, the sintered foams were treated exactly the 
same way but without using APTS and GA. They were only water-treated at 80 °C for 4 
hrs at pH 8. XRD analysis on the water-treated and SBF-soaked samples (Fig. 6.2c) 
revealed that the phase transformation kinetics in these samples was almost the same as 
that of surface modified samples (Fig. 6.2b). This confirmed the suggestion that water-
treatment was the key factor in accelerating the NaiCaiSiaOg transformation in the 
surface functionalised samples. 
In summary, XRD analysis revealed that the transformation of the crystalline phase 
NaiCaiSisOg to an amorphous phase was accelerated from 2 weeks (in as-sintered 
scaffolds) to 3 days (in surface-modified and water-treated scaffolds), and that the 
buffered aqueous treatment played a critical role in the acceleration. 
2.3. SURFACE MORPHOLOGY AND COMPOSITION 
Figs. 6.3 and 6.4 illustrate the micro structural evolution (upon immersion in SBF) of the 
strut surfaces of the as-sintered, surface-modified and water-treated foams, respectively. 
Fine crystalline particles (-0.5 |im in diameter) embedded in the glass matrix are the 
feature of the as-sintered microstructure (Fig. 6.3a). After soaking in SBF for up to 1 
week, HA-like bulbs were precipitated on the surface of foam struts in which the 
polycrystalline phase was very clear (Fig. 6.3b). However, a significant change occurred 
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in surface morphology after immersion in SBF for 2 weeks, i.e. the polycrystalline 
microstructure was replaced by an amorphous matrix containing HA crystallites (Fig. 
6.3c). The above observation was in agreement with the results of XRD analysis (Fig. 
6.2a). The boundaries of crystallites were unclear in the as-sintered samples (Fig. 6.3a) 
because they were embedded in the glass matrix. However, the crystalline phase/glass 
boundaries become sharp after 3 days in SBF (Fig. 6.3b). This is due to the faster 
dissolution of the glass phase compared to the crystalline phase and the fact that the 
interfaces between the glass matrix and crystalline particles were favourable sites for 
dissolution. 
Fig. 6.3 Macroporous structure of Bioglass®-derived scaffold sintered at 1000°C for : 
hr. Surface microstructure of struts of foams sintered at 1000°C for 1 hr followed by 
immersion in simulated body fluid for (a) 0, (b) 1 and (c) 2 weeks. 
The morphology of surface modified samples before immersion in SBF was typically 
composed of pores of -0 .5 |im diameter (Fig. 6.4a), similar to the size of the crystalline 
particles. The water-treated samples exhibited a very different microstructure; spindle-
shaped crystallites being the main feature (Fig. 6.4c). After immersion in SBF for 3 
days, the surface-modified and water-treated samples were both fully covered with very 
fine particles, the size being < 0.1 p,m (Figs. 6.4b and 6.4d). After 3 days of immersion 
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in SBF, there was no obvious change in microstructural morphology, which was 
consistent with the XRD results (Figs. 6.2b and 6.2c) 
Fig. 6.4 Scanning electron microscopic images of the microstructures of foams sintered 
at 1000°C for 1 hr followed by functionalisation: (a) before immersion in simulated 
body fluid (SBF) and (b) soaked in SBF for 3 days; or followed by water-treatment: (c) 
before immersion in SBF and (d) soaked in SBF for 3 days. 
Results from EDX analysis are presented in Figs. 6.5-6.7. The dotted lines in the graphs 
represent the EDX analysis of an as-sintered 45S5 Bioglass®-derived scaffold before 
immersion in SBF. The solid lines represent the theoretical composition of 
stoichiometric HA (Caio(P04)6(OFI)2) with a corresponding Ca to P ratio of 1.67. The 
main EDX results are summarised as follows: 
(i) Before SBF immersion, both the water-treated and the surface modified samples 
showed a significant drop in the level of Na (Figs. 6.6a and 6.7a), compared with 
the composition of as-sintered 45S5 glass-ceramic (dotted line). 
(ii) There was also an obvious reduction in Si content in the water-treated samples 
before SBF immersion (Fig. 6.6a). A similar release of silicate ions was expected 
to occur in the surface-functionalised glass-ceramic material as well. However, 
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the release of Si could be counteracted by the adhesion of APTS on the surface 
(Fig. 6.7a). 
(iii) After immersion in SBF, all samples showed continuous decrease in the Na and Si 
contents and concurrent increase in Ca and P fractions, approaching the 
composition of HA. 
(iv) A comparison of Fig. 6.5 with Figs. 6.6 and 6.7 reveals that the establishment of 
HA composition progressed slowly in the as-sintered foams, when compared with 
water-treated and surface-modified foams. In the latter two cases, HA formed at 
almost the same rate. 
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Fig. 6.5 Energy-dispersive x-ray results on the surfaces of as-sintered Bioglass'-based 
foam struts after immersion in simulated body fluid for (a) 1 week, (b) 2 weeks, and (c) 
4 weeks, together with the compositions of 45S5 Bioglass® (BG) and stoichiometric 
compositions of hydroxyapatite (HA). The foam was sintered at 1000°C for 1 hr. 
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Fig. 6.6 Energy-dispersive x-ray results on the strut surfaces of water-treated Bioglass -
derived foams after immersion in simulated body fluid for (a) 0 days, (b) 1 weeks, (c) 2 
weeks and (d) 4 weeks, together with the compositions of 45S5 Bioglass® (BG) and 
stoichiometric composition of hydroxyapatite (HA). The foam was sintered at 1000°C 
for 1 hr, followed by treatment in buffered (pH = 8) water at 80°C for 4 hrs. 
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Fig. 6.7 Energy-dispersive x-ray results on the strut surfaces of surface-modified 
Bioglass®-derived foams after immersion in simulated body fluid for (a) 0 days, (b) 1 
week, (c) 2 weeks and (d) 4 weeks, together with the compositions of 45S5 Bioglass® 
(BG) and hydroxyapatite (HA). The foam was sintered at 1000°C for 1 hr, followed by 
surface modification. 
276 It should be noted that the penetration depth of an electron beam at 20kV is ~lj.im 
Hence, the present EDX data also included the contribution of bulk material 
immediately beneath the surface layer. Therefore, it is not surprising to find that the 
EDX results are in agreement with XPS analysis qualitatively, but not quantitatively. 
2.4. COLLAGEN-LOADING AND -RELEASING 
This part of the investigation aimed to assess the ability of the functionalised scaffolds 
to support protein attachment. It was found that the protein loading procedure was 
equally efficient for all scaffolds and was not dependent on the surface precondition. 
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The initial amount of protein in solution was 1.68 mg, and after loading it was found 
that on average ~42.7 wt % of the protein was adsorbed to the scaffold's surfaces. The 
surface coverage was calculated to be 
1.68(mg)x42.7% 
= 4.5(mg/m^). 
0.8(m-/g)x0.2g 
where the specific surface area of the scaffolds was 0.80 m^/g and the samples' weight 
was 0.20 g (see Section 4.2 in Chapter 3). The macrostructure of a collagen loaded 
surface is shown in Fig. 6.8a. Fig. 6.8b illustrates the as-fabricated scaffold loaded with 
collagen and immersed in SBF for 3 days. HA depositions were recognizable beneath 
the collagen layer. 
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Fig. 6.8 Micrographs of as-sintered scaffolds after loading with collagen (a) before 
soaking in simulated body fluid (b) after 3 days in simulated body fluid 
Fig. 6.9a gives the curves of the cumulative collagen release in PBS for different 
scaffold pre-treatments. The as-fabricated and the water-treated scaffolds exhibited 
similar release amounts of collagen over time: 100 % of the initial collagen amount was 
released after 168 hrs. In contrast, the surface functionalized scaffolds featured a 
significantly slower release of collagen, compared to the other two types of scaffolds. 
After 168 hrs only ~20 wt % was released. In Fig. 6.9b the protein release curves are 
plotted for scaffolds immersed in SBF. However, no significant differences between the 
release curves could be observed. After 168 hrs ~15 wt. % of the initial collagen loading 
was released. At the same time, the pH levels were measured to be 11 and 9 in PBS and 
SBF, respectively. 
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Fig. 6.9 Cumulative collagen release rates as a function of the scaffold immersion time 
for as-fabricated, water-treated and surface functionalised scaffolds in (a) phosphate 
buffer saline, in which the surface functionalized scaffold exhibits the slowest release 
rate of collagen; and in (b) simulated body fluid at 37 °C with an initial pH of 7.4, in 
which the differently prepared scaffolds exhibit similar protein release rates. 
3. DISCUSSION 
3.1. EFFICIENCY OF SURFACE FUNCTIONALISATION 
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The XPS analysis of the non-modified and modified Bioglass" pellets in Fig. 6.1a 
shows an increase of the Si, C and N content on the materials surfaces. The increment in 
C and N contents can be attributed to the organic molecules used for the surface 
modification. The increase in the Si level is due to the attachment of APTS molecules. 
Each APTS molecule introduces one Si atom to the surface. After surface modification 
the unmodified and modified samples exhibited a different Si content, the ratio being 
-1:2, which verifies the successful surface silanization. The coupling of GA to the 
surface was confirmed qualitatively by a typical reddish colour of the samples obtained 
after GA treatment. The APTS presence on a surface is knovm to be the prerequisite for 
the successful GA coupling. It has been shown in the literature that GA has a 
very high affinity to APTS. On average it is assumed that one GA molecule docks to 
one APTS molecule. 
After 3 days in SBF, the Si content exhibited a similar reduction (~15 at. %) in 
untreated and surface-modified samples (Figs. 6.1a-b). It is suggested that the decrease 
of Si in the untreated sample was caused by silicate ion leaching. Hence, it can be 
assumed that a similar amount of Si reduction in the modified samples was mostly 
attributed to silicate ions leaching out of the glass-ceramic material, rather than caused 
by the releasing of APTS. This result indicates a stable attachment of APTS molecules. 
3.2. COLLAGEN RELEASE 
To assess the stability of protein attachment, which is relevant to the effectiveness of 
cell attachment on the Bioglass®-derived glass-ceramic substrates, collagen release was 
investigated. The desired behaviour is a low collagen release rate, e.g. a stable collagen 
attachment on the surfaces. It was found that the collagen release kinetics of the surface 
functionalized scaffolds was significantly reduced in PBS (Fig. 6.9a). This finding 
indicated that the collagen molecules were more firmly attached to the surface 
functionalized scaffolds than to the other two types. 
In SBF the collagen release was similar for all scaffold types (Fig. 6.9b). The reason for 
this observation is not evident. One reason might be the change in pH of the solution 
which was 9 in SBF. In PBS, the pH change was raised up to pH 11. The more basic pH 
might be a reason for the collagen detached into PBS solution from the non-modified 
scaffold surfaces. 
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3.3. DISSOLUTION PROCESS DURING TREATMENT IN WATER SOLUTION 
Since the treatment in buffered water solution has been shown to play a key role in 
accelerating the transformation of the crystalline phase NaiCazSisOg, this section is 
dedicated to elucidate the possible reaction processes involved based on investigation of 
the surface morphologies. The mechanisms proposed in this section form the basis for 
our understanding of the bioreaction kinetics of the present surface-functionalised 
scaffolds in SBF (see section 3.4) 
On the functionalised surface (Fig. 6.4a), the diameter of the pores approximates the 
size of the NazCaiSisOg particles. This suggests that the pores are likely the result of the 
leaching of Na2Ca2Si309 phase. The particle leaching could be caused by preferential 
dissolution (i.e. sodium and silicate ion releasing, as indicated by EDX analysis in Figs. 
6.5-6.7) at the interfaces between the glass matrix and the crystalline particles, as it is 
well-known that an interface is a high energy area (where the diffusion rate is high as 
well) and always the first place to be etched, corroded or dissolved. The surface 
morphology of water-treated glass-ceramics (Fig. 6.5a) indicates a continuous 
dissolution of both glass and crystalline phases without the intervention of APTS. 
Based on these SEM observations, two mechanisms are proposed to explain the 
formation of the surface morphologies during surface modification and water treatment, 
as illustrated in Fig. 6.10. 
In both treatments, the dissolution of the glass-ceramic material starts preferentially 
from the glass/crystalline phase interfaces. When the solution contains APTS (the left 
side of Fig. 6.10), the surface is rapidly covered by a layer of APTS molecules, which in 
turn reduces the dissolution rates of the glass matrix. But the preferential dissolution 
continues in the gaps between the glass matrix and crystalline particles because the 
gelated APTS molecules can hardily migrate to the narrow interstices while the water 
solution can. Hence, inside the formed cavities the amorphous matrix and NagCaiSisOg 
crystallites keep dissolving until the particles detached from the matrix and leached out, 
eventually leaving pores (Fig. 6.4a) in the glass matrix. Without APTS (the right side of 
Fig. 6.10), the glass matrix dissolves faster such that the crystalline particles are 
exposed on the surface, as seen in Fig. 6.4c where the spindle-shape of the crystallites 
was the result of preferential dissolution of certain crystallographic planes. 
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Fig. 6.10 Proposed dissolution processes during silanization and buffered water-
treatment: In both treatments, dissolution (i.e. ion leaching) starts preferentially at the 
interfaces between glass matrix and crystallite particles, (a) With APTS protection on 
the surface of the glass matrix, the crystalline particles leach out due to the faster 
dissolution at the interfaces of crystalline and amorphous phases, eventually producing 
the pore structure on the surface, as shown in Fig. 6.4a. (b) Without APTS intei-vention, 
the glass matrix dissolves faster such that the spindle-shaped crystals are exposed on the 
surface, as shown in Fig. 6.4c. 
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In brief, during the treatment in buffered water solution, dissolution (i.e. ion leaching) 
starts preferentially at the interfaces between glass matrix and crystallite particles. 
Without APTS intervention, the glass matrix dissolves faster than the crystallites, 
leaving the spindle-shaped crystals exposed on the surface (Fig. 6.4c). With APTS 
protection on the surface of the glass matrix, the crystalline particles could leach out due 
to the faster dissolution at the interfaces of crystalline and amorphous phases, eventually 
producing the pore structure on the surface (Fig. 6.4a). 
3.4. INFLUENCE OF SURFACE FUNCTIONALISATION ON BIOREACTIVITY 
OF BIOGLASS®-BASED FOAMS IN SBF 
XRD (Fig. 6.2) and EDX (Figs. 6.5-6.7) analysis consistently showed that the structural 
and compositional changes progressed faster in the surface-functionalised and water-
treated samples than in the as-sintered material. It must be emphasized that the 
structural transition detected by XRD occurred not only on the surface of the foam struts 
but also throughout the material. Therefore, the mechanism responsible for the 
acceleration of transformation rate must be a process occurring within the glass-ceramic 
microstructure during the treatment in the buffered (pH = 8) water solution at 80 °C for 
4 hrs. We suggest that the preferential dissolution at the interfaces between the glass 
matrix and the crystallites (Fig. 6.10) is responsible for the acceleration of the 
transformation of the crystalline particles in SBF. In the schematic diagram Fig. 6.11, 
the pre-treated samples are shown to contain many gaps between the glass matrix and 
crystalline particles throughout the glass-ceramic material. When the glass-ceramic 
samples are soaked in SBF, the fluid can quickly penetrate into the gaps, and ion 
(especially Na) leaching from the crystalline phase takes place immediately throughout 
the material (not just at the surface). As for the dissolution of an individual crystallite, it 
is likely that the ion exchange preferentially occurs at certain favourable micro locations 
(e.g. dislocations and subgrain boundaries), and that this process leads to breaking down 
the as-sintered crystalline particles into very fine parts (see also Fig. 6.4b and 6.4d). 
Moreover, ion exchange will produce a large amount of point defects, which in turn 
distort the periodic structure of the crystalline phase. This distortion of the crystalline 
structure can develop to such a level that an amorphous structure forms eventually. 
Certainly the above steps do not necessarily occur separately from one another; 
simultaneous occurrence of two, three or even four steps is likely to be the actual case. 
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Fig. 6.11 A proposed model for accelerated transformation of a crystalline phase to an 
amorphous phase in simulated body fluid after treatment in a buffered water solution, 
suggested to occur in the present Bioglass®-based glass-ceramic scaffolds. The model 
explains the scanning electron microscopic observation, as shown in Figs. 6.4b and 
6.4d. 
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The above proposed model, however, seems inconsistent with the fact that the formation 
of HA progressed at almost the same rate in the water-treated (no APTS) and surface 
modified foams, in respect with both structure (Fig. 6.2) and composition (Figs. 6.6 and 
6.7). One could argue that the barrier formed by APTS and GA molecules layers on the 
surface of the scaffold struts would have delayed the kinetics of forming the HA 
composition in SBF on the surface-modified foams, compared to the water-treated 
foams; since the same APTS layer had delayed the dissolution of the glass matrix in 
buffered water solution (pH = 8, at 80 °C) (Fig. 6.8). The above apparent contradiction 
can be addressed as follows (see also Fig. 6.12). 
EDX results have indicated that the formation of HA involves the leaching of sodium 
and silicate ions from the material to the surrounding solution and the absorption of 
calcium and phosphate ions from the solution to the solid. Assume that is the 
maximum number of certain ions that can pass through the APTS layer per second from 
the solid to liquid side of the layer, and that is the number of the same type of ions 
per second that leach from the solid matrix and reach the APTS layer (in order to go 
through it) (Fig. 6.12a). If ion releasing kinetics are slow (e.g. during the incubation in 
SBF) such that , all released ions will pass through the APTS layer as if no 
barrier were present. On the other hand, if the ion releasing kinetics is fast (e.g. during 
the treatment in the buffered water solution at 80 °C and pH 8) such that > A'^ Bamer' 
ions will be accumulated on the left side of the APTS layer, and the barrier function of 
the later will be manifested. In brief, the barrier function of the APTS layer is 
manifested under the condition of surface functionalisation, but not under the incubation 
condition in SBF. The same conclusion can also be obtained for the process of ion 
absorption (Fig. 6.12b) through a similar analysis. 
Therefore, it is concluded the APTS and GA layers themselves do not influence the 
kinetics of structural and chemical changes of the Bioglass®-derived glass-ceramic 
material in SBF; while the aqueous treatment involved during the surface modification 
plays a key role in speeding up these changes. 
The above mechanisms were proposed based on widely accepted knowledge (e.g. 
interfaces are corroded preferentially, and amorphous phases dissolve faster than their 
crystalline counterparts) and the present XRD, EDX and SEM results. The mechanisms 
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have quahtatively explained new phenomena discovered in this investigation: the 
formation of surface morphologies in both modified and unmodified Bioglass®-based 
glass-ceramics before and after incubation in SBF and the accelerated bioreaction in 
scaffolds pre-treated in a hot aqueous environment. 
1: Solid phase : APTS layer 
e 
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Fig. 6.12 Schematic diagram to explain ion exchange at the bioactive glass-
ceramic/APTS layer/liquid interface, (a) A^ Ba„ier is the maximum number of certain ions 
per second that can pass through the APTS layer to enter the liquid phase, and is 
the number of the same type of ions per second that reach the APTS layer (in order to 
go through it), (b) is the maximum number of certain ions per second that can 
pass through the APTS layer to enter solid phase, and is the number of the same 
type of ions per second that diffuse away from the APTS layer (in order to go into the 
solid phase). 
4. CONCLUSIONS 
Surface modification of 45S5 Bioglass®-based glass-ceramic scaffolds was carried out 
for the first time without using organic solvents. The process efficiency was verified by 
XPS analysis. The surface functionalized scaffolds are ready for protein immobilization 
and they can be used for protein release studies or to fabricate Bioglass®-protein 
hybrids. The results of this study indicated that the aqueous heat treatment (rather than 
the APTS and GA molecules themselves) during the surface functionalisation process 
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expedites the subsequent bioreaction of the scaffolds in SBF, and that the treatment in 
the buffered (pH = 8) water solution at 80 °C is an important factor that must be 
considered in the design of Bioglass®-derived glass-ceramic scaffolds with tailored 
bioactivity and biodegradability. 
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CHAPTER SEVEN 
IN VITRO ASSESSMENT OF BIOGLASS®-
DERIVED SCAFFOLDS BY CELL CULTURE 
1. INTRODUCTION 
45S5 Bioglass® has been reported to have the ability to foster cells, in particular 
enhancing osteoblast adhesion, growth, and differentiation, as well as inducing the 
differentiation of mesenchymal cells into osteoblasts Bioglass® has also been 
found to support protein (i.e. enzyme) activity vascularization (or angiogenesis) 
and osteoconductivity Moreover, a number of in vitro studies have focused 
recently on the effects of elements leaching from bioactive glasses into dissolution 
medium on osteoblast activity. Xynos et al for example, demonstrated that the 
ionic products of Bioglass® dissolution upregulated a number of genes involved in bone 
growth. Investigations using different cell lines suggested that Ca, P, and Si ions could 
affect the behaviour of osteoblasts or primary osteoblasts, i.e., proliferation and 
differentiation High Ca^ concentration in the extracellular environment 
stimulated chemotaxis and proliferation of mouse MC3T3-E1 cells, whereas inorganic 
phosphate has been found to play important roles: induction of skeletal cell apoptosis, 
upregulation of osteopontin expression, and mediation of osteoblast cell proliferation 
and differentiation Moreover, silicon was reported to have mitogenetic effects on 
osteoblasts and to stimulate collagen I synthesis 
These studies indicated that the dissolution of Bioglass® in a biological environment 
plays a beneficial role in upregulating cell viability and proliferation. As such, there has 
been a concern that the crystallisation of bioactive glasses, which is an essential 
treatment to achieve the required mechanical properties of the otherwise weak and 
brittle parent glasses, as discussed in Chapter four, could make a bioactive glass bioinert 
and thus impair the cytocompatibility of bioactive glasses The primary objective of 
this work, therefore, was to assess osteoblast cell proliferation on the present Bioglass®-
derived glass-ceramic (i.e. partially crystallised) scaffolds. Since the ingrowth of cells 
into macroporous three-dimensional scaffolds is also a key feature of an ideal scaffold, 
the second objective of the present research was to assess the scaffold function as 
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support for cells. With this objective, a short duration (up to 6 days) cell culture 
assessment was carried out in this preliminary work in order to investigate the initial 
interaction between cells and the sintered glass-ceramic surface. 
In Chapter four, the new 45S5 Bioglass®-derived glass-ceramic scaffolds were well 
described physically and chemically, including their macro- and micro-structure, 
mechanical properties, and biodegradability in simulated body fluid. The unique feature 
of these novel scaffolds is that the crystalline phase that provides the scaffold 
mechanical competence can transform into an amorphous calcium phosphate which is 
biodegradable. However, the biodegradation kinetics and mechanical performance of 
the cell-seeded scaffolds are still unknown. Therefore, this work also aimed to answer 
some questions that had remained unresolved: whether or not the above unique feature 
of the scaffolds is maintained in a relevant cell-culture environment, whether 
biodegradability is slowed down or speeded up in vitro, and how cell culture influences 
the mechanical performance of the scaffolds. 
2. RESULTS 
Because of the large particle size of the powder, the sintering condition was set at 
1100°C for 1 hr for the preparation of scaffolds used for cell culture, which would 
otherwise be too fragile to handle. The pellets used for the quantitative assessment of 
cell proliferation were sintered at the same condition used for scaffolds. The three 
groups of pellets used to assess cell proliferation have been given in Table 3.4 
2.1. SURFACE MORPHOLOGY OF PELLETS 
Fig. 7.1 shows the surface morphologies of the three types of pellets before cell culture; 
annealed (unsintered), as-sintered and surface functionalised pellets. After annealing at 
500°C for 24 h, the pellets were comprised of non-crystalline material, and the original 
glass particles could still be recognised (Fig. 7.1a). The pellets thus retained the initial 
amorphous glass structure. After sintering, the glass particles were partially melted and 
fused together (Fig. 7.1b). The sintered pellets were partially crystallised with 
NaiCaiSisOg as the main crystalline phase (see Chapter Four). On the surface of the 
sintered and functionalised pellets, a honeycomb-like morphology was observed, which 
is in agreement with the result in Chapter 6, where it was shown that this morphology 
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was formed by the leaching of crystalline grains during the aqueous treatment for 
surface functionalisation. 
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Fig. 7.1 Surface morphology of (a) annealed (unsintered, and thus non-crystallized) 
45S5 Bioglass® pellet, (b) as-sintered Bioglass®-based glass-ceramic, and (c) sintered 
and functionalised Bioglass® glass-ceramic pellets. 
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Fig. 7.2 Surface morphology of pellets after 6 days in cell-culture medium, (a) 
Unsintered (amiealed) 45S5 Bioglass®, (b) as-sintered 45S5 Bioglass®-derived glass-
ceramic, hydroxyapatite-like spheres being marked by arrows, and (c) sintered and 
surface-functionalised 45S5 Bioglass®-derived glass-ceramic. 
159 
After cell culture, the surfaces of the pellets were also observed by SEM, as shown in 
Fig. 7.2. On the pristine (unsintered and thus non-crystallised) Bioglass® pellets, fine 
and densely distributed hydroxyapatite-like particles (confirmed by EDX analysis) were 
seen to populate on the whole surface (Fig. 7.2a), whereas sparsely distributed 
hydroxyapatite-like particles were found on the sintered (partially crystallised) pellets, 
as marked by arrows in Fig. 7.2b. A comparison of Fig. 7.2c and Fig. 7.1c reveals that 
the surface of functionalised pellets was much rougher (by ~28%, as determined by 
Zygo® measurement) after cell culture than before cell culture. This observation was 
confirmed by white light interferometry measurements. The quantitative results of 
roughness, i.e. root mean square (RMS), using a Zygo® light interferometer instrument 
are given in Table 7.1. 
Table 7.1 Root mean square values of different Bioglass®-based pellets 
Sample As-sintered Sintered and Sintered, functioned and 
functionalised cell-cultured 
RMS / |am 1.02 + 0.03 1.06 + 0.05 ]L28+(X09 
Cell Proliferation up to 6 days 
1.200 
1 1.000 
^ 0.800 
2 0.600 
> 0.400 4 
•2 0.200 4 (1) 
^ 0.000 
• Day 1 
00 (/) 
CD CD 
Material 
Fig. 7.3 Cell proliferation data up to 6 days on the different materials investigated. 
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2.2. CELL PROLIFERATION ON 2D SURFACES (PELLETS) 
Cell proliferation was quantitatively measured using the AlamarBlue™ assay. The data 
are illustrated in Fig. 7.3. Firstly, the three types of pellets (Table 1) exhibited a better 
ability to foster cells than the Thermanox® control. Secondly, the armealed (non-
crystallised) Bioglass® pellets were the best among the three groups. The advantage of 
the annealed Bioglass® pellets over the other two types in supporting cell proliferation 
was statistically significant (^<0.05). However, this advantage of the non-crystallised 
Bioglass® pellets was reduced with the increase of culture time (day 6), even becoming 
statistically insignificant (p > 0.05) when compared with functionalised pellets. Finally, 
the functionalised pellets showed a better ability to foster cells than sintered pellets after 
day 6, but this result was not statistically significant {p > 0.05). 
Figs. 7.4-7.6 illustrate the SEM morphologies of cell-cultured pellets. Due to the fast 
dissolution of unsintered Bioglass® and the weak mechanical bonding between particles, 
the surface layer of these annealed Bioglass® pellets and thus the cells attached to it 
were inevitably peeled off during SEM sample preparation, leaving residual and discrete 
cellular areas on the surface, as shown in Figs. 7.4(a) and (c). Hence, only few cells 
were observed on the annealed pellets, as illustrated in Figs. 7.4 (b) and (d). The 
following observations were made on as-sintered and functionalised pellets. 
(1) After culture for 1 day, most cells were at the stage of attaching and dividing, as 
indicated by the paired cells in Figs. 7.5(a)-(b) and Figs 7.6 (a)-(b), showing cell 
membranes with numerous filipodia. 
(2) At day 6, the number of cells appeared to be reduced when observed at low 
magnification [Figs. 7.5(d) and 7.6(c)]. However, it was discovered at high 
magnification that in addition to well-attached cells [Fig. 7.5(e)], many cells spread 
extensively such that they were barely visible at low magnifications, as shown in 
Fig. 7.5(f) and Fig. 7.6(d). 
(3) A comparison of Fig. 7.5(a) and Fig. 7.6(a) revealed that cells attached and 
proliferated more efficiently on functionalised pellets than on sintered discs. 
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Fig. 7.4 Scanning electron micrographs of cultured MG 63 osteoblast-like cells on 
unsintered 45S5 Bioglass® pellets cultured for 1 or 6 days, (a) Residual islets (some 
marked by arrows) as a result of the peeling surface layer of a pellet, and (b) cells on a 
residual islet, after culture for 1 day. (c) Residual islets as a result of the peeling surface 
layer of a pellet, as marked by arrows, and (d) cells on a residual islet, after culture for 6 
days. 
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Fig. 7.5 Scanning electron micrographs of cultured MG 63 osteoblast-like cells on as-
sintered 45S5 Bioglass®-derived glass-ceramic pellets. 
(a)-(c) Cultured for 1 day, showing cell dividing and attachment. 
(d)-(f) Cultured for 6 days, showing attaching cells and well-attached cells. 
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Fig. 7.6 Scanning electron micrographs of cultured MG 63 osteoblast-like cells on 
sintered and surface-functionalised Bioglass®-derived glass-ceramic pellets, (a)-(b) 
Cultured for 1 day; and (c)-(d) cultured for 6 days. 
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Fig. 7.7 Cell proliferation data up to 6 days on the Bioglass®-derived glass-ceramic 
scaffolds investigated. Porosity is indicated by "pore per inch" (ppi). 
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2.3. CELL SEEDING OF SCAFFOLDS 
The foam-like scaffolds made from 45ppi and 60ppi PU foams (with porosities being 
91-93% and pores size being in the range 750-1100 )j,m and 510-720 |im, respectively) 
were cell seeded and cultured for up to 6 days. Cell proliferation was quantitatively 
measured using the AlamarBlue™ assay. The data are illustrated in Fig. 7.7. There are 
no significant differences (p > 0.05) in terms of cell proliferation in the two types of 
scaffolds (except day 1), however both exhibiting a significantly better {p < 0.05) 
ability to foster cells than the Thermanox® control, throughout the 6 days of culture. 
At day 1 and day 6, selected cell-seeded scaffolds were fixed and cut into 2 equal 
pieces, and the cross-section of the foam centre was observed by SEM. Visual 
inspection indicated that cells could easily infiltrate into the scaffolds. Fig. 7.8 shows 
that many osteoblast cells attached on the struts of the scaffolds, survived and 
proliferated at the core regions of the scaffolds. In particular at day 6, many cells were 
spread such that they could only be recognised at high magnification and slow scanning 
speed. That explains why the cell density appears to be lower in Fig. 7.8 (d) than that in 
Fig. 7.8 (a). These results confirm that the large pores (>400 (j.m) and completely open 
pore network of the present scaffolds seem to ensure a good mass transport of cells, 
nutrients, oxygen and waste products, an important consideration for potentially longer-
term cultures and in vivo applications. However this part of the study requires further 
quantitative investigation, which was beyond the scope of the present project. 
2.4. DEGRADATION OF CELL-CULTURED SCAFFOLDS 
The scaffolds were crushed into powder after either cell culture, incubation in culture 
medium (no cells), or immersion in simulated body fluid (SBF). The powders were 
analysed using XRD, as shown in Fig. 7.9. The crystallinities of the above three 
powders decreased, compared to that of the as-sintered material. The reduction in 
crystallinity was caused by the degradation of the crystalline phase (Na2Ca2Si309) into 
an amorphous calcium phosphate, a mechanism discussed in Chapter Four. A 
comparison of the peak intensity of spectra corresponding to the crystalline phase 
NazCazSisOg revealed that there was no obvious difference in the degradation kinetics in 
the three soaking media (cell-culture, cell-free culture medium and SBF). 
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Fig. 7.8 Scanning electron micrographs of cultured MG 63 osteoblast-like cells on 
sintered Bioglass®-derived glass-ceramic scaffolds. The size of the scaffolds was about 
5x10x10 (mm^), the SEM images were taken from the core region of the scaffolds, (a)-
(c) Cultured for 1 day. A majority of cells were dividing, as marked by arrows in (a) and 
shown in (b), with few spreading cells (c). (d)-(f) Cultured for 6 days. Many cells were 
spread extensively such that they could be observed only under high magnification, as 
shown in (e) and (f). 
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Fig. 7.9 X-ray diffraction spectra of 45S5 Bioglass®-derived scaffolds sintered at 
1100°C for 1 hr (as-sintered), sintered followed by cell-culture, immersion in cultured 
medium (without cells), or soaking in simulated body fluid (SBF) for 6 days. All spectra 
were obtained using 0.05g powder. The major peaks of Na^CaiSisOg phase and 
hydroxyapatite are marked by ( V ) and (•) , respectively. 
2.5. MECHANICAL STRENGTH OF CELL-SEEDED SCAFFOLDS 
Compression strength test was carried out on the scaffolds before and after cell-culture. 
Typical compressive stress-strain curves are shown in Fig. 7.10. Although there was no 
considerable change in the compressive strength after culture for 6 days, the 
morphology of stress-strain curves revealed a remarkable change. The compression 
curves of the as-sintered foams were 'jagged' throughout the testing, whereas the curves 
of the scaffolds after culture for 6 days were much less fluctuated. The compressive 
strength values of scaffolds of similar porosities (0.92-0.94) as-sintered, cultured for 6 
days, and immersed in cell-free culture medium or SBF for 6 days are given in Table 
7.2. The values measured on the as-sintered scaffolds are similar to those measured in 
Chapter Four. It was also confirmed that the mechanical strength of cell cultured 
scaffolds did not decline as fast as those immersed in cell-free culture medium or SBF 
for 6 days. 
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Fig. 7.10 Compressive stress-strain curves of sintered Bioglass®-derived glass-ceramic 
scaffolds before and after cell culture for 6 days. The porosity of the foams was -0.94. 
Table 7.2 Compressive strength of scaffolds of 0.92-0.94 porosity before and after cell 
culture 
Scaffold Compressive strength / MPa 
As-sintered 0.1-0.15 
Cultured for 6 days 0.1-0.15 
Immersed in cell-free medium or SBF for 6 days 0.05-0.1 
3. DISCUSSION 
3.1. EFFECTS OF CRYSTALLISATION AND SURFACE-FUNCTIONALISATION 
ON CELL PROLIFERATION 
It is clear from the quantitative data (Fig. 7.3) and SEM observations (Figs. 7.5 and 7.6) 
that osteoblasts proliferate better on the functionalised Bioglass® glass-ceramic surface, 
compared to as-sintered (non-functionalised) surfaces. This result can be attributed to 
both the APTS monolayer and the increased roughness of the functionalised surfaces. 
Topography is known to influence cell responses and it is generally accepted that a 
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roughened surface is preferential to cell attachment at the tissue-implant interface " . 
A wide variety of cells, including osteoblasts, are able to detect changes in the surface 
topography, and it is because of this feature of cells that much research has been carried 
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out to produce materials with grooved and roughened surfaces at the micrometer level, 
aiming at controlled cell behaviour on potential implant materials 
Nevertheless, our results showed that cells proliferated better on purely amorphous 
Bioglass® (unsintered pellets) than on the partially crystallised Bioglass®-derived glass-
ceramic pellets (Fig. 7.3), which indicates that roughness might be a secondary factor in 
the control of cell behaviour in these materials when compared with the influence of ion 
release from the material during degradation. The possible slower ion releasing kinetics 
due to crystallisation in the sintered pellets is thought to be responsible for the lower 
cell proliferation on the sintered pellets in comparison with the unsintered (amorphous, 
non-crystallised) Bioglass® pellets, in particular at day 1. However, it is anticipated that 
for long term cell-culture the kinetics of cell proliferation on the crystallised Bioglass® 
would match the cell proliferation rate on the amorphous Bioglass® surface, as indicated 
by the data in Fig. 7.3. This is because the crystalline phase in this material can 
transform into an amorphous calcium phosphate, as discussed in Chapter Four, which 
exhibits an excellent bioreactivity equivalent to that of amorphous Bioglass®. A number 
of clinical studies on the bioactivity of calcium phosphates with different 
crystallinities have also revealed that after initial slight differences there was no 
significant disadvantages of highly crystalline hydroxyapatite several months after 
implantation. 
3.2. INFLUENCE OF CELL CULTURE ON DEGRADATION AND 
MECHANICAL STRENGTH OF THE SCAFFOLDS 
While the XRD results suggested that the scaffolds degraded at the same rate in terms of 
crystallinity in the three environments: cell-culture, cell-free culture medium, and SBF 
(Fig. 7.8); their mechanical properties did not degrade at the same rate. The cell cultured 
scaffolds maintained a better strength than the other two groups (Table 7.2). More 
significantly, the cell-cultured scaffolds showed improved mechanical stability (Fig. 
7.10) compared to the as-sintered foams. These phenomena could be attributed to either 
the attachment of cells or the adhesion of cell culture medium, which contains a variety 
of biomolecules. It is predicted that the collagen secreted by the cells will play an 
important role in the improvement of mechanical properties of the scaffolds with 
increasing culture time, which is recommended as further work following this project. 
The possible mechanisms of improving mechanical stability are discussed in detail as 
follows. 
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Micropores and microcracks are inevitable in sintered glass-ceramic materials. In 
particular, surface microcracks initiate fracture when ceramic bodies are loaded. In the 
case of highly porous foams, the micropores and microcracks present on the strut 
surfaces cause local cracking of individual struts, leading to progressive failure of the 
glass-ceramic network Eventually an unstable, jagged stress-strain curve is produced 
Therefore, the frequency of jagging peaks is related to the mechanical stability of 
the network: a high frequency means an unstable mechanical performance. In Fig. 7.10 
the stress-strain curve of the cultured scaffold was much smoother than that of the as-
sintered foam. This indicates that the cell-cultured scaffold is mechanically more stable 
than the as-sintered one. We hypothesize that the attached cells and any protein 
attachment could fill the micropores and microcracks in the struts of the sintered 
scaffolds. Hence, the reduction in the number of micropores and microcracks on the 
strut surfaces could improve the mechanical stability. 
The above hypothesis is proposed based on the fact that collagen secreted by osteoblasts 
has been shown to have the ability to penetrate into the surface layer of bioceramic bone 
fillers in vivo, as shown in Fig. 7.11, which is observed with a transmission electron 
microscope (TEM) It is, therefore, reasonable to assume that collage that can grow 
on solid bioceramics can easily fill into surface defects or micropores and microcracks. 
This behaviour is expected in the present bioactive glass-ceramic material. 
The mechanical strength was almost unchanged after culture for 6 days (Table 7.2), 
while XRD analysis showed obvious degradation of the crystalline phase in the 
scaffolds (Fig. 7.9). The transformation of the crystalline phase into an amorphous 
phase upon immersion in cell culture medium should have caused an obvious decrease 
in mechanical strength of the cell-cultured scaffold. The above discrepancy is likely due 
to two opposite influences of the cell culture environment on the scaffolds. On one 
hand, the mechanical strength could be decreased by the degradation of the crystalline 
phase. However, in contrast, the mechanical strength might be improved by the 
attachment of cells and collagen on the strut surfaces, as discussed above. The 
simultaneous effects of mechanical strength enhancement/reduction could counteract 
one another, resulting in an almost unchanged mechanical strength of the construct. In 
brief, the scaffolds are biodegradable in cell-culture medium (manifested by the 
reduction in crystallinity), at the same time their mechanical strength is maintained 
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satisfactorily, and the mechanical stability is improved, by the attachment of cells and 
possibly collagens secreted by cells on the scaffolds surfaces. It is expected that the 
effect of collagen secretion on mechanical competence of the scaffolds will be 
significant with increasing cell culture time, offering the possibility for time-dependent 
(tuneable) mechanical properties of the scaffolds. 
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Fig. 7.11 Interdigitation of collagen fibres into the surface layer of HA particles after 
implantation into the ileum of a rabbit 
CONCLUSIONS 
(1) The present Bioglass®-derived glass-ceramic scaffolds have excellent osteoblast 
cell-support ability. Cells infiltrate effectively into the porous structure and 
proliferate in the central region of the highly porous scaffolds. 
(2) The cell proliferation on the Bioglass®-derived glass-ceramic material is 
comparable to that on its amorphous counterpart, and it is expected to be the 
same as that on the amorphous Bioglass® after long term cell culture (e.g. > 1 
week). 
(3) Surface functionalisation improved the cell attachment and proliferation, mainly 
due to the increase of surface roughness. Compared to the ion release effect, 
however, surface roughness is a secondary factor in the control of cell 
proliferation. 
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(4) While the scaffolds biodegrade in cell culture medium as requested for bone 
tissue engineering; their mechanical stability is maintained, probably due to the 
attachment of cells and extracellular matrix produced by the cells, but this 
hypothesis needs further investigation. 
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CHAPTER EIGHT 
SUMMARY AND FURTHER WORK 
This chapter at first summarises the four principal areas investigated during the course 
of this research, namely: fabrication of Bioglass®-derived glass-ceramic scaffolds, 
incorporation of poly (N.L-lactic acid) (PDLLA) coating, surface functionalisation of the 
scaffolds, and in vitro trial of the scaffold via cell culture. This research challenged a 
traditional concept (i.e. mechanically stable materials tend to be bioinert, while 
degradable materials are generally very fragile), with a strategy that the large surface 
area in a highly porous structure could change the biodegradation kinetics of a 
mechanically strong network. In many respects this approach was proved to be 
successful, but it is also clear that to achieve clinical applications of the scaffolds much 
further work is needed in terms of both basic science and technology. A series of topics 
recommended to take this research further is presented in the second part of this chapter. 
1. SUMMARY 
1.1. FABRICATION OF BIOGLASS®-DERIVED GLASS-CERAMIC SCAFFOLDS 
Highly porous, mechanically competent, bioactive and biodegradable 45S5 Bioglass®-
based scaffolds for bone engineering have been successfully synthesized using the 
replication technique. The 45S5 Bioglass®-based scaffolds sintered under the optimum 
conditions have a similar macroporous structure to spongy bone: (a) they are highly 
porous (-90%), (b) they have completely open porosity, and (c) they have appropriate 
pore size to deliver bone cells, transport nutrients, remove wastes, and to vascularize 
(510-720pim). The significant finding is that the mechanically strong crystalline phase 
can transform into a bioactive and biodegradable amorphous calcium phosphate upon 
immersion in simulated body fluid (SBF). Therefore, the goal of an ideal scaffold that 
provides good temporary mechanical support while maintaining bioactivity and that can 
biodegrade later at a tailorable rate is achievable with the present Bioglass®-based 
scaffolds. 
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1.2. PDLLA COATING ONTO THE SCAFFOLDS 
To improve the mechanical stability of the above glass-ceramic scaffolds, a poly (D,L-
lactic acid) (PDLLA) coating layer was applied on the foam struts by slurry dipping. 
The bioactivity of Bioglass®-based foams has been maintained after application of 
PDLLA coatings while their mechanical stability has been considerably enhanced by 
the coating, as demonstrated by the remarkable increase of the work of fracture, 
measured by three-point bending test. The work of fracture of the PDLLA-coated foams 
was on average approximately 20 times greater than that of the uncoated foams. The 
most important finding is that in SBF the mechanical stability of the PDLLA-coated 
scaffolds was greatly improved by the PDLLA coating, which is the result of the in-situ 
formation of a nanocomposite film of PDLLA and hydroxyapatite crystals on the strut 
surface of the foams. 
1.3. SURFACE MODIFICATIONS OF THE SCAFFOLDS 
Surface modification was carried out on the 45S5 Bioglass®-based glass-ceramic 
scaffolds, using 3-aminopropyl-triethoxysilane and glutaraldehyde. The process 
efficiency was verified by XPS analysis. The surface fanctionalized scaffolds are ready 
for protein immobilization and they can be used for protein release studies or to 
fabricate Bioglass®-protein hybrids. The aqueous heat treatment during the surface 
functionalisation process expedites the subsequent bioreaction of the scaffolds in SBF. 
It was also found that the treatment in the buffered (pH = 8) water solution at 80 °C is 
an important factor that must be considered in the design of Bioglass®-derived glass-
ceramic scaffolds with tailored bioactivity and biodegradability. The mechanism of the 
expedited bioreaction has been proposed. 
1.4. CELL CULTURE ON THE SCAFFOLDS 
Cell attachment and proliferation on the Bioglass®-derived glass ceramic scaffolds have 
been assessed in vitro using osteoblast-like cells (MG63) cultured for up to 6 days. The 
biodegradation and mechanical stability of the scaffolds in the cell-culture medium have 
also been investigated. It was found that the scaffolds have excellent cell supporting 
ability, with cells smoothly infiltrating into and surviving at the centre of the scaffolds. 
The quantitative study using AlamarBlue™ revealed that the proliferation of cells on 
the glass-ceramic materials was also comparable to that on the pure Bioglass®. While 
the crystalline phase in the glass-ceramic scaffolds was degrading into a biodegradable 
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amorphous calcium phosphate, the mechanical properties (e.g. compression strength) of 
the scaffolds were maintained better during cell culture than when incubated in 
simulated body fluid or immersed in cell-free culture medium. It is hypothesised that the 
attached cells and collagen coating could filled the micropores and microcracks on the 
foams struts and this effect could contributed to the mechanical stability of the 
degrading scaffolds. In summary, the present scaffolds possess the most essential 
features of an optimal scaffold for bone tissue engineering; capable to deliver and foster 
cells, able to provide temporary mechanical function, and biodegradable. 
2. FURTHER WORK 
2.1. ON MATERIAL PHYSICS OF 45S5 BIOGLASS® 
Although Bioglass® was invented more than 30 years ago, some fundamental aspects 
have remained unaddressed, one of which is the kinetics of sintering of Bioglass® 
powder. There is, for example, no viscosity data available for Bioglass®. It is necessary 
to carry out a systematic research on the sintering kinetics of Bioglass® powder (and 
related bioactive glasses). Variables to be investigated include heating rate, sintering 
temperature, holding time, particle size, and green body density. The interaction of 
densification (by viscous f l o w ) and crystallization should also be investigated in detail. 
The result of the work would provide a precise guide in designing a sintering program 
for powders with different initial particle sizes and chemical compositions, providing a 
broader scope than the trial-and-error approach presented in this study. 
2.2. ON MATERIAL CHEMISTRY OF THE BIOGLASS®-DERIVED SCAFFOLDS 
The biodegradability of the Bioglass®-based scaffolds can be tailored according to the 
application requirement, depending on the anatomic position. On the other hand, the 
bioreactivity of the scaffolds is influenced by several factors, such as crystallinity, 
densification of the foam struts, porosity of the foam, surface chemical modification, 
and the presence of a coating. Therefore, it is essential to build a database on the 
bioreactivity of the scaffolds in dependence of these individual factors, for supporting 
the scope for clinical application. 
2.3. TO IMPROVE THE BIOLOGICAL FUNCTIONS OF THE SCAFFOLDS 
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It has been suggested that tissue engineering scaffolds should be developed to include 
more biological functions, and made of combinations of synthetic and natural materials 
Therefore, the incorporation of growth factors, such as bone growth factors (BFG) 
and vascularisation growth factors (VGF), or specific peptide sequences into the 
scaffolds could be a necessary step in the future development of the scaffolds. 
In addition, the influence of surface functionalisation on long-term cell attachment, 
proliferation and differentiation were not investigated and the conditions of surface 
functionalisation were not optimised. These issues must be addressed combined with in 
vitro assessment, i.e. cell culture. Specifically, the following questions should be 
answered: 
(1) Regarding the APTS monolayer and the surface topography, which of them plays 
the major role in the improvement of the attachment of cells? This question can be 
answered by carrying out a comparative investigation on the surface treatments with and 
without APTS. 
(2) Regarding the change of surface roughness with functionalisation, can sharp 
topographic characteristics produced during surface functionalisation damage attached 
cells? A long-term cell culture investigation should be carried out to address this 
question. If the answer to this question is affirmative, an optimal condition of surface 
functionalisation must be determined so as to reduce the sharpness of the surface 
topography while maintaining the effectiveness of the APTS monolayer attachment. It is 
obvious that the quantitative characterisation of the surface roughness is necessary in 
this regard. 
2.4. STUDY 
Inducing tissue regeneration to take place in vitro is a distinguishing feature of tissue 
engineering. Embryonic and adult stem cells have shown great potentials to develop 
into the different cell lines necessary for effective tissue regeneration Although it 
has been documented that osteoblasts proliferate well in vitro, an increasing number of 
studies demonstrate that mesenchymal stem cell source provides a more cost-
effective approach in bone engineering because of their ability to be easily isolated and 
expanded from adult bone marrow aspirates and their versatility for differentiation into 
mesenchymal tissue, compared with the conventional method using osteoblasts. The 
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combination of bone tissue-specific scaffolds, like the Bioglass®-derived glass-ceramic 
scaffolds developed here, with the use of the optimal stem cell type will ultimately 
enable dentists, orthopaedists and tissue engineers to repair or replace injured or 
damaged bone. 
Since tissue will further remodel in the in vivo environment, there are two other key 
issues to be addressed: vascularisation and innervation To reduce the cost of clinical 
studies, one needs to carry out in vitro investigations using appropriate cell types to 
predict in vivo performance of the scaffolds. 
Another interesting topic is associated with the mechanical improvement of scaffolds 
during in vitro cell culture. We hypothesis that the collagen secreted by the cells could 
improve the mechanical strength and stability of the brittle scaffolds by filling the 
surface defects, such as micropores or microcracks. Therefore, a long term cell culture 
investigation with the scaffolds is recommended. 
2.5. WF7FO STUDY 
It is also equally important to move studies into the living system. When using a 
synthetic scaffold, its use should be as short lived as possible, at the same time it must 
maintain its viability and integrity long enough for the cells to produce their own matrix 
A unique feature of the present scaffolds is that the mechanical strong crystalline 
phase can transform into a degradable amorphous phase in a highly porous scaffold 
under biological conditions, which does not usually occur in dense materials at the body 
temperature. This transformation effectively combines mechanical strength (associated 
with the crystalline phase) with tailorable biodegradability (associated with the 
amorphous phase) in one scaffold. However, this has not been proved in vivo. It is likely 
that the kinetics of biodegradation in vivo is different from in vitro. Furthermore, how 
the mechanical properties of the scaffolds change in vivo during scaffold degradation is 
another important question to be addressed. 
3. CONCLUSIONS 
This research has developed highly porous scaffolds for bone tissue engineering, using 
45S5 Bioglass®. The scaffolds combine appropriate mechanical strength and tailorable 
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biodegradability, and thus are very promising. Further work should focus on in vitro and 
in vivo investigations on the scaffolds, the application of stem cells and 
prevascularisation being highly recommended. 
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